

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

IN RE: INSULIN PRICING
LITIGATION

THIS DOCUMENT RELATES TO:

City of Tacoma v. Eli Lilly, et al.
Case No. 2:24-cv-10375

CASE NO. 2:23-md-03080 (BRM-LDW)
MDL No. 3080

JUDGE BRIAN R. MARTINOTTI
JUDGE LEDA DUNN WETTRE

AMENDED COMPLAINT

JURY TRIAL DEMANDED

TABLE OF CONTENTS

I.	INTRODUCTION	2
II.	PARTIES.....	22
A.	Plaintiff Tacoma	22
B.	Manufacturer Defendants.....	23
1.	Eli Lilly	23
2.	Sanofi-Aventis	24
3.	Novo Nordisk	26
C.	PBM Defendants.....	27
1.	Express Scripts and Ascent Health Services LLC	27
2.	CVS Caremark and Zinc Health Services, LLC	34
3.	OptumRx and Emisar Pharma Services LLC	40
III.	JURISDICTION AND VENUE.....	48
IV.	FACTUAL ALLEGATIONS.....	51
A.	Life Saving Insulin Is Not a New Drug.....	51
1.	Diabetes Requires Insulin.	51
2.	Discovery and History of Insulin	54
3.	The Unavailability of Generic Insulin.	58
B.	The Insulin Market Is Enormous.....	59
C.	The Pharmaceutical Supply and Payment Chains.....	61
1.	The Rise of PBMs in the Pharmaceutical Supply Chain	65
2.	The Current Size and Role of PBMs in the Pharmaceutical Supply Chain	66

3.	The Close Relationship Between the PBM Defendants and Manufacturer Defendants	72
D.	The Insulin Pricing Scheme	75
1.	Insulin’s Price Has Risen Dramatically.....	76
2.	Insulin List Prices Have Increased in Lockstep.....	80
3.	The Growing Gap Between List Prices and Net Prices	84
4.	Rebates Gone Awry	88
5.	Clawbacks	96
6.	Spread Pricing.....	97
7.	Defendants’ Admissions	99
E.	The Insulin Pricing Scheme Reflects the PBM Defendants’ Self-Dealing.....	109
1.	Relabeling of “Rebates”	111
2.	Rebate Aggregators.....	116
3.	Illusory Audit Provisions	142
F.	Insulin Adjuncts: Type 2 Medications.....	143
G.	Plaintiff Pays for the At-Issue Drugs.....	149
H.	The Insulin Pricing Scheme Has Injured the City of Tacoma.	152
V.	TOLLING OF THE STATUTES OF LIMITATIONS.....	155
A.	Accrual Rule.....	155
B.	Discovery Rule	157
C.	Nullum Tempus	158
D.	Fraudulent Concealment	160

E.	Equitable Estoppel & Equitable Tolling.....	160
VI.	CLAIMS FOR RELIEF	162
COUNT ONE — VIOLATIONS OF THE RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS ACT ("RICO") 18 U.S.C. §1962(C)		162
A.	Defendants Are Culpable "Persons" Under RICO.....	162
B.	The Manufacturer–PBM RICO Enterprises	163
C.	The Enterprises Misrepresent and Fail to Disclose Material Facts in Furtherance of the Insulin Pricing Scheme.	169
D.	Defendants' Use of the U.S. Mails and Interstate Wire Facilities.	172
E.	Conduct of the Manufacturer–PBM Enterprises' Affairs.	176
F.	Defendants' Pattern of Racketeering Activity.	178
G.	The RICO Defendants' Motive	180
H.	The Manufacturer–PBM Enterprises' Insulin Pricing Scheme Injured Plaintiff.	180
COUNT TWO — VIOLATIONS OF RICO, 18 U.S.C. § 1962(D) BY CONSPIRING TO VIOLATE 18 U.S.C. § 1962(C)		183
COUNT THREE — CIVIL CONSPIRACY		185
COUNT FOUR — COMMON LAW FRAUD		189
COUNT FIVE — UNJUST ENRICHMENT.....		193
COUNT SIX — WASHINGTON CONSUMER PROTECTION ACT, WASHINGTON REVISED CODE SECTION 19.86.010 <i>ET SEQ.</i>		194
I.	PRAYER FOR RELIEF.....	198
II.	JURY DEMAND.....	200

Pursuant to this Court’s Case Management Order No. 9, the “Designated Forum”—the federal district court in which Plaintiff would have filed its case in the absence of direct filing—is the United States District Court for the Western District of Washington. Plaintiff City of Tacoma (“Tacoma” or “the City” or “Plaintiff”), by and through its undersigned attorneys, brings this action against Defendants Novo Nordisk Inc. (“Novo Nordisk”); Eli Lilly and Company (“Eli Lilly”); Sanofi-Aventis U.S. LLC (“Sanofi”); CVS Health Corporation; CVS Pharmacy, Inc.; Caremark Rx, L.L.C.; CaremarkPCS Health, L.L.C.; Caremark Rx, Inc.; Zinc Health Services, LLC, (together with CVS Health Corporation, CVS Pharmacy Inc., CaremarkPCS Health, L.L.C., Caremark Rx, L.L.C., and CaremarkRx, Inc., “CVS Caremark”); Express Scripts, Inc.; Express Scripts Administrators, LLC; Express Scripts Pharmacy, Inc.; Evernorth Health, Inc. (formerly Express Scripts Holding Company); Medco Health Solutions, Inc.; The Cigna Group; Ascent Health Services LLC, (together with Express Scripts, Inc., Express Scripts Administrators, LLC, Express Scripts Pharmacy, Inc., Evernorth Health, Inc., Medco Health Solutions, Inc., and The Cigna Group, “Express Scripts”); UnitedHealth Group, Inc.; Optum, Inc.; OptumRx, Inc., Emisar Pharma Services LLC, (together with UnitedHealth Group, Inc., Optum, Inc., and OptumRx, Inc. “OptumRx”), and allege as set forth below.

I. INTRODUCTION

1. The three largest pharmacy benefit managers in the United States—CVS Health, Express Scripts, and OptumRx (the “PBM Defendants”¹)—engage in unfair and deceptive conduct designed to artificially inflate the list price of insulin and other diabetes medications and extract ever-larger portions of rebates and other payments from the three largest insulin manufacturers—Eli Lilly, Novo Nordisk, and Sanofi (the “Manufacturers” or the “Manufacturer Defendants”). The Manufacturer Defendants, seeking to secure preferential or exclusionary placement on the PBM Defendants’ drug formularies, have paid the PBM Defendants ever-increasing rebates, fees, and kickbacks and have inflated the list prices of rapid- and long-acting analog insulins, human insulin drugs, and other diabetes medications to fund these rebates, fees, and kickbacks.

2. The PBM Defendants and Manufacturer Defendants conspired to prevent disclosure of this scheme by obscuring the true price of insulin, the amount and nature of rebates and fees paid by the Manufacturer Defendants to the PBM

¹ Between 2019 and 2021, each PBM Defendant or their parent companies created a rebate aggregator (also called a “group purchasing organization” or “GPO”) to negotiate and enter into rebate contracts with the Manufacturer Defendants on behalf of the PBM Defendants. These Rebate Aggregator Defendants—Ascent Health Services LLC; Zinc Health Services, LLC; and Emisar Pharma Services LLC—perform much of the same contracting functions that the PBM Defendants previously handled themselves. Hereinafter, references to actions by the “PBM Defendants” include actions taken by the Rebate Aggregator Defendants on behalf of the PBM Defendants.

Defendants in exchange for preferred formulary placement, and the fraction of rebates passed through to clients and health plan payors. This misconduct, and the misconduct described below, is referred to herein as the Insulin Pricing Scheme.

3. Defendants' Insulin Pricing Scheme directly and foreseeably causes payors like Tacoma to overpay for these life-saving medications. Thus, this action is brought to redress Plaintiff's injuries flowing from Defendants' Insulin Pricing Scheme—which has driven up the price of insulin to the substantial benefit of PBMs and insulin manufacturers—and to obtain prospective injunctive relief to curtail Defendants' practices, provide greater transparency in insulin pricing, and lower the price health plans and consumers pay for insulin going forward.

4. Over the past twenty years, the prices paid by consumers and health plan payors, like Tacoma, for diabetes medications have skyrocketed—the prices of some diabetes medications have risen more than tenfold.² In contrast, the average cost of consumer goods and services has merely doubled during the same time period. The surging costs of diabetes medications are not due to competitive market forces or climbing expenditures on goods, production, or research and development. Defendants have engineered these escalating prices to exponentially

² Brenna Miller, *After Decades of Profiteering, Insulin Manufacturer Finally Cuts the Price*, Lown Inst. (Mar. 2, 2023), <https://lowninstitute.org/after-decades-of-profiteering-insulin-manufacturer-finally-cuts-the-price/#:~:text=Just%20twenty%20years%20later%2C%20the,rationing%20or%20f oregoing%20their%20medication.>

increase their profits at the expense of payors, like Plaintiff, and their plan beneficiaries.

5. Diabetes is an epidemic in the United States. In total, nearly forty million people, or 11.6% of the country, live with diabetes.³ Of this number, approximately six million people rely on daily insulin treatments to survive. In addition to natural or synthetic human insulin, several analogs of human insulin have been developed since the mid-1990s. These insulin analogs act more rapidly and for a longer period of time than earlier developed drugs, making them potentially more convenient or effective for patients.

6. Interruptions to or interference with insulin therapy (e.g., cutting back insulin use due to cost) lead to severe consequences, including sustained damage to the kidneys, heart, nerves, eyes, feet, and skin. Indeed, diabetes is the leading cause of kidney failure, adult-onset blindness, and lower-limb amputations in the United States.⁴ Missed or inadequate insulin therapy can leave people with diabetes with too little insulin in their system, triggering hyperglycemia (hyperosmolar hyperglycemic state or “HHS”) followed by diabetic ketoacidosis (“DKA”). Left

³ Am. Diabetes Assoc., *Statistics About Diabetes*, Diabetes.org, <https://diabetes.org/about-diabetes/statistics/about-diabetes> (last visited Oct. 15, 2024).

⁴ *Diabetes Basics*, Ctrs. for Disease Control & Prevention (May 15, 2024), https://www.cdc.gov/diabetes/about/?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/diabetes.html.

untreated, DKA can lead to loss of consciousness and death within days.⁵ DKA is responsible for more than 500,000 hospital days per year in the United States, and the annual hospital cost for patients with DKA is approximately \$2.4 billion.⁶ The medical expenses for individuals with diabetes are approximately 2.6 times higher than those for individuals without diabetes.⁷ According to the Centers for Disease Control and Prevention, the total annual cost of diabetes in the U.S. is \$413 billion, with \$307 billion spent each year on direct medical costs and \$106 billion lost each year due to reduced productivity.⁸

7. The amount consumers and health plan payors spend on these medications is in addition to the hundreds of dollars people living with diabetes must spend every year on diabetes management supplies (e.g., test strips and glucose meters used to read blood sugar levels and syringes, pen needles, infusion sets, and/or pods needed to administer insulin). In short, living with diabetes now

⁵ *Diabetic Ketoacidosis*, Mayo Clinic: Diseases and Conditions, <https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551> (last visited Oct. 15, 2024).

⁶ Abbas E. Kitabchi, *et al.*, *Hyperglycemic Crises in Adult Patients with Diabetes*, 32 *Diabetes Care* 7, 1335–1343 (2009), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699725/>.

⁷ *The Burden of Diabetes in Oregon*, Am. Diabetes Assoc. (Mar. 2024), https://diabetes.org/sites/default/files/2024-03/adv_2024_state_fact_oregon.pdf.

⁸ *Health and Economic Benefits of Diabetes Interventions*, Ctrs. for Disease Control & Prevention, https://www.cdc.gov/nccdphp/priorities/diabetes-interventions.html?CDC_AAref_Val=https://www.cdc.gov/chronicdisease/programs-impact/pop/diabetes.htm.

costs more than \$1,000 per month per patient, resulting in significant costs to individuals and payors like Plaintiff, who cover some or all costs of such care.⁹

8. From 2021 through 2023 alone, diabetes cost an estimated \$6.7 billion in Washington State.¹⁰ In 2021, more than 530,000 Washingtonians—9% of the adult population—had a diagnosis of diabetes.¹¹ In 2021, over 690,000 Washingtonians – 11% of the adult population – had a diagnosis of prediabetes.¹² The Washington Department of Health crucially notes, however, that it is “very likely that many people in Washington may not know they are prediabetic,” suggesting this figure is likely a significant undercount.¹³

9. Tacoma, the third largest city in Washington, is located in Pierce County. In Pierce County, the incidence of diabetes is slightly higher than that of Washington State, with approximately 10% of adults having been diagnosed. Between 2014 and May 2024, Plaintiff spent over \$13 million on the at-issue drugs.¹⁴

⁹ *Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug*, U.S. S. Fin. Comm., [https://www.finance.senate.gov/imo/media/doc/Grassley-Wyden%20Insulin%20Report%20\(FINAL%201\).pdf](https://www.finance.senate.gov/imo/media/doc/Grassley-Wyden%20Insulin%20Report%20(FINAL%201).pdf) (last visited Oct. 15, 2024).

¹⁰ Diabetes Epidemic & Action Report, Wash. Dep’t Health, at 4 (Dec. 2023), <https://doh.wa.gov/sites/default/files/2024-01/140255-DiabetesEpidemicActionReport-20240124.pdf>.

¹¹ *Id.*

¹² *Id.*

¹³ *Id.*

¹⁴ The at-issue drugs are listed in a chart at the beginning of the Factual Allegations.

10. Defendants Eli Lilly, Novo Nordisk, and Sanofi manufacture insulins, analog insulins, and other medications used to treat diabetes. In 2020, as in years past, the three Manufacturer Defendants controlled 92% (by volume) and 96% (by revenue) of the global market for diabetes drugs.¹⁵

11. Between 2004 and 2022, each Manufacturer raised the list prices of their respective at-issue drugs in an astounding and inexplicable manner. For example, between 2004 and 2006, four of the main analog insulins—Levemir, Novolog, Lantus, and Humalog—cost consumers between \$50 and \$75 per prescription.¹⁶ In 2022, the cost per prescription for those drugs was between \$275 and \$308. Between 2004 and 2022, Eli Lilly, Novo Nordisk, and Sanofi have raised their list prices for analog insulins by more than 150%.¹⁷

12. Eli Lilly, Novo Nordisk, and Sanofi's analog insulin price increases have been both rapid and in lockstep for years, as shown below:¹⁸

¹⁵ William Herman & Shihchen Kuo, *100 years of insulin: Why is insulin so expensive and what can be done to control its cost*, Endocrinol Metab. Clin. North Am., (Sept. 2021), at e21.


¹⁶ See *infra* ¶ 12.

¹⁷ *Id.*

¹⁸ William Newton, *Insulin pricing: could an e-commerce approach cut costs?*, Pharm. Tech. (Mar. 31, 2022), <https://www.pharmaceutical-technology.com/features/insulin-pricing-could-an-e-commerce-approach-cut-costs/>; see also Robert Langreth, *Hot Drugs Show Sharp Price Hikes in Shadow Market*, Bloomberg (May 6, 2015), <https://www.bloomberg.com/news/articles/2015-05-06/diabetes-drugs-compete-with-prices-that-rise-in-lockstep>.

**Comparison of Analog Insulin Price Increases—Lantus, Humalog, Novolog,
and Levemir, 2004-2022**

Manufacturer price for 1000 IU insulin vial, sorted by year



Source: GlobalData Price Intelligence Database

13. These rapid and lockstep price increases are seen across all at-issue drugs.

14. The skyrocketing cost of insulin cannot be explained away by the drug companies' typical rationalizations for high prices. Indeed, the manufacturers admit that their price hikes are unrelated to any increase in production or research and development costs. Instead, the inflated list prices result from the Insulin Pricing Scheme.

15. In furtherance of this scheme, the Manufacturer Defendants effectively set two different prices for the at-issue drugs: a publicly-available "list" price, which serves as the basis for what health plans and consumers pay for insulin, and an undisclosed, lower "net" price that reflects what Manufacturer Defendants

actually receive after accounting for their rebates and other kickbacks to the PBM Defendants. The gap between the “list” price and the “net” price of these medications has increased significantly in the last twenty years.¹⁹ This widening gap means that health plan payors, like Plaintiff, pay ever increasing amounts for the at-issue drugs.

16. Defendants CVS Caremark, Express Scripts, and OptumRx are pharmacy benefit managers that, together with the Manufacturer Defendants, dictate the availability and price of the at-issue drugs for most of the U.S. market. The PBM Defendants serve as both middlemen and gatekeepers between drug manufacturers on one side, and health insurers, payors, and patients on the other. The PBM Defendants control nearly 80% of the PBM market; additionally, they own three of the largest pharmacies in the United States (three of the top five dispensing pharmacies) and are housed within the same corporate families as three of the largest insurance companies in the United States—Aetna (CVS Health), Cigna (Express Scripts), and UnitedHealthcare (OptumRx). Together, the PBM Defendants report more than \$300 billion a year in revenue.

¹⁹ See, e.g., Adam Fein, *Five Top Drugmakers Reveal List vs. Net Price Gaps (Plus: The Trouble With Insulin Prices)*, Drug Channels (Aug. 11, 2020), <https://www.drugchannels.net/2020/08/five-top-drugmakers-reveal-list-vs-net.html>.

17. Indeed, for transactions where the PBM Defendants also control the insurer and the pharmacy (e.g., Aetna–Caremark–CVS Pharmacy), these middlemen capture as much as half of the money spent on each insulin prescription, even though they contribute nothing to the development, manufacture, or innovation of the drugs.²⁰

18. The PBM Defendants establish national formulary offerings, which are lists of medications covered by health plans that influence which drugs patients use and determine out-of-pocket costs. The PBM Defendants develop and control these formularies, and are therefore able to extract rebates, fees, and discounts from the Manufacturer Defendants in exchange for favorable or exclusive formulary placement.

19. Formularies also include a ranked list of drugs, with each drug placed into a “tier” dictating the cost and resulting accessibility to consumers. Health plans rely on these formularies to determine what proportion of their members’ drug costs they will cover; for higher formulary tiers, plan members will pay the highest copay. Drugs in lower, “preferred” formulary tiers are supposed to be cheaper for

²⁰ Testimony of Karen Van Nuys before the U.S. S. Fin. Comm. (Mar. 30, 2023), at 4, <https://www.finance.senate.gov/imo/media/doc/Van%20Nuys%20Senate%20Finance%20Committee%20Statement%2003.27.23.pdf>.

plan members.²¹

Drug tier	Type of drugs included	Your cost
Tier 1	Most generic drugs	Lowest copay
Tier 2	Most common brand name drugs Preferred brand name drugs Some high-cost generic drugs	Medium copay
Tier 3	Non-preferred brand name drugs	Highest copay
Tier 4 (Specialty Tier)	Unique or very high-cost drugs	Percentage of total drug cost, called "coinsurance"

20. Where two medicines are largely interchangeable, a pharmacy benefit manager will sometimes exclude the more expensive of the two from its formulary—again purportedly based on the price of the drug for patients. When a drug is excluded from or disfavored in the formulary, health insurers using that formulary will either not cover any portion of the cost of the drug or require their members to pay a larger coinsurance amount. As a result, exclusionary formularies enable pharmacy benefit managers, including the PBM Defendants here, to push patients toward certain brands of drugs over others. This power gives pharmacy benefit managers enormous control over drug purchasing behavior as well as leverage over drug manufacturers.

²¹ See *What is a tiered formulary and what does it mean for me?*, UnitedHealthcare, <https://www.uhc.com/news-articles/medicare-articles/what-is-a-tiered-formulary-and-what-does-it-mean-for-me> (last visited Oct. 15, 2024).

21. While the PBM Defendants could use their considerable market power to drive down drug prices by forcing drug manufacturers to compete on price for formulary placement, instead, they and the Manufacturer Defendants figured out a way to game the system for their mutual benefit. To gain formulary access, the Manufacturer Defendants raised their published list prices and then “rebate” a significant portion of the list price to the PBM Defendants. The rebates²² are provided under a variety of labels—discounts, credits, concession fees, etc. But however they are described, they are a quid pro quo for formulary inclusion or placement.²³

22. The result of this rebate scheme is a significant difference between the list price set by the Manufacturer Defendants, and the net price realized by the manufacturers once all rebates paid to the PBM Defendants are taken into account. The PBM Defendants may pass a portion of the rebates on to their insurer clients (some of which are owned by or affiliated with them) and pocket the rest. The greater the rebate, the more the PBM Defendants pocket. Although the true rebate

²² In the context of this Complaint, “rebates” should be understood to include all payments, fees, or financial benefits of any kind conferred by the Manufacturer Defendants to the pharmacy benefit managers, either directly via contract or indirectly via Manufacturer or pharmacy benefit manager-controlled intermediaries. But the actual “Manufacturer Payments” are distinct from and much larger than “Payor Rebates,” which in some cases are required by contract to be provided to health plans by their respective pharmacy benefit managers.

²³ See, e.g., Linda Cahn, *Don’t Get Trapped By PBMs’ Rebate Labeling Games*, 18 Managed Care 31 (2009).

amounts are unknown, the difference between the list price and the net price suggests that the rebates may be as great as, or even greater than, 50% of the list price.


23. While the PBM Defendants' contracts imply that such rebates benefit consumers and health plan payors such as Plaintiff, in reality, the rebates that the PBM Defendants pass along ("Payor Rebates") are a fraction of the rebates and other fees the PBM Defendants actually received from the manufacturers ("Manufacturer Payments"). The total amount and nature of the Manufacturer Payments, the amount the PBM Defendants pocket, and the amount the PBM Defendants pass through to clients/payors are all carefully guarded secrets. The true nature of the scheme is thus concealed from patients and health plan payors, such as Plaintiff.

24. This rebate scheme creates a "best of both worlds" scenario for the Defendants. The PBM Defendants obtain ever larger rebates in exchange for granting access to the exclusionary formularies, increasing their take, and the Manufacturer Defendants increase their list prices so they can pay the rebates to the PBM Defendants without cutting into their profit margins. In effect, the quid pro quo arrangement between the PBM Defendants and Manufacturer Defendants creates a price war in reverse. The Manufacturer Defendants keep raising their list prices, so that they can pay larger and larger "rebates" to the PBM Defendants. One

astute commentator refers to this as “bubblenomics.”²⁴ The “gross-to-net bubble”—that is, the gap between sales based on the list prices and sales based on the net prices of drugs—was \$204 billion in 2021 for patent-protected brand name drugs.²⁵

25. The result of the scheme is an ever-widening gap between the publicly available Manufacturer list price, which determines what consumers and health plans pay, and the net realized price actually received by Manufacturer Defendants. The following chart shows this gap for Lantus, Sanofi’s top-selling analog insulin.²⁶

Comparison of List and Net Price of Lantus (Sanofi), 2007-2016




²⁴ Adam J. Fein, *Novo Nordisk Sheds New Light on PBM Rebates, the Gross-to-Net Bubble, and Warped Channel Incentives*, Drug Channels (Dec. 6, 2016), <http://www.drugchannels.net/2016/12/novo-nordisk-sheds-new-light-on-pbm.html>.

²⁵ Adam J. Fein, *Warped Incentives Update: The Gross-to-Net Bubble Exceeded \$200 Billion in 2021*, Drug Channels (Mar. 22, 2022), <https://www.drugchannels.net/2022/03/warped-incentives-update-gross-to-net.html>.

²⁶ Denise Roland & Peter Loftus, *Insulin Prices Soar While Drugmakers’ Share Stays Flat*, Wall St. J. (Oct. 7, 2016), <https://www.wsj.com/articles/insulin-prices-soar-while-drugmakers-share-stays-flat-1475876764>.

26. And in more recent years, the gap has continued to widen, as confirmed by Eli Lilly and Sanofi's own reports:²⁷


Comparison of List and Net Price of Humalog (Eli Lilly), 2015-2019



The last list price increase for Humalog vial was May 2017. The net price in the chart represents the revenue Lilly realized per Humalog and Insulin Lispro vial after rebates and discounts. Increases in list prices do not always create increases in net prices.

²⁷ Eli Lilly and Company, *Twenty Nineteen Eli Lilly and Company Integrated Summary Report*, <https://assets.ctfassets.net/srys4ukjcerm/4OhD66szgxpHhhCqzE2Ev/983bd8407c49928f309936e1161bec47/Lilly-2019-Integrated-Summary-Report.pdf#page=23> (last visited Oct. 15, 2024); Sanofi, *Sanofi: 2023 Pricing Principles Report*, <https://www.sanofi.com/assets/dotcom/pages/docs/investor-relations/environmental-social-governance/Sanofi-2023-Pricing-Principles-Report.pdf>.

Comparison of List and Net Price of Sanofi Insulin, 2012-2022



27. The PBM Defendants tout their market power to drive down drug prices. They boast about the “rebates” or “discounts” they bargain with drug manufacturers. The story they tell is that these rebates and discounts are obtained for the benefit of patients since they purportedly result in lower costs for prescription drugs. For example, Cigna, which owns Express Scripts Holding, claims, “[w]e consult with our clients on how best to structure and leverage the pharmacy benefit to meet plan objectives for affordable access to the prescription medications customers need to stay healthy and to ensure the safe and effective use of those medications.”²⁸

28. CVS Health Corp. contends it “assists its PBM clients in designing pharmacy benefit plans that help improve health outcomes while minimizing the

²⁸ The Cigna Group, Annual Report (Form 10-K) (Feb. 23, 2023) at 5.

costs to the client.”²⁹

29. OptumRx claims that its PBM businesses “improve overall health system performance by optimizing care quality and delivery, reducing costs and improving consumer and provider experience, leveraging distinctive capabilities in data and analytics, pharmacy care services, health care operations, population health and health care delivery.”³⁰

30. But the story the PBM Defendants tell is far from the whole truth. While it is true that they obtain rebates and discounts, they neglect to reveal the large portion of these payments that they pocket. They also neglect to reveal that their formulary decisions are based on the amount of the rebates paid by drug manufacturers, including the Manufacturer Defendants, even if other, lower-priced alternatives exist. And they neglect to reveal that the consequence of this scheme is higher drug costs for payors like Tacoma, whose payments (like the payments of their health plan beneficiaries) are calculated based on the list price (i.e., average wholesale price), not the lower “net” price actually received by the Manufacturer Defendants once all rebates and other payments to PBM Defendants are taken into account. Indeed, the PBM Defendants misrepresent the role they play in the supply chain, and their impact on the prices actually paid by health plan payors, like

²⁹ CVS Health Corp., Annual Report (Form 10-K) (Feb. 8, 2023) at 8.

³⁰ UnitedHealth Group, Annual Report (Form 10-K) (Feb. 24, 2023) at 1.

Plaintiff, for drugs.

31. The PBM Defendants are avaricious middlemen, with a stranglehold on the prescription drug supply chain. Their scheme to sell formulary access for rebates drives up the cost of prescription drugs for the people who need to use them to stay alive. This scheme serves one simple purpose for the PBM Defendants—to make more money.

32. The Manufacturer Defendants are equally at fault. Their conduct deprives patients of a fair price—a price that would result from the operation of normal market forces. Through the scheme, they maintain the ability to sell the at-issue medications to the millions of Americans who depend on them, without having to lower the “real” net prices to gain market share. They bargain for market share by providing ever-larger rebates to the PBM Defendants and entering into exclusive relationships with those PBM Defendants, inflating the prices paid by consumers and health plan payors in order to preserve their net realized price and to ensure that they maximize the number of individuals and payors like the City of Tacoma who continue purchasing the insulin they manufacture. The Manufacturer Defendants’ refusal to disclose their net realized prices for insulins and the web of confidentiality agreements they have created and/or participated in with PBM Defendants have been critical to the furtherance of the Insulin Pricing Scheme.

33. Recognizing the growing discrepancy between published list prices

and net prices, a New York Times op-ed called for transparency in setting prices:

In the meantime, we need a fair and transparent system for setting prices. In much of Europe, insulin costs about a sixth of what it does here. That's because the governments play the role of pharmacy benefit managers. They negotiate with the manufacturer directly and have been very effective at driving down prices. In the United States, we rely on the private sector and a free market for drug pricing. But in order for this to work, we need to regulate it better and demand greater transparency.³¹

34. The physical, emotional, and financial tolls of the excessive prices for the at-issue medications are devastating. Many patients cannot afford their medications and suffer dire consequences as a result. Others resort to under-dosing their insulin, injecting expired insulin, and starving themselves to control their blood sugars with as little insulin as possible. These behaviors are dangerous for people living with diabetes. Because such behaviors inadequately control those individuals' blood sugar levels, they can lead to serious complications such as kidney failure, heart disease, blindness, infection, and amputations. In some cases, patients are forced by exclusionary formulary tiering to use an insulin brand that is less effective in controlling their individual blood sugars, or to which they have some degree of allergic reaction—or to pay increased cost-sharing to access the non-preferred brand of insulin they need.

³¹ Kasia Lipska, *Break Up the Insulin Racket*, N.Y. Times (Feb. 20, 2016), <https://www.nytimes.com/2016/02/21/opinion/sunday/break-up-the-insulin-racket.html>.

35. The cost of analog insulin—the most effective and favored type—has gone up so much that some prominent physicians have started encouraging patients to switch to human insulin despite its many disadvantages, thus undermining the U.S. standard of care in relation to international best medical practices for diabetes.³²

36. These price increases also put significant strain on municipalities like the City of Tacoma, which pay increasing costs for insulin through self-funded health plans for its government employees. The City currently provides health benefits to over 10,000 individuals, and makes payments to its PBM on a regular basis to cover a portion of the cost of insulin for beneficiaries of the plan. Indeed, between 2014 and May 2024, the gross amount that Tacoma has paid just to cover its portion of the cost of the at-issue drugs for the Beneficiaries of its self-funded insurance plan is over \$13 million—costs that will continue in the future under the ongoing Insulin Pricing Scheme.

37. Yet, even amid public scrutiny and government investigations, the full magnitude of the Insulin Pricing Scheme and its impact on pricing to patients and payors was never fully revealed. In particular, the Defendants conspired to conceal from payors, including the City of Tacoma, the marked difference between the size

³² Irl B. Hirsch, MD, *Changing Cost of Insulin Therapy in the U.S.* (Mar. 6, 2016), https://web.archive.org/web/20201005020028/https://professional.diabetes.org/files/media/Changing_Cost_Insulin.pdf.

of the Manufacturer Payments obtained by the PBM Defendants when compared to the rebates passed along to the City and other customers, the extent of the resulting pricing overcharges secured by the Manufacturer Defendants, and the vast sums that the PBM Defendants retained as kickbacks.

38. This profound lack of transparency continues to this day. In March 2023, in the face of consumer litigation and mounting public and political pressure, Eli Lilly announced price concessions that were matched shortly thereafter by its competitors. While the price concessions are substantial, the announced price reduction of 70%, capping out of pocket costs at \$35 per month not only demonstrates the magnitude of overcharge previously enforced, it is a significant markup over the \$6 per vial production cost, and does not apply to all insulin products, nor to all insulin purchasers.³³ Indeed, some commentators have claimed that the coordinated price reductions might ultimately lead to even higher profits for manufacturers. In short, these recent concessions merely demonstrate the depth and magnitude of the Insulin Pricing Scheme; the full extent of which is still not fully, publicly known.

39. This action seeks to hold the PBM Defendants and Manufacturer

³³ Dzintars Gotham, Melissa J. Barber, & Andrew Hill, *Production Costs and Potential Prices for Biosimilars of Human Insulin and Insulin Analogues*, BMJ Glob. Health (Sept. 25, 2018), <https://gh.bmj.com/content/bmjgh/3/5/e000850.full.pdf>.

Defendants liable for their exploitation of the pharmaceutical supply chain for their financial benefit. There is simply no reason that prices for the at-issue medications—which costs just a fraction of the price health plans and consumers pay to produce—has skyrocketed other than to increase the profits of the Defendants.

II. PARTIES

A. Plaintiff Tacoma

40. Plaintiff City of Tacoma is a municipal corporation organized under Washington State law. Plaintiff has all the powers of local self-government and all other powers possible for a city to have under the Constitution and the laws of the State of Washington.

41. Tacoma brings this case in its sovereign capacity for the benefit of the State of Washington. This action is brought to promote the public welfare and for the common good of the State of Washington.

42. Plaintiff, as a government entity, provides vital services including public safety, emergency management, and health services to over 220,000 residents.

43. Any increase in spending has a detrimental effect on Plaintiff's overall budget and, in turn, negatively impacts its ability to provide necessary services to the community.

44. The Insulin Pricing Scheme has had such an effect.

45. Additionally, as a government employer, Tacoma maintains self-insured health plans and provides health benefits to its over 10,000 employees and their dependents (“Beneficiaries”). One benefit the City offers its Beneficiaries is paying a substantial share of the purchase price of their pharmaceutical drugs, including the at-issue diabetes medications, as further defined below.

46. Insulin drugs, including those manufactured by the Manufacturer Defendants, are a significant prescription expense for the City. As prices continued to rise over the past several years, Plaintiff spent substantial public monies on overcharges to the detriment of its Beneficiaries and the residents of Tacoma.

47. Plaintiff seeks relief for the harm suffered as a result of Defendants’ misrepresentations and omissions regarding their illegal Insulin Pricing Scheme.

B. Manufacturer Defendants

48. As set forth above, Defendants Eli Lilly, Novo Nordisk, and Sanofi are all manufacturers of insulins, analog insulins, and other diabetes medications.

1. Eli Lilly

49. Defendant Eli Lilly and Company (“Eli Lilly”) is an Indiana corporation with its principal place of business in Indianapolis, Indiana.

50. Eli Lilly manufactures, promotes, and distributes several at-issue diabetes medications in Washington, including: Humulin N (first approved in

1982), Humulin R (first U.S. approval in 1982), Humalog (first approved in 1996), Trulicity (first approved in 2014), and Basaglar (first approved in 2015).

51. Eli Lilly transacts business in Washington, including in Tacoma, by targeting the local market with its products, including the at-issue diabetes medications. From 2019 to 2021, Eli Lilly's domestic revenues were \$11.9 billion from Trulicity, \$4.48 billion from Humalog, \$2.58 billion from Humulin, and \$2.31 billion from Basaglar.

52. Eli Lilly also directs advertising and informational materials to Washington and Tacoma physicians and potential users of Eli Lilly's products, and employs sales representatives throughout Washington to promote and sell its diabetes medications.

53. At all relevant times, in furtherance of the Insulin Pricing Scheme, Eli Lilly caused the publication of prices for the at-issue diabetes medications throughout Washington with the express knowledge that payment by Plaintiff would be based on those false list prices.

54. During the relevant period, Plaintiff purchased Eli Lilly's at-issue drugs through its employee health plans at prices based on false list prices generated by the Insulin Pricing Scheme.

2. Sanofi-Aventis

55. Defendant Sanofi-Aventis U.S. LLC ("Sanofi") is a Delaware limited

liability company with its principal place of business in Bridgewater, New Jersey.

56. Sanofi manufactures, promotes, and distributes pharmaceutical drugs in Washington, including several at-issue diabetes medications: Lantus (first approved in 2000), Apidra (first approved in April 2004), Toujeo (first approved in 2015), and Soliqua (first approved in 2016).

57. Sanofi transacts business in Washington, including in Tacoma, by targeting the local market with its products, including the at-issue diabetes medications. In 2019, Sanofi's U.S. net sales were \$1.29 billion from Lantus, \$323.7 million from Toujeo, and \$51.5 million from Apidra.

58. Sanofi directs advertising and informational materials to Washington physicians and potential users of Sanofi's products for the specific purpose of selling the at-issue drugs in Washington, including Tacoma, and profiting from the Insulin Pricing Scheme.

59. At all relevant times, in furtherance of the Insulin Pricing Scheme, Sanofi caused the publication of prices of its at-issue diabetes medications in Washington for the purpose of payment by payors, including Plaintiff Tacoma.

60. During the relevant period, Plaintiff purchased Sanofi's at-issue drugs through its employee health plans at prices based on false list prices generated by the Insulin Pricing Scheme.

3. Novo Nordisk

61. Defendant Novo Nordisk Inc. (“Novo Nordisk”) is a Delaware corporation with its principal place of business in Plainsboro, New Jersey.

62. Novo Nordisk manufactures, promotes, and distributes pharmaceutical drugs in Washington, including at-issue diabetes medications: Novolin R (first approved in 1991), Novolin N (first approved in 1991), Novolog (first approved in 2002), Levemir (first approved in 2005), Victoza (first approved in 2010), Tresiba (first approved in 2015), and Ozempic (first approved in 2017). Nordisk’s combined net sales of these drugs in the U.S. from 2018 to 2020 totaled approximately \$18.1 billion.

63. Novo Nordisk transacts business in Washington and in Tacoma, by targeting the local market with its products, including the at-issue diabetes medications. In 2015, Novo Nordisk’s revenue from Novolog was \$3.03 billion, and its revenue from Levemir was \$2.68 billion.

64. Novo Nordisk directs advertising and informational materials to Washington and Tacoma physicians and potential users of Novo Nordisk’s products.

65. At all relevant times, in furtherance of the Insulin Pricing Scheme, Novo Nordisk caused the publication of prices of its at-issue diabetes medications in Washington for the purpose of payment by Plaintiff.

66. During the relevant period, Plaintiff purchased Novo Nordisk's at-issue drugs through its employee health plans at prices based on false list prices generated by the Insulin Pricing Scheme.

C. PBM Defendants

1. Express Scripts and Ascent Health Services LLC

67. Collectively, Defendants Evernorth Health, Inc., Express Scripts, Inc., Express Scripts Administrators, LLC, Express Scripts Pharmacy, Inc., Medco Health Solutions, Inc., and The Cigna Group, including all predecessor and successor entities, are referred to as "Express Scripts."

68. Defendant Evernorth Health, Inc. ("Evernorth"), formerly known as Express Scripts Holding Company, is a Delaware corporation with its principal place of business in St. Louis, Missouri. Evernorth Health, Inc. is a wholly owned subsidiary of The Cigna Group. Evernorth, through its executives and employees, including its CEO and Vice Presidents, is directly involved in shaping the company policies that inform its PBM services and formulary construction, including with respect to the at-issue drugs, related to the Insulin Pricing Scheme. Evernorth is the immediate or indirect parent of pharmacy and PBM subsidiaries operating in Washington, who engaged in the activities giving rise to this action.

69. Defendant Express Scripts, Inc. is a Delaware corporation and is a wholly owned subsidiary of Defendant Evernorth. Express Scripts, Inc.'s principal

place of business is at the same location as Evernorth. Express Scripts, Inc. holds one or more pharmacy licenses in Washington. Express Scripts, Inc. is the immediate or indirect parent of pharmacy and PBM subsidiaries that operate throughout Washington that engaged in the conduct, which gave rise to this action.

70. Defendant Express Scripts Administrators, LLC, doing business as Express Scripts and formerly known as Medco Health, LLC, is a Delaware limited liability company and is a wholly owned subsidiary of Evernorth. Its principal place of business is in Franklin Lakes, New Jersey. During the relevant period, Express Scripts Administrators, LLC provided the PBM services to Tacoma, such as offering formularies that included the diabetes medications at issue here. Express Scripts Administrators, Inc. participated in pricing these drugs based off the list prices it knew to be false and thereby implemented the Insulin Pricing Scheme that damaged payors, including Plaintiff.

71. Defendant Express Scripts Pharmacy, Inc. is a Delaware corporation and is a wholly owned subsidiary of Defendant Evernorth. Express Scripts Pharmacy, Inc.'s principal place of business is at the same location as Evernorth. During the relevant period, Express Scripts Pharmacy, Inc. provided mail-order pharmacy services in Washington that gave rise to and implemented the Insulin Pricing Scheme, which damaged payors such as Tacoma.

72. Defendant Medco Health Solutions, Inc. is a Delaware corporation

with its principal place of business in Franklin Lakes, New Jersey. Medco Health Solutions, Inc. is a wholly owned subsidiary of The Cigna Group. Prior to 2012, Medco provided the at-issue PBM and mail order pharmacy services in Washington; following its merger with Express Scripts in 2012, Medco continued to provide those services under the Express Scripts name.

73. Defendant The Cigna Group is a Delaware corporation with its principal place of business in Bloomfield, Connecticut. The Cigna Group, through its executives and employees, including its CEO and Vice Presidents, is directly involved in shaping the company policies that inform its PBM services and formulary construction, including with respect to the at-issue drugs, related to the Insulin Pricing Scheme. The Cigna Group is the immediate or indirect parent of pharmacy and PBM subsidiaries operating in Washington, who engaged in the activities giving rise to this action.

74. In 2019, Defendant Express Scripts created its rebate aggregator, Ascent Health Services LLC (“Ascent”). Ascent is a Delaware limited liability company with its principal place of business at Mühlentalstrasse 36, 8200 Schaffhausen, Switzerland.

75. Ascent is part of Evernorth and a subsidiary of Cigna Corporation.

76. Defendant Express Scripts co-owns Ascent and Ascent negotiates and enters into rebate contracts with the Manufacturer Defendants on behalf of

Defendant Express Scripts. Hereinafter, references to actions by Defendant Express Scripts include actions taken by Ascent on behalf of Defendant Express Scripts.

77. During the relevant period, Ascent negotiated rebates with the Manufacturers for the at-issue drugs sold and distributed in Washington.

78. As a result of numerous interlocking directorships and shared executives, Evernorth (f/k/a Express Scripts Holding Company, Inc.) and Express Scripts, Inc. control Express Scripts Administrators, LLC's, ESI Mail Pharmacy Service, Inc.'s, Medco Health Solutions, Inc.'s, and Express Scripts Pharmacy, Inc.'s operations, management, and business decisions related to the at-issue formulary construction, negotiations, and mail-order pharmacy services to the ultimate detriment of Plaintiff. For example:

A. During the relevant period, these entities have had common officers and directors:

i. Officers and/or directors shared between Express Scripts, Inc. and Evernorth include Bradley Phillips, Chief Financial Officer; David Queller, President; Jill Stadelman, Managing Counsel; Dave Anderson, VP of Strategy; Matt Perlberg, President of Pharmacy Businesses; Bill Spehr, SVP of Sales; and Scott Lambert, Treasury Manager Director;

ii. Executives shared between Express Scripts Administrators, LLC and Evernorth include Bradley Phillips, Chief Financial Officer; and Priscilla Duncan, Associate Senior Counsel;

iii. Officers and/or directors shared between ESI Mail Pharmacy Service, Inc. and Evernorth include Bradley Phillips, Chief Financial Officer; Priscilla Duncan, Associate Senior Counsel; and Joanne Hart, Treasury Director; and

iv. Officers and/or directors shared between Express Scripts Pharmacy, Inc. and Evernorth include Bradley Phillips, Chief Financial Officer; Jill Stadelman, Managing Counsel; Scott Lambert, Treasury Manager Director; and Joanne Hart, Treasury Director.

B. Evernorth directly or indirectly owns all the stock of or otherwise controls Express Scripts Administrators, LLC, Medco Health Solutions, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Express Scripts, Inc., and Ascent.³⁴

C. The Evernorth corporate family does not operate as separate entities. Evernorth's public filings, documents, and statements present its subsidiaries, including Express Scripts Administrators, LLC, ESI Mail

³⁴ Express Scripts Annual Report (Form 10-K, Exhibit 21) (FYE Dec. 31, 2018).

Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Express Scripts, Inc., and Ascent, as divisions or departments of a single company which “includes a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy solutions, benefits management solutions, care delivery and care management solutions and intelligence solutions to deliver custom and flexible solutions that meet the needs of our clients and customers.”³⁵ The day-to-day operations of this corporate family reflect these public statements. All of these entities constitute a single business enterprise and should be treated as such as to all legal obligations detailed in this Complaint.

D. All of the executives of Express Scripts Administrators, LLC, ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Express Scripts, Inc., and Ascent ultimately report to the executives, including the CEO, of Evernorth.

E. As stated above, Evernorth’s CEO and other executives and officers are directly involved in the policies and business decisions of Express Scripts Administrators, LLC, ESI Mail Pharmacy Service, Inc., Medco Health Solutions, Inc., Express Scripts Pharmacy, Inc., Ascent, and Express Scripts, Inc. that gave rise to Plaintiff’s claims in this Complaint.

³⁵ Cigna Corporation Annual Report (Form 10-K) at 2 (FYE Dec. 31, 2021).

79. Defendants Evernorth Health, Inc., Express Scripts, Inc., Express Scripts Administrators, LLC, ESI Mail Pharmacy Service, Inc., Medco Health Solutions, Inc., Express Scripts Pharmacy, Inc., and Ascent, including all predecessor and successor entities, are referred to collectively as “Express Scripts.”

80. Express Scripts is named as a Defendant in its capacities as a PBM, rebate aggregator, and mail-order pharmacy.

81. Express Scripts offered pharmacy benefit services to Washington payors, including through its collaboration with Prime Therapeutics, to Plaintiff, and derived substantial revenue therefrom. In doing so, it made misrepresentations while concealing the Insulin Pricing Scheme and utilized the false prices generated by the Insulin Pricing Scheme.

82. During the relevant period, Express Scripts handled rebate negotiations with the Manufacturer Defendants for the at-issue drugs. In doing so, Express Scripts effectively set the prices that Plaintiff paid for these at-issue drugs based on the false list prices generated by the Insulin Pricing Scheme.

83. At all relevant times, Express Scripts dispensed the at-issue insulin medications to the City’s Beneficiaries through its mail service and participating retail pharmacies and indirectly through partner pharmacies, charged prices based on the false list prices generated by the Insulin Pricing Scheme, and derived substantial revenue from these activities in Washington.

84. In short, Express Scripts played a critical role in the overall Insulin Pricing Scheme and caused Plaintiff harm.

85. Express Scripts also purchased drugs from manufacturers for dispensing through its pharmacy network.

86. In its capacity as a mail service pharmacy and through its participating retail pharmacies, Express Scripts knowingly profited from the false list prices generated through the Insulin Pricing Scheme by pocketing the spread between the acquisition cost for the at-issue drugs (an amount well below the list price published through the Insulin Pricing Scheme), and the amounts it received from payors (amounts based on the false list prices).

87. At all relevant times, Express Scripts had express agreements with Defendants Eli Lilly, Novo Nordisk, and Sanofi related to the payments by the Manufacturer Defendants to Express Scripts, as well as agreements related to the Manufacturers' at-issue drugs sold through Express Script's pharmacies.

2. CVS Caremark and Zinc Health Services, LLC

88. Collectively, Defendants CVS Health Corporation ("CVS Health"), CVS Pharmacy, Inc., Caremark Rx, L.L.C., CaremarkPCS Health, L.L.C., and Caremark, L.L.C., including all predecessor and successor entities, are referred to as "CVS Caremark."

89. Defendant CVS Health is a Delaware corporation with its principal

place of business in Woonsocket, Rhode Island.

90. CVS Health is a pharmacy benefit manager that contracts on behalf of health plans and insurers with the Manufacturer Defendants for purchase of the analog insulin medications that the manufacturers make. CVS Health Corporation provides comprehensive prescription benefit management services to numerous health plans, including corporations, managed care organizations, insurance companies, unions and government entities. CVS Health transacts business and has locations throughout the United States and Washington, including in Tacoma.

91. Defendant CVS Pharmacy, Inc. (“CVS Pharmacy”) is a Rhode Island corporation whose principal place of business is at the same location as CVS Health. It is a citizen of the State of Rhode Island. CVS Pharmacy is a wholly owned subsidiary of CVS Health. During the relevant period, CVS Pharmacy provided retail pharmacy services in Washington that gave rise to and implemented the Insulin Pricing Scheme, which damaged payors, including Plaintiff.

92. Defendant Caremark Rx, LLC is a Delaware limited liability company whose principal place of business is in Rhode Island. Caremark Rx, LLC is a subsidiary of Defendant CVS Pharmacy, which is a wholly owned subsidiary of Defendant CVS Health.

93. Defendant CaremarkPCS Health, L.L.C. is a Delaware limited liability company whose principal place of business is at the same location as CVS

Health. CaremarkPCS Health, L.L.C. is a subsidiary of CaremarkPCS, LLC, which is a subsidiary of Caremark Rx, LLC, which is a subsidiary of Defendant CVS Pharmacy, which is a wholly owned subsidiary of Defendant CVS Health. It is also directly involved in PBM and mail-order pharmacy services giving rise and in furtherance of the Insulin Pricing Scheme.

94. Defendant Caremark LLC is a California limited liability company whose principal place of business is at the same location as CVS Health. Caremark, LLC is a subsidiary of Caremark Rx, LLC, which is a subsidiary of Defendant CVS Pharmacy, which is a wholly owned subsidiary of Defendant CVS Health.

95. Defendant Zinc Health Services, LLC (“Zinc”) is a Delaware limited liability company with its principal place of business at 8300 Norman Center Drive, Suite 850, Bloomington, Minnesota 55437.

96. Zinc is a direct subsidiary of CVS Pharmacy, which is a direct subsidiary of CVS Health.

97. In March 2020, CVS Health established Zinc as a rebate aggregator for CVS Caremark’s PBM business in March 2020. Zinc was founded, at least in part, to negotiate rebates with drug manufacturers for CVS Caremark.

98. Zinc negotiates and enters into rebate contracts with the Manufacturer Defendants on behalf of Defendant CVS Caremark. Hereinafter, references to actions by Defendant CVS Caremark include actions taken by Zinc on behalf of

Defendant CVS Caremark. During the relevant period, Zinc negotiated rebates with the Manufacturers for the at-issue drugs sold and distributed in Washington.

99. Defendants CaremarkPCS Health and Caremark, LLC, and Zinc are agents and/or alter egos of Caremark Rx, LLC, CVS Pharmacy, and CVS Health.

100. Defendants CVS Health, CVS Pharmacy, Caremark Rx, LLC, CaremarkPCS Health, L.L.C., and Caremark, LLC all operate as a single business entity, doing business as CVS Caremark. As a result of their numerous interlocking directorships and shared executives, each entity is directly involved in the conduct and control of CVS Caremark's operations, management, and business decisions related to the at-issue diabetic medications. For example:

A. During the relevant period, these entities had common officers and directors, including:

i. Thomas S. Moffatt, Vice President and Secretary of Caremark Rx, LLC, CaremarkPCS Health, L.L.C., and Caremark, LLC, also served as Vice President, Assistant Secretary, and Senior Legal Counsel at CVS Health and as Vice President, Secretary and Senior Legal Counsel of CVS Pharmacy;

ii. Melanie K. Luker, Assistant Secretary of Caremark Rx, LLC, CaremarkPCS Health, L.L.C., and Caremark, LLC, also served as Manager of Corporate Services at CVS Health;

iii. Carol A. Denale, Senior Vice President and Treasurer of Caremark Rx, LLC, also served as Senior Vice President, Treasurer, and Chief Risk Officer at CVS Health;

iv. John M. Conroy was VP of Finance at CVS Health in 2011 and President and Treasurer of Caremark, LLC and CaremarkPCS Health, L.L.C. in 2019; and

v. Sheelagh Beaulieu served as Senior Director of Income Tax at CVS Health while also acting as the Assistant Treasurer at CaremarkPCS Health, L.L.C. and Caremark, LLC.

B. CVS Health owns all the stock of CVS Pharmacy, which owns all the stock of Caremark Rx, LLC, which owns all the stock of Caremark LLC. CVS Health directly or indirectly owns CaremarkPCS Health, L.L.C. in its entirety.

C. CVS Health, as a corporate family, does not operate as separate entities. Its public filings, documents, and statements present its subsidiaries—including CVS Pharmacy, Caremark Rx, LLC, Caremark, LLC, and CaremarkPCS Health, L.L.C. as divisions or departments of one unified “diversified health services company” that “works together across our disciplines” to “create unmatched human connections to transform the health care experience.” CVS Health’s recent public filings also disclose that the

company “operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants,” without identifying Zinc by name.³⁶ The day-to-day operations of this corporate family reflect these public statements. These entities are a single business enterprise and should be treated as such as to all legal obligations discussed in this Complaint.

D. All executives of CaremarkPCS Health, L.L.C., Caremark, LLC, Caremark Rx, LLC, CVS Pharmacy, and Zinc ultimately report to the executives at CVS Health, including its President and CEO.

101. Defendants CVS Health, CVS Pharmacy, Caremark Rx, LLC, Caremark, LLC, Zinc, and CaremarkPCS Health, including all predecessor and successor entities, are referred to collectively as “CVS Caremark.”

102. CVS Caremark offered pharmacy benefit services to Washington payors, and derived substantial revenue therefrom. In doing so, it made misrepresentations while concealing the Insulin Pricing Scheme and utilized the false prices generated by the Insulin Pricing Scheme.

103. At all relevant times, CVS Caremark dispensed the at-issue insulin medications to the City’s Beneficiaries through its retail pharmacies, and indirectly through partner pharmacies, charged prices based on the false list prices generated

³⁶ CVS Health Corp. Form 10-K, FYE Dec. 31, 2020, 2021, 2022, 2023.

by the Insulin Pricing Scheme, and derived substantial revenue from these activities in Washington.

104. In short, CVS Caremark played a critical role in the overall Insulin Pricing Scheme and caused Plaintiff harm.

105. CVS Caremark also purchased drugs from manufacturers for dispensing through its pharmacy network.

106. In its capacity as a retail pharmacy, CVS Caremark knowingly profited from the false list prices generated through the Insulin Pricing Scheme by pocketing the spread between the acquisition cost for the at-issue drugs (an amount well below the list price published through the Insulin Pricing Scheme), and the amounts it received from payors (amounts based on the false list prices).

107. At all relevant times, CVS Caremark had express agreements with Defendants Eli Lilly, Novo Nordisk, and Sanofi related to the payments by the Manufacturer Defendants to CVS Caremark.

3. OptumRx and Emisar Pharma Services LLC

108. Collectively, Defendants UnitedHealth Group, Inc., OptumRx, Inc., and Optum, Inc., including all predecessor and successor entities, are referred to as “OptumRx.”

109. Defendant UnitedHealth Group, Inc. (“UnitedHealth Group”) is a corporation organized under the laws of Delaware with its principal place of

business in Minnetonka, Minnesota. UnitedHealth Group is a diversified managed healthcare company that offers a spectrum of products and services including health insurance plans through its wholly owned subsidiaries and prescription drugs through its PBM, OptumRx. Its total revenues in 2021 exceeded \$287 billion, which was up more than \$30 billion from 2020. The company has been ranked fifth on the Fortune 500 list. UnitedHealth Group's conduct had a direct effect in Washington and damaged Plaintiff.

110. UnitedHealth Group states in its annual reports that UnitedHealth Group “utilizes Optum’s capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively and create a simpler consumer experience.” Its most recent annual report states plainly that UnitedHealth Group is “involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members” As of December 31, 2021, “total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to \$7.2 billion [2021] and \$6.3 billion [2020].”

111. Defendant Optum, Inc. is a Delaware corporation with its principal place of business located in Eden Prairie, Minnesota. Optum, Inc. is a health

services company managing subsidiaries that administer pharmacy benefits, including Defendant OptumRx, Inc. Optum, Inc. is directly involved, through its executives and employees, in the company policies that inform its PBM services and formulary construction, including with respect to the at-issue drugs and related to the Insulin Pricing Scheme, which had a direct effect in Washington and damaged Plaintiff.

112. For example, according to Optum Inc.’s press releases, Optum, Inc. is “UnitedHealth Group’s information and technology-enabled health services business platform serving the broad healthcare marketplace, including care providers, plan sponsors, payors, life sciences companies and consumers.” In this role, Optum, Inc. is directly responsible for the “business units – OptumInsight, OptumHealth and OptumRx” and the CEOs of all these companies report directly to Optum, Inc. regarding their policies, including those that inform the at-issue formulary construction and mail-order activities.

113. Defendant OptumRx, Inc. is a California corporation with its principal place of business in Irvine, California. OptumRx, Inc. operates as a subsidiary of OptumRx Holdings, LLC, which in turn operates as a subsidiary of Defendant Optum, Inc. During the relevant period, OptumRx, Inc. provided PBM and mail order pharmacy services in Washington that gave rise to and implemented the Insulin Pricing Scheme, which damaged Plaintiff. OptumRx is named as a

Defendant in its capacities as a PBM and mail order pharmacy.

114. In June 2021, Defendant OptumRx founded its rebate aggregator, Emisar Pharma Services LLC (“Emisar”). Emisar is a Delaware limited liability company with its principal address at 1 Optum Circle, Eden Prairie, Minnesota 55344, headquarters in Dublin, Ireland, and operations in the United States and Ireland.

115. Emisar is a wholly owned indirect subsidiary of UnitedHealth Group, Inc.

116. Emisar negotiates and enters into rebate contracts with the Manufacturer Defendants on behalf of Defendant OptumRx. Hereinafter, references to actions by Defendant OptumRx include actions taken by Emisar on behalf of Defendant OptumRx.

117. During the relevant period, Emisar negotiated rebates with the Manufacturers for the at-issue drugs sold and distributed in Washington.

118. As a result of numerous interlocking directorships and shared executives, UnitedHealth Group, OptumRx Holdings, LLC, and Optum, Inc are directly involved in the conduct of and control OptumInsight’s and Optum Rx, Inc.’s operations, management, and business decisions related to the at-issue formulary construction, negotiations, and mail-order pharmacy services to the ultimate detriment of Plaintiff. For example:

- A. These entities have common officers and directors, including:
- i. Andrew Witty is the CEO and on the Board of Directors for UnitedHealth Group and previously served as CEO of Optum, Inc.;
 - ii. Dan Schumacher is Chief Strategy and Growth Officer at UnitedHealth Group and is CEO of Optum Insight, having previously served as president of Optum, Inc.;
 - iii. Dirk McMahon is President and COO of UnitedHealth Group. He served as President and COO of Optum from 2017 to 2019 and as CEO of OptumRx from 2011 to 2014.
 - iv. John Rex has been an Executive Vice President and CFO of UnitedHealth Group. since 2016 and previously served in the same roles at Optum beginning in 2012.
 - v. Terry Clark is a senior vice president and has served as chief marketing officer at UnitedHealth Group since 2014 while also serving as chief marketing and customer officer for Optum.
 - vi. Tom Roos has served since 2015 as SVP and chief accounting officer for UnitedHealth Group and Optum, Inc.
 - vii. Heather Cianfrocco joined UnitedHealth Group in 2008 and has held numerous leadership positions within the company while today she is CEO of OptumRx.
 - viii. Peter Gill has served as SVP and Treasurer for UnitedHealth Group and also as Treasurer at OptumRx, Inc.
 - ix. John Santelli led Optum Technology, the leading technology division of Optum, Inc. serving the broad customer base of Optum and UnitedHealthcare and also served as UnitedHealth Group's chief information officer.
 - x. Eric Murphy, now retired, was the Chief Growth and Commercial Officer for Optum, Inc. and also was CEO of OptumInsight beginning in 2017.

B. UnitedHealth Group directly or indirectly owns all the stock of Optum, Inc., OptumRx, Inc., OptumInsight, and Emisar;

C. The UnitedHealth Group corporate family does not operate as separate entities. The public filings, documents, and statements of UnitedHealth Group present its subsidiaries, including Optum, Inc., OptumRx, Inc., and OptumInsight as divisions, departments, or “segments” of a single company that is “a diversified family of businesses” and that “leverages core competencies” to “help[] people live healthier lives and helping make the health system work better for everyone.” The day-to-day operations of this corporate family reflect these public statements. These entities constitute a single business enterprise and should be treated as such as to all legal obligations detailed in this Complaint.³⁷

D. All executives of Optum, Inc., OptumRx, Inc., OptumInsight, and Emisar ultimately report to the executives, including the CEO, of UnitedHealth Group.

E. As stated above, UnitedHealth Group’s executives and officers are directly involved in the policies and business decisions of Optum, Inc., OptumRx, Inc., and OptumInsight, and Emisar that gave rise to Plaintiff’s

³⁷ UnitedHealth Group, Quarterly Report (Form 10-Q) (Mar. 31, 2017).

claims.

119. Defendants UnitedHealth Group, Inc., OptumRx, Inc., OptumInsight, Inc., Optum, Inc., and Emisar, including all predecessor and successor entities, are collectively referred to as “OptumRx.”

120. OptumRx is named as a Defendant in its capacities as a PBM, rebate aggregator, and mail-order pharmacy.

121. OptumRx is a pharmacy benefit manager and, as such, coordinates with Eli Lilly, Novo Nordisk, and Sanofi regarding the price of the at-issue diabetes medications, as well as for the placement of these firms’ diabetes medications on OptumRx’s drug formularies.

122. OptumRx provides pharmacy care services to more than 65 million people in the nation through a network of more than 67,000 retail pharmacies and multiple delivery facilities. It is one of UnitedHealth Group Inc.’s “four reportable segments” (along with UnitedHealthcare, Optum Health, and Optum Insight). In 2021, OptumRx “managed \$112 billion in pharmaceutical spending, including \$45 billion in specialty pharmaceutical spending.”

123. OptumRx, through UnitedHealth, offered pharmacy benefit services to Washington payors, including Plaintiff, and derived substantial revenue therefrom. In doing so, it made misrepresentations while concealing the Insulin Pricing Scheme and utilized the false prices generated by the Insulin Pricing

Scheme.

124. At all relevant times, OptumRx offered PBM services nationwide and maintained standard formularies that were used nationwide, including in Washington. Those formularies included the diabetes medications at issue here, and OptumRx participated in pricing these drugs based off the list prices it knew to be false.

125. During the relevant period, OptumRx dispensed the at-issue medications nationwide through its pharmacies. OptumRx derived substantial revenue from these activities in Washington.

126. In short, OptumRx played a critical role in the overall Insulin Pricing Scheme as a co-conspirator and caused Plaintiff harm.

127. OptumRx purchased drugs directly from manufacturers for dispensing through its pharmacy network.

128. In its capacity as a retail pharmacy, OptumRx further and knowingly profited from the false list prices produced by the Insulin Pricing Scheme by pocketing the spread between acquisition cost for the at-issue drugs (an amount well below the list price generated by the Insulin Pricing Scheme), and the amounts it received from payors (which amounts were based on the false list prices and, in many cases, were set by OptumRx in its capacity as a PBM).

129. At all relevant times, OptumRx provided pharmacy services

nationwide and within the State of Washington and employed prices based on the false list prices generated by the Insulin Pricing Scheme, and dispensed the at-issue medications within the State of Washington through its pharmacies and it derived substantial revenue from these activities in Washington.

III. JURISDICTION AND VENUE

130. Pursuant to this Court’s Case Management Order No. 9 (“CMO 9”), this Complaint is filed as an original action in the United States District Court for the District of New Jersey.

131. But for CMO 9, Plaintiff would have filed this Complaint in the United States District Court for the Western District of Washington (hereinafter, the “Western District of Washington”). In accordance with CMO 9, the “Designated Forum” for this action is the Western District of Washington.

132. The Western District of Washington has subject-matter jurisdiction pursuant to 28 U.S.C. § 1331 and pursuant to 18 U.S.C. § 1964(c) because this action alleges violations of the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1962. The Western District of Washington also has supplemental jurisdiction over the state law claims in this action pursuant to 28 U.S.C. § 1367.

133. The Western District of Washington has personal jurisdiction over Defendants. Each Defendant: (1) transacts business in Washington; (2) maintains substantial contacts in Washington, and (3) committed the violations of federal

statutes, the Washington statute, and the common law at issue in this action, in whole or part within the State of Washington. This action arises out of and relates to each Defendant's contacts with this forum.

134. The Insulin Pricing Scheme has been directed at and has had the foreseeable and intended effect of causing injury to persons residing in, located in, or doing business in Washington, including Plaintiff. All transactions at issue occurred in the State of Washington and involved Washington residents.

135. Each Defendant purposefully availed itself of the privilege of doing business within this state, including within this district and division, and each derived substantial financial gain from doing so. These continuous, systematic, and case-related business contacts—including the tortious acts described herein—are such that each Defendant should reasonably have anticipated being brought into the Western District of Washington.

136. Each Defendant submitted itself to jurisdiction through marketing; encouraging the use of its services, and its purposeful cultivation of profitable relationships in the State of Washington and within this forum.

137. In short, each Defendant has systematically served a market in Washington relating to the Insulin Pricing Scheme and has caused injury in Washington such that there is a strong relationship among Defendants, this forum, and the litigation.

138. The Western District of Washington has personal jurisdiction over all Defendants pursuant to Fed. R. Civ. P. 4(k)(1)(A) because they would be subject to the jurisdiction of a court of general jurisdiction in Washington.

139. The Western District of Washington also has personal jurisdiction over all Defendants under 18 U.S.C. § 1965(b). The Western District of Washington may exercise nationwide jurisdiction over the named Defendants where the “ends of justice” require national service and Plaintiff demonstrates national contacts. The interests of justice require that Plaintiff be allowed to bring all members of the nationwide RICO enterprise before the Western District of Washington in a single action for a single trial.

140. Venue is proper in the Western District of Washington pursuant to 28 U.S.C. § 1391(b) and (c), because each Defendant transacts business in, is found in, and/or has agents in this District, and because a substantial part of the events or omissions giving rise to this action took place, or had their ultimate injurious impact, within the Western District of Washington. In particular, at all times relevant, Defendants provided pharmacy benefit services, mail-order pharmacy services, and retail pharmacies; employed sales representatives; promoted and sold diabetes medications; caused and directed the published prices of the at-issue drugs; and manufactured, distributed, and sold the at-issue drugs in and caused injury to Plaintiff in the Western District of Washington.

141. Venue is proper in the Western District of Washington pursuant to 18 U.S.C. § 1965, because all Defendants reside, are found, have an agent, or transact their affairs in this District, and the ends of justice require that any Defendant residing elsewhere be brought into the Western District of Washington.

IV. FACTUAL ALLEGATIONS

A. Life Saving Insulin Is Not a New Drug.

1. Diabetes Requires Insulin.

142. Diabetes is a condition in which the body does not properly process food for use as energy. The hormone insulin controls the rate at which food is converted to glucose, or sugar. In individuals without diabetes, the pancreas secretes insulin into the bloodstream, where converted glucose is used by the body as energy. People with diabetes are unable to make enough insulin or cannot use it as effectively as necessary, causing glucose to build up in the bloodstream. Consistently high levels of blood glucose pose a number of serious health risks including “heart disease, vision loss, and kidney disease.”³⁸ Diabetes-related complications are the “seventh leading cause of death in the United States.”³⁹ Though treatable, diabetes can be fatal or severely debilitating if left untreated.

143. As of 2019, 37.3 million people in the United States, or 11.3% of the

³⁸ Ctr.’s for Disease Control & Prevention, *supra* n.3.

³⁹ Am. Diabetes Assoc., *supra* n.2.

population, had diabetes—and that number continues to grow.⁴⁰ The most common types of diabetes in the U.S. are type 1, type 2, and gestational diabetes.⁴¹ Individuals with type 1 diabetes are unable to produce insulin at all, as their immune system attacks and destroys the cells in the pancreas that make it.⁴² People with type 2 diabetes—about 95% of cases of diabetes in adults—are able to produce insulin, but unable to use it effectively.⁴³ Regular use of prescription insulin is necessary to treat type 1 and type 2 diabetes to prevent life-threatening health complications.⁴⁴

144. At-issue in this lawsuit are several insulin medications as well as other medications used to treat type 2 diabetes. The following is a table of diabetes medications at issue in this lawsuit:

Insulin Type	Action	Name	Company	FDA Approval	Current/Recent List Price
Human	<i>Rapid-Acting</i>	Humulin R	Eli Lilly	1982	\$178 (vial)
		Humulin R 500	Eli Lilly	1982	\$1784 (vial)

⁴⁰ *National Diabetes Statistics Report*, Ctr.'s for Disease Control & Prevention (May 15, 2024), https://www.cdc.gov/diabetes/php/data-research/?CDC_Aref_Val=https://www.cdc.gov/diabetes/data/statistics-report/index.html.

⁴¹ *What is Diabetes?*, Nat'l Inst. of Diabetes & Digestive & Kidney Diseases (Apr. 2023), <https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes>.

⁴² *Id.*

⁴³ *Type 2 Diabetes: Symptoms and Treatments*, Yale Medicine, <https://www.yalemedicine.org/conditions/type-2-diabetes-symptoms-treatments> (last visited Oct. 17, 2024).

⁴⁴ Valencia Higuera, *Everything You Need to Know About Insulin*, Healthline (Apr. 20, 2023), <http://www.healthline.com/health/type-2-diabetes/insulin>.

		\$689 (pens)			
		Novolin R	Novo Nordisk	1991	\$165 (vial) \$312 (pens)
	<i>Intermediate</i>	Humulin N	Eli Lilly	1982	\$178 (vial) \$566 (pens)
		Humulin 70/30	Eli Lilly	1989	\$178 (vial) \$566 (pens)
		Novolin N	Novo Nordisk	1991	\$165 (vial) \$312 (pens)
		Novolin 70/30	Novo Nordisk	1991	\$165 (vial) \$312 (pens)
Analog	<i>Rapid-Acting</i>	Humalog	Eli Lilly	1996	\$342 (vial) \$636 (pens)
		Novolog	Novo Nordisk	2000	\$347 (vial) \$671 (pens)
		Apidra	Sanofi	2004	\$341 (vial) \$658 (pens)
	<i>Pre-mixed</i>	Humalog 50/50	Eli Lilly	1999	\$93 (vial) \$180 (pens)
		Humalog 75/25	Eli Lilly	1999	\$99 (vial) \$140 (pens)
		Novolog 70/30	Novo Nordisk	2001	\$203 (vial) \$246 (pens)
	<i>Long-Acting</i>	Lantus	Sanofi	2000	\$340 (vial) \$510 (pens)
		Levemir	Novo Nordisk	2005	\$370 (vial) \$555 (pens)
		Basaglar (Kwikpen)	Eli Lilly	2015	\$392 (pens)
		Toujeo (Solostar)	Sanofi	2015	\$466 (pens) \$622 (max pens)
		Tresiba	Novo Nordisk	2015	\$407 (vial) \$610 (pens – 100u) \$732 (pens – 200u)
Type 2 Medications		Trulicity (Dulaglutide)	Eli Lilly	2014	\$1013 (pens)
	GLP-1	Mounjaro (Tirzepatide/GIP)	Eli Lilly	2022	\$1068 (pens)
		Victoza (Liraglutide)	Novo Nordisk	2010	\$813 (2 pens) \$1220 (3 pens)
		Xultophy (insulin degludec/liraglutide)	Novo Nordisk	2016	\$1295 (pens)
		Ozempic (Semaglutide)	Novo Nordisk	2017	\$1022 (pens)

		Rybelsus (semaglutide tablets)	Novo Nordisk	2019	\$1029 (30 day supply)
		Adylxin (lixisenatide)	Sanofi	2016	Discontinued 2023
		Soliqua (insulin glargine/lixisenatide)	Sanofi	2016	\$928 (pens)

2. Discovery and History of Insulin

145. Until 1922, diabetes was considered a death sentence, but that changed with the discovery of insulin in the pancreas of dogs in 1921 by an unknown orthopedic surgeon, Dr. Frederic Banting, and a medical student, Charles Best, at the University of Toronto.⁴⁵ Less than a year later, in 1922, Banting and Best used the hormone to successfully treat human patients.⁴⁶

146. In an act of gratitude and humanitarianism, Banting and Best sold the patent for insulin to the University of Toronto for just one dollar.⁴⁷ “It was the best way, they believed, to ensure that no company would have a monopoly and patients would have affordable access to a safe, effective drug.”⁴⁸

147. In order to facilitate widespread distribution of the medication, the

⁴⁵ *History of Insulin*, Diabetes.co.uk (Jan. 25, 2023), <http://www.diabetes.co.uk/insulin/history-of-insulin.html>.

⁴⁶ *Id.*

⁴⁷ Serena Gordon, *Insulin prices skyrocket, putting many diabetics in a bind*, Chi. Trib. (June 19, 2018, 2:14 AM), <https://www.chicagotribune.com/2016/11/30/insulin-prices-skyrocket-putting-many-diabetics-in-a-bind/>.

⁴⁸ Carolyn Y. Johnson, *Why treating diabetes keeps getting more expensive*, Wash. Post (Oct. 31, 2016), <https://www.washingtonpost.com/news/wonk/wp/2016/10/31/why-insulin-prices-have-kept-rising-for-95-years>.

University of Toronto partnered with drug manufacturers in the United States and abroad, including Eli Lilly & Co., which as early as 1923 was producing enough insulin to supply the entire North American continent. In exchange for this assistance with widespread insulin distribution, however, the University gave up its exclusive control over the patent for insulin to private manufacturers.⁴⁹

148. Nevertheless, the drug was made widely available at a low cost. In fact, the New York Times estimated that, in 1924, many patients received the drug for less than seven cents a week in 2016 dollars.⁵⁰

149. The earliest insulin available to the public was derived from cow and pig hormones and, until the 1980s, this “animal-derived” insulin was the only treatment for diabetes.⁵¹ Although effective, animal-derived insulin created the risk of an allergic reaction in many human patients. That risk was lessened in 1982 when synthetic insulin, or “human insulin,” was developed and marketed by Eli Lilly and other manufacturers, after insulin became the first protein in history to be sequenced and chemically synthesized.⁵² This type of insulin was marketed as

⁴⁹ Gordon, *supra* n.43.

⁵⁰ Hirsch, *supra* n.32.

⁵¹ *Animal Insulin*, Diabetes.co.uk (Apr. 25, 2023), <http://www.diabetes.co.uk/insulin/animal-insulin.html>.

⁵² *History of Insulin*, *supra* n.41.

Humulin R (rapid) and N (NPH, intermediate-acting).⁵³

150. But, even after the development of “human insulin,” doctors found that “there’s no one insulin that’s right for everyone,” and each diabetes patient may react differently to each formulation of the protein.⁵⁴ This recognition gave rise to “analog insulin,” the most recent iteration of insulin available on the market today.

151. Analog insulin is a “genetically modified form of insulin whereby the amino acid sequence is altered to change how the insulin is absorbed, distributed, metabolized and excreted.”⁵⁵

152. Analog insulins are closely related to the human insulin structure and were developed for specific aspects of glycemic control in terms of fast action (prandial insulins) and long action (basal insulins). The first biosynthetic insulin analog was developed by Eli Lilly and Company for clinical use at mealtime (prandial insulin): Humalog (insulin lispro). Humalog is more rapidly absorbed after subcutaneous injection than regular insulin, with an effect just fifteen minutes after injection. Other rapid-acting analogs with similar profiles are Novolog (insulin aspart) and Apidra (insulin glulisine). These are often used in combination

⁵³ Celeste C. Quianzon & Issam Cheikh, MD, *History of insulin*, J. Cmty. Hosp. Intern. Med. Perspect. (July 16, 2012), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714061/>.

⁵⁴ Gordon, *supra* n.43.

⁵⁵ *History of Insulin*, *supra* n.41.

basal-bolus therapy with longer-acting insulins Lantus and Levemir. These rapid-acting and long-acting analog insulins were introduced in the U.S. between 1996 and 2006. They replaced older insulins, such as NPH, that had been developed during the 1940s, and regular insulin (e.g., Lente, Humulin) that was developed in the 1970s and marketed in the early 1980s.

153. When first introduced, analog insulins were affordable, and remained so for many years after. Today, however, Defendants' Insulin Pricing Scheme has resulted in extreme price increases that have put the 100-year-old medicine out of reach for many people in the United States with diabetes.⁵⁶

154. The newer, analog insulins provide important benefits over older "human" insulin for some people with diabetes. As the mother of a diabetic child explained, older types of insulin require diabetics to follow rigid meal schedules that correspond to insulin doses so that they can avoid blood sugar fluctuations.⁵⁷

155. More modern insulins, such as Humalog, which is rapid acting, and Lantus, a long-acting insulin, can help diabetics maintain blood sugar levels and improve their quality of life.⁵⁸ The analog insulins are particularly important for children, who face a higher risk of nocturnal hypoglycemia; there is a known

⁵⁶ Hirsch, *supra* n.32.

⁵⁷ Nicki Nichols, *Why Walmart Insulins Aren't the Answer to High Insulin Prices*, Insulin Nation (Sept. 16, 2016), <http://insulinnation.com/treatment/why-walmart-insulins-arent-the-answer-to-high-insulin-prices/>.

⁵⁸ *See id.*

prevalence of dead-in-bed syndrome among children and young adults with type 1 diabetes.⁵⁹

156. The prices of the at-issue insulin drugs have gone through the roof since they have been on the market.

3. The Unavailability of Generic Insulin.

157. While generic forms of many drugs are available to purchase for as little as a few dollars, in the United States there is no true generic form of insulin. Even though insulin was first extracted nearly 100 years ago, only three major pharmaceutical companies hold patents in the United States that allow them to manufacture insulin.⁶⁰ Part of the reason that no generic insulin is available in the United States may be that large-molecule biologic drugs, such as insulin, are more difficult to copy than small-molecule drugs.⁶¹ But insulin manufacturers also have incrementally changed their insulin products, and “the trailing edge of old insulin products did not generate a market for generic competition but rather became a set of obsolete products that were promptly removed from the U.S. market.”⁶² Even

⁵⁹ A.M. Secrest et al., *Characterizing sudden death and dead-in-bed syndrome in Type 1 diabetes*, 28 *Diabetes Med.* 7, 293-300 (Mar. 2011), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045678/>.

⁶⁰ See Lipska, *supra* n.31.

⁶¹ Jeremy A. Greene & Kevin R. Riggs, *Why Is There No Generic Insulin? Historical Origins of a Modern Problem*, 372 *N. Eng. J. Med.* 1171, 1172–73 (2015), <https://www.nejm.org/doi/full/10.1056/NEJMms1411398>.

⁶² *Id.* at 1174.

when practitioners prescribe cheaper versions of insulin that still are available in the United States, the prescriptions instead are filled with newer recombinant products.⁶³

158. In 2019, Eli Lilly introduced a lower-priced insulin called Lispro—a “generic” version of their Humalog insulin.⁶⁴ But Eli Lilly has not lived up to its promise to make insulin more affordable for Americans. In 2023, a study conducted by the offices of Senators Elizabeth Warren, Richard Blumenthal, and Raphael Warnock found that “[w]hile Eli Lilly’s list price for [Lispro] was \$25, the average cost of Lispro at the pharmacy—without health insurance coverage—was \$97.51,” with the most expensive pharmacy in the study pricing Lispro at \$330.⁶⁵

B. The Insulin Market Is Enormous.


159. More than 34 million Americans live with diabetes, and another 88 million Americans have prediabetes, a health condition that significantly increases a person’s risk of type 2 diabetes. Diabetes is a significant source of health care

⁶³ *Id.*

⁶⁴ *Lilly to Introduce Lower-Priced Insulin*, Lilly: Invs. (Mar. 4, 2019), <https://investor.lilly.com/news-releases/news-release-details/lilly-introduce-lower-priced-insulin>.

⁶⁵ Kelsey Waddill, *Generic Insulin Drug Pricing, Access Still Pose Problems for Uninsured*, HealthPayerIntelligence (July 17, 2023), <https://healthpayerintelligence.com/news/generic-insulin-drug-pricing-access-still-pose-problems-for-uninsured>.

costs. One in four health care dollars nationwide—and one in three Medicare dollars—is spent caring for people with diabetes.⁶⁶



160. Thus, millions of purchasers of insulin whose lives depend on the drug

⁶⁶ *New American Diabetes Association Report Finds Annual Costs of Diabetes to be \$412.9 Billion*, Am. Diabetes Assoc. (Nov. 1, 2023), <https://diabetes.org/newsroom/press-releases/new-american-diabetes-association-report-finds-annual-costs-diabetes-be>; Adam Edelstein, *Affordable Insulin Now Act Includes a Monthly Out-Of-Pocket Patient Maximum of \$35 for Insulin Prescriptions*, UMass Diabetes Ctr. of Excellence, <https://www.umassmed.edu/dcoe/news/umass-diabetes-news/2022/02/affordable-insulin-now-act> (last visited Oct. 15, 2024).

are captive to the market manipulation and other harmful aspects of Defendants' Insulin Pricing Scheme that has unlawfully hiked the price of this needed drug.

161. This conduct occurred throughout the United States and its territories and concerned the at-issue drugs listed above.

162. As evidence of the astronomical prices of the at-issue drugs, revenue from these top selling analog insulins tops \$15.9 billion: \$6.98 billion for Sanofi's Lantus and \$376 million for its Apidra;⁶⁷ \$3.03 billion for Novo Nordisk's NovoLog and \$2.68 billion for its Levemir;⁶⁸ and \$2.84 billion for Eli Lilly's Humalog).⁶⁹ By 2029, the global insulin market is expected to top \$90 billion.⁷⁰ The high cost of this needed drug has severely limited access and hurt patients physically, financially, and psychologically.

C. The Pharmaceutical Supply and Payment Chains

163. Just as only three large companies—Eli Lilly, Novo Nordisk, and Sanofi— manufacture insulin for the entire United States market, there are three large pharmacy benefit managers that control the vast majority of the PBM market. PBM Defendants CVS Caremark, Express Scripts, and OptumRx control nearly

⁶⁷ Sanofi, Annual Report (Form 20-F) (Mar. 3, 2017) at 24.

⁶⁸ *The world's top selling diabetes drugs*, Pharm. Tech. (Mar. 30, 2016), <http://www.pharmaceutical-technology.com/features/featurethe-worlds-top-selling-diabetes-drugs-4852441/>.

⁶⁹ *Id.*

⁷⁰ *Global Insulin Market \$90 Billion by 2029*, ihealthcare (Sept. 4, 2023), <https://www.ihealthcareanalyst.com/global-human-insulin-market/>.

80% of the PBM market and exercise enormous control over the cost of insulin in tandem with the Manufacturer Defendants.

164. Pharmaceutical products originate in manufacturing sites; are transferred to wholesale distributors (in the case of insulin); are stocked at retail, mail-order, and other types of pharmacies; are subject to price negotiations and processed through quality and utilization management screens by pharmacy benefit managers; are dispensed by pharmacies; and ultimately are delivered to and taken by patients.⁷¹

165. The technical function of a pharmacy benefit manager is to administer a health coverage provider's prescription drug program. A pharmacy benefit manager develops the coverage provider's drug formulary (the list of drugs included in coverage at various pricing "tiers"), processes claims, creates a network of retail pharmacies that provide discounts in exchange for access to a provider's plan participants, and negotiates with pharmaceutical manufacturers. Often, pharmacy benefit managers are also responsible for performing drug utilization reviews. Pharmacy benefit managers also contract with a network of retail and community pharmacies. Pharmacies agree to dispense prescription drugs to covered patients. The contract provides for a payment rate for each prescription,


⁷¹ *Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain*, Health Strategies Consultancy LLC (Mar. 2005), <https://www.kff.org/other/report/follow-the-pill-understanding-the-u-s/>.

plus a dispensing fee. Pharmacies are also responsible for collecting patient cost-sharing payments. Many pharmacy benefit managers also own mail-order and specialty pharmacies, which directly supply prescription drugs to patients.

166. In addition, and of particular significance here, pharmacy benefit managers have contractual relationships with pharmaceutical manufacturers. Pharmacy benefit managers negotiate rebates, fees, and other concessions with the manufacturers. These relationships allow pharmacy benefit managers to exert tremendous influence and control over what drugs are made available to health plans and insureds.

167. The following figure illustrates the flow of funds, products, and services between pharmaceutical manufacturers, pharmacy benefit managers, health plans, health plan sponsors, drug wholesalers, pharmacies, and beneficiaries. Importantly, this figure does not include all relevant relationships and entities, nor does this figure capture the vertical integration that occurs between and amongst some of these entities.

Conceptual Model of the Flow of Products, Services, and Funds for Non-Specialty Drugs Covered under Private Insurance and Purchased in a Retail Setting⁷²



168. At a high level, the complex supply chain for the flow of brand name drugs, including the at-issue insulin drugs, generally works as follows: (1) the manufacturer sells a drug to a wholesaler at a discounted rate; (2) the wholesaler marks up the drug and sells it to the pharmacy; (3) the pharmacy fills the prescription for a beneficiary; and (4) the pharmacy benefit manager reimburses the pharmacy for the drug resulting in a meager amount of profit (if not at a loss) for the pharmacy.

169. The core of this case centers, however, not on the flow of brand-name drugs through the system, but on the flow of funds and services between health

⁷² Neeraj Sood et al., *Flow of Money Through the Pharmaceutical Distribution System*, USC Schaeffer Ctr. for Health Pol’y & Econ. (June 6, 2017), <https://healthpolicy.usc.edu/research/flow-of-money-through-the-pharmaceutical-distribution-system/>.

plan payors, such as Plaintiff, the pharmacy benefit managers, and the pharmaceutical manufacturers. Here, the complex chain generally works as follows: (1) the pharmacy benefit managers negotiate with the drug manufacturers to receive discounts from list prices, rebates, and other fees in exchange for preferred placement on their plan formularies; (2) the pharmacy benefit managers manage the drug benefits for the health plan payors, such as Plaintiff; (3) the health plan payors pay their pharmacy benefit managers for the prescription drugs purchased by their beneficiaries; and (4) the health plan payors, such as Plaintiff, receive an unknown portion of the rebate amount negotiated between the pharmacy benefit managers and manufacturers from their pharmacy benefit managers.

1. The Rise of PBMs in the Pharmaceutical Supply Chain

170. When they first came into existence in the late 1960s, pharmacy benefit managers provided administrative services to health plans by processing claims and maintaining formularies. Over time, they began to play a larger role, including negotiating prices with drug manufacturers. Since pharmacy benefit managers were independent, they generally were thought to pass savings back to health plans and consumers by using their leverage to negotiate lower reimbursement rates with pharmacies and discounts with drug manufacturers.⁷³

⁷³ Brian Feldman, *Big pharmacies are dismantling the industry that keeps US drug costs even sort-of under control*, Quartz (Mar. 17, 2016),

171. In the 1990s, drug manufacturers began acquiring pharmacy benefit managers, which caused an “egregious conflict[] of interest,” prompting the Federal Trade Commission to undo those deals. The deals allowed drug manufacturers to coordinate pricing policies, see their competitors’ sensitive pricing information, and favor their own drugs over those of their competitors.⁷⁴

172. In the early and late 2000s, pharmacy benefit managers started buying pharmacies, which has caused a similar conflict of interest that resulted from the merger of drug manufacturers and pharmacy benefit managers in the 1990s. When a pharmacy benefit manager combines with a pharmacy, they “lose the incentive to police against pharmaceutical company schemes to steer patients to more expensive drugs. Indeed, they may collude in them.”⁷⁵ The power of the largest pharmacy benefit managers has continued to grow, allowing them to distort the pharmaceutical supply chain to their own financial advantage.

2. The Current Size and Role of PBMs in the Pharmaceutical Supply Chain

173. According to the Pharmaceutical Care Management Association, the trade group that represents the PBM industry, pharmacy benefit managers manage

<https://qz.com/636823/big-pharmacies-are-dismantling-the-industry-that-keeps-us-drug-costs-even-sort-of-under-control/>.

⁷⁴ *Id.*

⁷⁵ *Id.*

pharmacy benefits for over 275 million Americans.⁷⁶ Three large companies dominate the PBM market: Express Scripts, CVS Health, and OptumRx.

174. These PBM Defendants provide services to plans that administer prescription drug benefits to more than 275 million Americans and process more than 3 billion claims per year, and the PBM Defendants earn an enormous amount of revenue from the services described above.

175. Express Scripts is the largest PBM in the United States.⁷⁷ In 2022, annual revenue for Express Scripts' parent, Cigna Corp., was approximately \$180.5 billion.⁷⁸ As of December 31, 2022, more than 67,000 retail pharmacies participated in one or more of Express Scripts' networks.⁷⁹

176. Insulin is a substantial part of Express Scripts' business. Indeed, Express Scripts reported that diabetes was the second highest therapeutic class of drugs in terms of spending in both 2021 and 2022.⁸⁰

⁷⁶ *About PCMA*, Pharm. Care Mgmt. Ass'n, <https://www.pcmanet.org/about> (last visited Oct. 15, 2024).

⁷⁷ Anne Steele, *Express Scripts Revenue Falls*, Wall St. J. (Feb. 14, 2017), <https://www.wsj.com/articles/express-scripts-revenue-falls-1487108990>.

⁷⁸ The Cigna Group Annual Report, *supra* n.28.

⁷⁹ *Id.*

⁸⁰ *Express Scripts Canada, 2023 Drug Trend Report*, <https://www.express-scripts.ca/sites/default/files/2023-04/ESC%20DTR%20EN%20April%205%202023%20final.pdf> (last visited Oct. 15, 2024).

177. In 2022, Defendant CVS Health Corporation’s (“CVS Health”) annual revenue was approximately \$322.5 billion.⁸¹ Its pharmacy services segment, which includes the corporation’s PBM activities but not its retail/long-term care segment, brought in \$169.2 billion in net revenues in 2022.⁸² And CVS Health’s health services business, which includes its PBM CVS Caremark, saw revenue of \$90.8 billion for the first half of 2023 alone, up 8.9% with the same period in 2022.⁸³

178. CVS Health, through its subsidiary PBM, provides pharmacy benefit administration for a network of more than 66,000 retail pharmacies, including approximately 40,000 chain pharmacies and 26,000 independent pharmacies.⁸⁴ CVS Health’s PBM filled or managed approximately 2.3 billion prescriptions during the year ending on December 31, 2022.⁸⁵

179. The third largest PBM, OptumRx, is owned by UnitedHealth and provides pharmacy care services through a network of more than 67,000 retail pharmacies and multiple delivery facilities. In 2022, UnitedHealth Group’s total

⁸¹ CVS Health Corp., Annual Report (Form 10-K) (Feb. 8, 2023) at 8.

⁸² *Id.*

⁸³ Denise Myshko, *CVS’s Health Services Business Grows 9% in First Half of 2023*, Formulary Watch (Aug. 3, 2023), <https://www.formularywatch.com/view/cvs-s-health-services-business-grows-9-first-half-of-2023>.

⁸⁴ *Id.*


⁸⁵ *Id.*

revenue was \$324.2 billion.⁸⁶ In 2022, total revenue for OptumRx alone was \$99.8 billion.⁸⁷

180. In 2022, OptumRx managed more than \$124 billion in pharmaceutical spending,⁸⁸ and fulfilled 1.438 billion adjusted scripts.⁸⁹

181. As described above, the PBM Defendants also control the market nationally. In particular, as recently as 2021, PBM Defendants make up nearly 80% of the market in terms of total prescription claims managed.⁹⁰

PBM Market Share, By Total Equivalent Prescription Claims Managed, 2021



182. The PBM Defendants' total earnings come directly from the pockets of payors, including municipal corporation payors such as the City of Tacoma,

⁸⁶ UnitedHealth Group, Annual Report (Form 10-K) (Feb. 24, 2023) at 1.

⁸⁷ *Id.*

⁸⁸ *Id.*

⁸⁹ *Id.*

⁹⁰ Adam J. Fein, *The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger*, Drug Channels (Apr. 5, 2022), <https://www.drugchannels.net/2022/04/the-top-pharmacy-benefit-managers-of.html>.

which cover the ever-increasing costs of insulin for their Beneficiaries.

183. Due to the PBM Defendants' market share, smaller pharmacy benefit managers and other health insurers have significantly less bargaining power with drug manufacturers.

184. Recognizing this disadvantage, smaller pharmacy benefit managers have partnered with the major PBM Defendants, delegating responsibility for rebate negotiations with drug manufacturers to the major PBM Defendants.

185. On December 19, 2019, Express Scripts entered into a three-year collaboration agreement with Prime Therapeutics LLC ("Prime Therapeutics"), Plaintiff's PBM, under which Express Scripts would provide Prime Therapeutics services related to pharmaceutical manufacturer contracts. This agreement was renewed as of July 5, 2023. Under this agreement, Express Scripts handles negotiations for pharmacy benefit drugs, including the at-issue drugs, with the Manufacturer Defendants and retail pharmacy network contracting for most of Prime Therapeutics' business.

186. Due to the collaboration with Prime Therapeutics, Express Scripts now provides pharmacy benefit services to an additional 28 million individuals. As a result, Express Scripts has gained substantial additional bargaining leverage in the marketplace.

187. Earlier in 2019, prior to entering into a collaboration agreement with

Prime Therapeutics, Express Scripts formed Ascent, a group purchasing organization. Express Scripts later invited Prime Therapeutics into Ascent's ownership. Under Express Scripts and Prime Therapeutic's collaboration, rebate negotiations with manufacturers for a number of pharmacy benefit drugs were to be handled by Ascent.

188. The partnership between Express Scripts and Prime Therapeutics has come under scrutiny. The 2021 Grassley-Wyden Senate Report on the rising cost of insulin wrote that "it is noteworthy that industry observers have suggested that the recent partnership between Express Scripts and Prime Therapeutics may serve as a vehicle to avoid increasing legislative and regulatory scrutiny related to administrative fees by channeling such fees through a Swiss-based group purchasing organization (GPO), Ascent."⁹¹

189. Although Prime Therapeutics and Express Scripts touted their new partnership as a means to deliver "more affordable health care," in reality, their partnership has enabled both Express Scripts and Prime Therapeutics to profit off of increased rebates that are not passed on to the consumer, while further escalating the already artificially high cost of insulin.

⁹¹ U.S. S. Fin. Comm., *supra* n.9.

3. The Close Relationship Between the PBM Defendants and Manufacturer Defendants

190. The Insulin Pricing Scheme relies on close negotiations and communications between the PBM Defendants and Manufacturer Defendants. The pharmaceutical industry, being especially insular in nature, has provided both the Manufacturer Defendants and the PBM Defendants opportunities for contact and communication with their direct competitors, in addition to negotiations and communications between the PBM and Manufacturer Defendants.

191. All Manufacturer Defendants are members of the Pharmaceutical Research and Manufacturers of America (“PhRMA”). Each Manufacturer Defendant routinely interacts and communicates with the other Manufacturer Defendants through PhRMA meetings and platforms. David Ricks, CEO of Eli Lilly, Paul Hudson, CEO of Sanofi, and Douglas Langa, President of Novo Nordisk, all serve on the PhRMA Board of Directors.

192. All PBM Defendants are members of the Pharmaceutical Care Management Association (“PCMA”).

193. David Joyner, Executive Vice President of CVS Health and President of CVS Caremark, Patrick Conway, CEO of OptumRx, Adam Kautzner, President of Express Scripts, and Mostafa Kamal, President and CEO of Prime Therapeutics, all serve on the PCMA Board of Directors.

194. The PBM Defendants regularly interact with the Manufacturer Defendants at trade associations and conferences. For example, the PCMA Annual Meeting’s website states that the conference is “tailored specifically for senior executives from PBMs and their affiliated business partners – most notable drug manufacturers.”⁹² These conferences provide prime opportunities for PBM members and drug manufacturers to interact. Indeed, these conferences specifically advertise the opportunities for members to have conversations in “Private Meeting Rooms.”⁹³

195. Not only are the Manufacturer Defendants attendees at the PCMA conferences, but they are also sponsors. Novo Nordisk is listed as a 2023 Partner Sponsor for the PCMA Annual Meeting, Eli Lilly is listed as an Executive Sponsor, and Sanofi is listed as a Presidential Sponsor.⁹⁴

196. Through these conferences and other communications, the PBM Defendants and the Manufacturer Defendants are free to secretly discuss rebates, administrative fee arrangements, and the like, to artificially inflate the price of insulin, while pocketing substantial sums of money.

⁹² PCMA Ann’l Meeting 2021, <https://web.archive.org/web/20230930190841/https://www.pcmanet.org/events/past-events/pcma-annual-meeting-2021/> (last visited Oct. 15, 2024).

⁹³ *Id.*

⁹⁴ *Sponsors*, PCMA Ann’l Meeting 2023, <https://web.archive.org/web/20230926120140/https://www.pcmanet.org/pcma-event/annual-meeting-2023/> (last visited Oct. 15, 2024).

197. Notably, at-issue lockstep price increases for insulin occurred shortly following PCMA meetings. For example, on May 30, 2014, a few weeks following a Spring 2014 PCMA conference, Novo Nordisk raised the list price of Levemir mere hours after Sanofi increased the list price of Lantus.

198. On September 26 and 27, 2017, the PCMA held its annual meeting. On October 1, 2017, Sanofi increased the list price of Lantus by 3% and the list price of Toujeo by 5.4%. Also, shortly after the PCMA meeting, Novo Nordisk recommended a 4% increase in the list price of their insulin drugs, effective January 1, 2018.

199. Given the enormous size of the PBM Defendants and their omnipresent role in the pharmaceutical supply chain, it is crucial that the PBM Defendants avoid conflicts of interest and deal fairly with customers, a fact expressly recognized by Defendants Express Scripts, UnitedHealth Group, and CVS Health.

200. Defendant Express Scripts has a published Code of Conduct, which emphasizes the importance in avoiding conflicts of interest.⁹⁵

201. UnitedHealth Group, which owns PBM Defendant OptumRx, has a published Code of Conduct that stresses the importance of fair dealing, stating that

⁹⁵ *Code of Conduct*, Express Scripts, <https://www.express-scripts.com/aboutus/codeconduct/ExpressScriptsCodeOfConduct.pdf> (last visited Oct. 15, 2024).

“each employee, director and contractor must deal fairly with the Company’s customers, service providers, suppliers, competitors, and employees.”⁹⁶ The Code of Conduct further states that, “[n]o employee or director should take unfair advantage of anyone through unfair-dealing practices.”⁹⁷

202. Defendant CVS Health also has a published Code of Conduct, which emphasizes the importance of fair dealing.⁹⁸ CVS Health’s Code of Conduct states that it “will deal fairly with our customers, members, providers, clients, suppliers, regulators, shareholders and others around the world with whom we do business.”⁹⁹ The Code of Conduct further states that CVS Health “refuse[s] to participate in any conduct or sales or other practice that is intended to mislead, manipulate or take unfair advantage of anyone, or misrepresent products, services, contract terms or policies to anyone.”¹⁰⁰

D. The Insulin Pricing Scheme

203. The Insulin Pricing Scheme describes the coordinated unfair and deceptive conduct of the three largest PBMs (CVS Health, Express Scripts, and

⁹⁶ *Code of Conduct: Our Principles of Ethics and Integrity*, UnitedHealth Group (2018), https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/resources/FWA_CoCs_2018.pdf.

⁹⁷ *Id.*

⁹⁸ *Code of Conduct*, CVS Health (March 2024), <https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/cvs-health-code-of-conduct.pdf>.

⁹⁹ *Id.*

¹⁰⁰ *Id.*

OptumRx) and the three largest insulin manufactures (Eli Lilly, Novo Nordisk, and Sanofi) to artificially inflate the cost of insulin, analog insulins, and related diabetes medications. As a result of the Insulin Pricing Scheme, the PBM Defendants, in exchange for placing the Manufacturer Defendants' drugs in premium placements on their formulary lists, receive higher rebates along with other payments from the Manufacturer Defendants. The PBM and Manufacturer Defendants conspired to prevent disclosures of the drugs' net prices to payors and consumers, including Plaintiff, leading to outsize profits for Defendants because of the inflated list prices resulting from the Insulin Pricing Scheme.

204. The Insulin Pricing Scheme is evidenced by the astronomic increase in the price of insulin, the Manufacturer Defendants' lockstep increases in insulin prices, the growing gap between the list price of insulin and the net price realized by the Manufacturer Defendants, and the massive profits the PBM Defendants receive as a result of the negotiated drug rebates and fees paid to them by the Manufacturer Defendants in exchange for favorable formulary placement.

205. As a direct and proximate cause of Defendants' Insulin Pricing Scheme, payors like the City of Tacoma are overpaying for life-saving medications.

1. Insulin's Price Has Risen Dramatically.

206. The prices of the at-issue drugs have increased dramatically. For example, since 2003, the list price of certain insulins has increased by more than

500%—an astounding increase, especially when compared to a general inflation rate of 8.3% and a “medical inflation [rate] of 46% in this same time period.”¹⁰¹

207. According to a report by Business Insider, similar price increases can be identified across insulin products and across manufacturers: a version of insulin that carried a list price of \$93 a vial in 2009 was priced at close to \$275 in September 2019. Another type of insulin that cost only \$93 in 2009 cost nearly \$290 a vial in September 2019.¹⁰² The prices of insulin have increased especially sharply in the past two decades. According to a report published by the American Journal of Managed Care, in 1996, the price an individual would need to pay for a vial of insulin made by one manufacturer was \$21.¹⁰³ In 2001, this same vial cost an individual \$35, and in 2019, that vial cost approximately \$275—a 1200% increase from its original price.¹⁰⁴

208. Since 2004, analog insulin from the Manufacturer Defendants have more than quadrupled in price, as shown below:¹⁰⁵


¹⁰¹ Hirsch, *supra* n.32.

¹⁰² Rachel Gillett & Shayanne Gal, *One chart reveals how the cost of insulin has skyrocketed in the US, even though nothing about it has changed*, Bus. Insider (Sept. 18, 2019), <https://www.businessinsider.com/insulin-price-increased-last-decade-chart-2019-9>.

¹⁰³ Danielle K. Roberts, *The Deadly Costs of Insulin*, Am. J. Managed Care (June 10, 2019), <https://www.ajmc.com/view/the-deadly-costs-of-insulin>.

¹⁰⁴ *Id.*

¹⁰⁵ Newton, *supra* n.18.



209. These price increases have occurred even in the face of supposed competition between manufacturers making similar drugs. Since the mid-1990s, there have been more than two dozen price increases on a vial of Humalog insulin.¹⁰⁶

210. The Manufacturer Defendants have represented that the price of the at-issue insulin drugs is determined, in part, by the need to fund research, development, and innovation. And the PBM Defendants have continually claimed that they intentionally work to reduce insulin prices. For example:

A. In 2010, CVS Caremark represented that it was focused on diabetes to “help us add value for our PBM clients and improve the health of plan members . . . a PBM client with 50,000 employees whose population

¹⁰⁶ Johnson, *supra* n.44.

has an average prevalence of diabetes could save approximately \$3.3 million a year in medical expenditures.”¹⁰⁷

B. In the same year, Andrew Sussman, CVS Caremark’s Chief Medical Officer, stated that CVS was “working to develop programs to hold down [diabetes] costs.”¹⁰⁸

211. In 2016, the SVP and Chief Innovation Officer at Express Scripts stated that “[d]iabetes is wreaking havoc on patients, and it is also a runaway driver of costs for payors . . . [Express Scripts] helps our clients and diabetes patients prevail over cost and care challenges created by this terrible disease,” and that it “broaden[s] insulin options for patients and bend[s] down the cost curve of what is currently the costliest class of traditional prescription drugs.”¹⁰⁹

212. Despite this, the U.S. House of Representatives Committee on Oversight and Reform concluded in its Drug Pricing Investigation that these claims

¹⁰⁷ Chain Drug Review, *CVS Expands Extracare for Diabetes Products* (May 11, 2010), <https://www.chaindrugreview.com/cvs-expands-extracare-for-diabetes-products/> (last visited Oct. 15, 2024).

¹⁰⁸ CBS News, *Diabetes Epidemic Growing* (June 22, 2010), <https://www.cbsnews.com/news/diabetes-epidemic-growing/>.

¹⁰⁹ Jon Kamp & Peter Loftus, *CVS’ PBM Business Names Drugs It Plans to Block Next Year*, Wall St. J. (Nov. 8, 2012), <https://www.wsj.com/articles/SB10001424127887324439804578107040729812454>; Angela Mueller, *Express Scripts launches program to control diabetes costs*, St. Louis Bus. J. (Aug. 31, 2016), <https://www.bizjournals.com/stlouis/news/2016/08/31/express-scripts-launches-program-to-control.html>.

were unsupported.¹¹⁰

213. For example, between 2005 and 2018, Eli Lilly spent only \$680 million on research and development costs for Humalog, while its net sales for Humalog were \$31.35 billion.¹¹¹ In other words, net sales were 46 times the reported research and development costs.

214. Driven by these price hikes, patient and health plan payor spending on insulin has skyrocketed, with totals in the tens of billions of dollars. In Washington, “many find insulin inaccessible or unaffordable due to its high list price,” and as a result skip doses or otherwise ration their insulin.¹¹²

2. Insulin List Prices Have Increased in Lockstep.

215. These price increases are even more troubling when one considers their timing and context, which seem to bear little relation to developmental advances or market demand. For example, as indicated below, between 2006 and


¹¹⁰ U.S. H.R., Comm. on Oversight and Reform, *Drug Pricing Investigation*, OVERSIGHTDEMOCRATS.HOUSE.GOV, (Dec. 2021), <https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/DRUG%20PRICING%20REPORT%20WITH%20APPENDIX%20v3.pdf>.

¹¹¹ *Id.*

¹¹² Wash. Health Care Auth., *Total Cost of Insulin Work Group: Final Report 4* (July 1, 2023), https://app.leg.wa.gov/ReportsToTheLegislature/Home/GetPDF?fileName=Total%20Cost%20of%20Insulin%20Work%20Group%20Final%20Report_14954d3d-cc6d-41d2-bb5a-ecb01027fa31.pdf.

2019, prices for two competing long-acting analog insulin products—Sanofi’s Lantus and Novo Nordisk’s Levemir—went up in lockstep.¹¹³

Comparison of Long-Acting-Insulin Price Increases—
Lantus (Sanofi) and Levemir (Novo Nordisk), 2005–2019




216. Similarly, the price of Humalog, a rapid-acting analog insulin produced by Eli Lilly, and the price of its direct competitor, Novolog, produced by Novo Nordisk, increased in lockstep from 2001 through 2018.¹¹⁴

¹¹³ U.S. H.R., Comm. on Oversight and Reform, *supra* n.106; *see also* Langreth, *supra* n.18.

¹¹⁴ U.S. H.R., Comm. on Oversight and Reform, *supra* n.106.

**Comparison of Rapid-Acting-Insulin Price Increases—
Humalog (Eli Lilly) and NovoLog (Novo Nordisk), 1996–2018**



217. This practice of increasing drug prices in lockstep with competitors is known as “shadow pricing”¹¹⁵ and, as noted by Dr. Irl B. Hirsch, has functioned to precipitously increase the price of insulin in the United States.¹¹⁶


218. The overlap in price hikes across both categories of analog insulins (rapid and long-acting) is remarkable as well:¹¹⁷

¹¹⁵ Lydia Ramsey, *There’s something odd about the way insulin prices change*, Bus. Insider (Sept. 17, 2016), <https://www.businessinsider.com/rising-insulin-prices-track-competitors-closely-2016-9>.

¹¹⁶ Hirsch, *supra* n.32.

¹¹⁷ Rebecca Robbins, *The Insulin Market is Heading for a Shakeup. But Patients May Not Benefit*, STAT (Oct. 14, 2016), <https://www.statnews.com/2016/10/14/insulin-prices-generics/>.

Comparison of Insulin List Prices of Rapid-Acting and Long-Lasting Insulin



JEFFERY DELVISCIO/STAT
Source: Truven Health Analytics

219. In thirteen instances since 2009, Sanofi and Novo Nordisk raised the list prices of their long-acting analog insulins, Lantus and Levemir, in tandem, “taking the same price increase down to the decimal point within a few days of each other.”¹¹⁸ As one healthcare analyst put it: “That is pretty much a clear signal that your competitor doesn’t intend to price-compete with you.”¹¹⁹ Eli Lilly and Novo Nordisk have engaged in the same lockstep behavior with respect to their rapid-acting analog insulins, Humalog and Novolog.

220. Because of Defendants’ Insulin Pricing Scheme and the lockstep increases in the price of insulin, “[n]early a century after its discovery, there is still no inexpensive supply of insulin for people living with diabetes in North

¹¹⁸ Langreth, *supra* n.18.

¹¹⁹ *Id.*

America....”¹²⁰ Instead, diabetes patients who need insulin to survive are forced to pay exorbitant costs to survive.

3. The Growing Gap Between List Prices and Net Prices

221. The Insulin Pricing Scheme is further evidenced by the growing gap between the list price of insulin drugs and net price realized by the Manufacturer Defendants once all rebates and fees paid to the PBM Defendants are taken into account.

222. While the Defendants often obscure their true net realized prices for insulin, the escalating list price is generally public information. Defendants know that the public list prices do not bear a reasonable relationship to the profits and actual net prices realized by Defendants, and that payors, including the City of Tacoma, made payments for insulin based on the false list prices generated by the scheme.

223. As noted above, the list prices for analog insulins sold by Eli Lilly, Novo Nordisk, and Sanofi have increased rapidly in lockstep with one another. The question, then, is why the Manufacturer Defendants are not competing on price. They sell similar, and in many ways interchangeable drugs, and have been for years. Indeed, the drugs are the same as they were ten years ago, and the clinical benefit of the drugs remains unchanged. Yet, the list price keeps going up.

¹²⁰ Greene & Riggs, *supra* n.57, at 1175.


224. The answer is the Insulin Pricing Scheme. The Manufacturer Defendants are not competing on price because, instead, they are competing on rebates and other fees paid to the PBM Defendants. This unfair and deceptive conspiracy explains the spectacular rise in list prices for the at-issue drugs, while the Manufacturer Defendants' net prices remain relatively constant—though of course the volume of sales and the amount of drugs they are able to sell and provide on formularies remains high. Indeed, as set forth herein, the City of Tacoma continued to pay for the at-issue drugs throughout the relevant time period and several of the drugs were among the most the City paid for by gross cost.

225. In exchange for the rebates and fees paid to the PBM Defendants, the PBM Defendants provide the Manufacturer Defendants with favorable formulary placement for their drugs. As explained by David Kliff, editor of the website Diabetic Investor, “Insulin is a commodity, so formulary position is everything. It’s like location in real estate.”¹²¹ The Manufacturer Defendants are thus incentivized to participate in the Insulin Pricing Scheme because this favorable formulary placement results in increased sales and revenue of their at-issue insulin drugs.

226. The following figures, provided by Sanofi and Eli Lilly, illustrate the

¹²¹ Arthur Allen, *Insulin’s High Costs Goes Beyond Drugmakers to Industry’s Price Mediators*, CNN (Mar. 9, 2023), <https://www.cnn.com/2023/03/09/health/insulin-cost-khn-partner/index.html>.

growing gap between list price and net price.¹²²




227. The below figure demonstrates the difference between the list price and net price of Sanofi insulins from 2012 to 2022.¹²³


¹²² Denise Roland, *Sanofi, Fighting Back in Insulin Price Debate, Says Its Net Prices Fell 11%*, Wall St. J. (Mar. 4, 2020), <https://www.wsj.com/articles/sanofi-fighting-back-in-insulin-price-debate-says-its-net-prices-fell-11-11583340721> (Figure 1); Peter Loftus, *As Political Scrutiny Mounts, Eli Lilly Divulges New Insulin Pricing Data*, Wall St. J. (Mar. 24, 2019), <https://www.wsj.com/articles/as-political-scrutiny-mounts-eli-lilly-divulges-new-insulin-pricing-data-11553436000> (Figure 2).

¹²³ Prescription Medicine Pricing: Our principles and perspectives, Sanofi, <https://web.archive.org/web/20230327030218/https://www.sanofi.us/dam/jcr:356cc1f5-92dd-47a1-9770-ba60dfdfab1e/Sanofi-2023-Pricing-Principles-Report.pdf>.

Comparison of List and Net Price (Sanofi Insulin), 2012-2022



228. As indicated in the below diagrams prepared by SSR Health,¹²⁴ a health-industry research firm, the same widening gap between net price and list price has occurred for the other major analog insulins:



229. The Manufacturer Defendants have publicly represented that these

¹²⁴ Robert Langreth, et al., *Decoding Big Pharma's Secret Drug Pricing Practices*, Bloomberg (June 29, 2016), <https://www.bloomberg.com/graphics/2016-drug-prices/>.

price increases are related to the drugs' value to the healthcare system and the need to fund research and development. For example, "briefing materials prepared for [Eli Lilly's] Chief Executive Officer (CEO) Dave Ricks as a panelist at the 2017 Forbes Healthcare Summit included 'Reactive Key Messages' on pricing that emphasized the significant research and development costs for insulin."¹²⁵ Executives for other insulin manufacturers similarly represented that research and development costs were key factors driving the price increases for insulin.¹²⁶

230. Despite these representations, the Manufacturer Defendants' price increases far exceeded any related research and development costs. Eli Lilly, as mentioned above, reported that it spent approximately \$680 million on research and development related to Humalog globally between 2005 and 2018; over that same period, worldwide net sales of Humalog were \$31.35 billion—forty-six times more than reported research and development costs.¹²⁷ Similarly, Sanofi spent 2.4% of its U.S. net sales generated by Lantus on research and development.¹²⁸

4. Rebates Gone Awry

231. The PBM Defendants turn a profit in numerous ways. Their health plan clients pay them service fees for processing prescriptions and operating mail-

¹²⁵ U.S. H.R., Comm. on Oversight and Reform, *supra* n.106.

¹²⁶ *Id.*

¹²⁷ *Id.*

¹²⁸ *Id.*

order pharmacies. Health plans also pay transaction fees on the different operations required to manage the complex cash flows between insurers, pharmacists, and manufacturers. But one of the primary sources of PBM Defendants' profits in recent decades has been the drug "rebates" and other fees they negotiate with drug companies.

232. If the PBM Defendants operated ethically and honestly, they would negotiate lower drug prices in exchange for formulary access.¹²⁹ Indeed, pharmacy benefit managers have the greatest leverage to negotiate lower prices when two or more drug companies make ostensibly interchangeable products—i.e., drugs within the same therapeutic class. In such a scenario, the drug manufacturers should compete on price, as in normal competitive markets.

233. The PBM Defendants acknowledge this leverage: CVS Health boldly boasts on its website that one of the "basic services" it provides is "negotiating low costs and rebates with pharmaceutical manufacturers."¹³⁰ Express Scripts says in its

¹²⁹ Although the pharmacy benefit managers treat different insulin as if they were completely interchangeable, in fact, they have different inactive ingredients that can cause allergic reactions for diabetes patients. Type 1 diabetes is an autoimmune disease, and many patients are sensitive to insulin changes. Moreover, the treatment of different insulins as therapeutically interchangeable is also based on the assumption that all insulins are absorbed based on the same normal curve, which is not always true. Patients can have different duration of insulin action on one insulin versus another.

¹³⁰ *Pharmacy benefits management*, CVS Health, <https://www.cvshealth.com/services/prescription-drug-coverage/pharmacy-benefits-management.html> (last visited Oct. 15, 2024).

“About Us FAQ” that it “make[s] prescription medications safer and more affordable for [its] members.”¹³¹ And OptumRx says that members can expect “lowest net cost drug procurement and pharmaceutical manufacturer negotiations.”¹³²

234. In addition to these general misrepresentations, the PBM Defendants have consistently specifically disavowed that their conduct drives prices higher:

A. In 2017, Express Scripts CEO Tim Wentworth stated that “[d]rugmakers set prices, and we exist to bring those prices down.”¹³³

B. In the same year, CVS Caremark’s Larry Merlo stated that “[a]ny suggestion that PBMs are causing prices to rise is simply erroneous.”¹³⁴

C. OptumRx’s Sumit Dutta, when asked by Congress if PBM-negotiated rebates and discounts were causing the price of insulin to

¹³¹ *About us*, Express Scripts, <https://www.express-scripts.com/frequently-asked-questions/about> (last visited Oct. 15, 2024).

¹³² *Pharmacy benefit management (PBM)*, Optum, <https://www.optum.com/business/employers/pharmacy-care-services.html> (last visited Oct. 15, 2024).

¹³³ Samantha Liss, *Express Scripts CEO Addresses Drug Pricing ‘Misinformation’*, St. Louis Post-Dispatch (Feb. 17, 2017), https://www.stltoday.com/business/local/express-scripts-ceo-addresses-drug-pricing-misinformation/article_8c65cf2a-96ef-5575-8b5c-95601ac51840.html.

¹³⁴ Lynn R. Webster, *Who Is To Blame For Skyrocketing Drug Prices?*, The Hill (July 27, 2017), <https://thehill.com/blogs/pundits-blog/healthcare/344115-who-is-to-blame-for-skyrocketing-drug-prices/>.

increase, said that “we can’t see a correlation when rebates raise list prices.”¹³⁵

D. And in 2019, Amy Bricker—who worked for Express Scripts at the time before moving to CVS—testified, “I have no idea why the prices [for insulin] are so high, none of it is the fault of rebates.”¹³⁶

235. However, contrary to the PBM Defendants’ representations, their arrangement with the Manufacturer Defendants is not operated ethically and honestly. The Manufacturer Defendants and PBM Defendants have realized that they both benefit if, instead of forcing the Manufacturer Defendants to sell their drugs for cheaper prices, the PBM Defendants induce the Manufacturer Defendants to “compete” by paying ever-increasing rebates and fees to the PBM Defendants. Because they are no longer competing on price, this arrangement induces the Manufacturer Defendants to raise their publicly reported list prices, which enables them to largely maintain their net realized price. The increased list prices create what is, in effect, a massive slush fund that can be used by the Manufacturer Defendants to pay the larger and larger rebates and fees demanded by the PBM Defendants for formulary placement.¹³⁷

¹³⁵ *Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin*, Congress.gov (Apr. 10, 2019), <https://www.congress.gov/event/116th-congress/house-event/109299?s=1&r=3>.

¹³⁶ *Id.*

¹³⁷ Roland & Loftus, *supra* n.26.

236. The Insulin Pricing Scheme allows the Manufacturer Defendants to maintain their profit margins on drugs sold in the United States—which are higher than anywhere else in the world—and ensure their access to the millions of Americans whose drugs are made available via the PBM Defendants’ formularies. And the Insulin Pricing Scheme allows the PBM Defendants to leverage their control over formularies to obtain kickbacks. With list prices going up, the rebates get bigger, and so does the PBM Defendants’ cut. The Insulin Pricing Scheme artificially drives up list prices so the Manufacturer Defendants can earn more profit. And the Manufacturer Defendants can pay the PBM Defendants what they demand without significantly impacting their profits.

237. Thus, far from using their prodigious bargaining power to lower drug prices as they repeatedly claim, the PBM Defendants abuse their position to benefit both themselves and the Manufacturer Defendants. It is a profitable enterprise but deeply unethical enterprise that takes advantage of consumers and health plan payors, who do not pay the “net” price but instead pay amounts derived from the ever-increasing list price. Thus, while the PBM and Manufacturer Defendants benefit, it is consumers and health plans who shoulder the burden of the higher list prices through increased payments. This dynamic lies at the heart of the surging cost of insulin, and the resulting public health disaster.

238. Drug manufacturers well understand the power of pharmacy benefit managers.¹³⁸ Because of their size, and the many thousands of health plan clients they serve, pharmacy benefit managers can steer business from one drug manufacturer to another based on which one pays the larger kickback.

239. Pharmacy benefit managers make outsize profits by exploiting the United States' complex pharmaceutical distribution system. While the existence of pharmacy benefit managers in the supply chain is known, the nature and magnitude of the rebates and other fees they extract from drug companies for formulary placement, and the portion of these payments they pocket, are carefully guarded secrets.¹³⁹


240. Although the true amount of rebates received by the PBM Defendants is unknown, available data demonstrates an increase over time in the aggregate rebates made by Manufacturer Defendants Eli Lilly, Novo Nordisk and Sanofi to pharmacy benefit managers and insurers. This is illustrated in the figures below. The figure below illustrates the growth in Novo Nordisk's aggregate rebates from 2007 to 2014.¹⁴⁰

¹³⁸ See Roland & Loftus, *supra* n.26.

¹³⁹ See, e.g., Lydia Ramsey, *One of the largest middlemen in the drug industry just released a video showing why it should be able to remain secretive*, Bus. Insider (Feb. 9, 2017), <http://www.businessinsider.com/what-pharmacy-benefit-managers-are-doing-about-trump-and-drug-pricing-2017-2>.

¹⁴⁰ Jeffrey Balin, et al., *Global Pharma: Rising US Rebates Limit Margin Expansion*, Credit Suisse, 23 (May 1, 2015).


Reported Rebates as a Percentage of U.S. Gross Sales for Novo Nordisk, 2007-2014



Source: Company data, Credit Suisse estimates

241. Sanofi has also greatly increased its rebates. The figure below shows the amount Sanofi has increased its rebates from 2007 to 2014.


Reported Rebates as a Percentage of U.S. Gross Sales for Sanofi, 2007-2014



Source: Company data, Credit Suisse estimates

242. Finally, Eli Lilly has greatly increased its rebates. The figure below shows the amount Eli Lilly has increased its rebates from 2007 to 2014. Contrary to Novo Nordisk, for which insulin represents a substantial amount of gross revenues, Eli Lilly is an extremely diversified manufacturer. As a result, the impact of the very steep insulin rebating that has gained Lilly the lion's share of the U.S. insulin market in recent years is attenuated in the graph below by less aggressive rebating on other drug classes.

Reported Rebates as a Percentage of U.S. Gross Sales for Eli Lilly, 2007-2014



Source: Company data, Credit Suisse estimates

5. Clawbacks

243. In addition to profiting off increasing rebates, the PBM Defendants use clawbacks to profit from the Insulin Pricing Scheme.

244. Non-PBM affiliated pharmacies state that pharmacy benefit managers have forced them to sign contracts that include clawbacks or post-purchase discount provisions, under which the pharmacies have to pay the pharmacy benefit managers money, sometimes long after sales take place.¹⁴¹ Mel Brodsky, the Executive Director of the Philadelphia Association of Retail Druggists noted that the contracts between pharmacies and pharmacy benefit managers are “usually

¹⁴¹ Arthur Allen, *What to know about the drug price fight in those TV ads*, NPR.org (July 7, 2023), <https://www.npr.org/sections/health-shots/2023/07/07/1186317498/pharmacy-benefit-manager-pbm-ads-congress>.

take-it-or-leave-it contracts.”¹⁴²

245. Clawbacks are typically a percentage of a drug’s list price. Because the Insulin Pricing Scheme has artificially inflated the list price of insulin drugs, it creates greater clawbacks for the PBM Defendants.¹⁴³ This further adds to the already strong incentives for the PBM Defendants to aggressively pursue conduct that artificially inflates list prices.

6. Spread Pricing

246. Another way that the PBM Defendants profit from the Insulin Pricing Scheme is through spread pricing.

247. The PBM Defendants determine which pharmacies they want to contract with and include in their networks. In these contractual agreements, the PBM Defendants determine how much they will reimburse pharmacies for drugs (typically a percentage of the list price).

248. The PBM Defendants charge health plan payor clients more for a drug (a higher percentage of the list price) than the PBM Defendants pay the pharmacies. The PBM Defendants keep the difference. Because both the client and pharmacy

¹⁴² Jared S. Hopkins, *You’re Overpaying for Drugs and Your Pharmacist Can’t Tell You*, Bloomberg (Feb. 24, 2017) <https://www.bloomberg.com/news/articles/2017-02-24/sworn-to-secrecy-drugstores-stay-silent-as-customers-overpay>.

¹⁴³ Bob Herman, *How drug middlemen take back money from pharmacies*, Axios.com (July 25, 2019), <https://www.axios.com/2019/07/25/express-scripts-pharmacies-quality-clawbacks-contract>.

contracts are structured as a percentage of the list price, the amount of “spread” the PBM Defendants retain increases as the list price increases, thus further adding to the PBM Defendants’ incentives to artificially increase list prices.

249. In 2022, the Pharmacy Benefit Manager Transparency Act—S. 4293, was introduced to prohibit spread pricing: when a pharmacy benefit manager “[charges] a health plan or payer a different amount for a prescription drug’s ingredient cost or dispensing fee than the amount the pharmacy benefit manager reimburses a pharmacy for the prescription drug’s ingredient cost or dispensing fee where the pharmacy benefit manager retains the amount of any such difference.”¹⁴⁴ The bill has not yet been enacted into law.

250. The PBM Defendants also benefit from a related concept when health plan members fill prescriptions through the PBM Defendant’s affiliated retail and mail-order pharmacies. The PBM Defendants’ in-house pharmacies acquire drugs at a lower cost than what the PBM Defendants charge their health plan payor clients. The PBM Defendants (together with their affiliated pharmacies) thus profit off the spread between their acquisition costs and the amounts paid by health plan payors.

251. The size of this spread is further increased by various discounts the

¹⁴⁴ Pharmacy Benefit Manager Transparency Act of 2022, S. 4293, 117th Cong., <https://www.govtrack.us/congress/bills/117/s4293> (last visited Oct. 15, 2024).

PBM Defendants and their affiliated pharmacies negotiate with the Manufacturer Defendants. Moreover, the PBM Defendants' negotiations with the Manufacturer Defendants may give them inside information as to when the Manufacturer Defendants will increase list prices, allowing the PBM Defendants (and their affiliated pharmacies) to maximize their spread income by stocking up on drugs before price increases and then later selling them to health plan members and payors at the increased price.

7. Defendants' Admissions

252. Defendants have acknowledged these price increases and their impact on payors and patients. On April 10, 2019, the United States House of Representatives Committee on Energy and Commerce held a hearing on industry practices titled, "Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin."

253. Representatives from all Defendants testified at the hearing and admitted that the price for insulin had increased exponentially over the past fifteen years.

254. Each Defendant also conceded that the price that diabetics pay out-of-pocket for insulin is too high. For example:

A. Dr. Sumit Dutta, SVP and Chief Medical Officer of OptumRx since 2015, stated that "[a] lack of meaningful competition allows the

[M]anufacturers to set high [list] prices and continually increase them which is odd for a drug that is nearly 100 years old and which has seen no significant innovation in decades. These price increases have a real impact on consumers in the form of higher out-of-pocket costs.”

B. Thomas Moriarty, General Counsel for CVS Health admitted that “[a] real barrier in our country to achieving good health is cost, including the price of insulin products which are too expensive for too many Americans. Over the last several years, prices for insulin have increased nearly 50 percent. And over the last ten years, [list] price of one product, Lantus, rose by 184 percent.”

C. Mike Mason, Senior Vice President of Eli Lilly when discussing how much diabetics pay out-of-pocket for insulin stated “it’s difficult for me to hear anyone in the diabetes community worry about the cost of insulin. Too many people today don’t have affordable access to chronic medications . . .”

D. Kathleen Tregoning, Executive Vice President External Affairs at Sanofi, testified, “Patients are rightfully angry about rising out-of-pocket costs and we all have a responsibility to address a system that is clearly failing too many people. . . we recognize the need to address the very real challenges of affordability . . . Since 2012, average out-of-pocket costs for

Lantus have risen approximately 60 percent for patients . . .”

E. Doug Langa, Executive Vice President of Novo Nordisk, stated, “On the issue of affordability . . . I will tell you that at Novo Nordisk we are accountable for the [list] prices of our medicines. We also know that [list] price matters to many, particularly those in high-deductible health plans and those that are uninsured.”¹⁴⁵

255. Notably, none of the testifying Defendants blamed the significant increase in the price of insulin on competitive factors such as increased production costs or improved clinical benefit.

256. Instead, Novo Nordisk’s President Doug Langa’s written testimony for the April 2019 hearing recognized “misaligned incentives” that have led to higher drug costs, including for insulin: “Chief among these misaligned incentives is the fact that the rebates pharmaceutical companies pay to PBMs are calculated as a percentage of wholesale acquisition cost (“WAC”) [list] price. That means a pharmaceutical company fighting to remain on formulary is constrained from lowering WAC price, or even keeping the price constant, if a competitor takes an increase. This is because PBMs will then earn less in rebates and potentially choose

¹⁴⁵ *Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin*, Hearing before the Subcomm. on Oversight & Investigations, 116 Cong. (Apr. 10, 2019), <https://www.govinfo.gov/content/pkg/CHRG-116hhrg39747/html/CHRG-116hhrg39747.htm>.

to place a competitor's higher-priced product on their formulary to the exclusion of others." Likewise, Mr. Langa's responses to questions for the record conceded that "[t]he disadvantage of a system in which administrative fees are paid as a percentage of the list price is that there is increased pressure to keep list prices high. . . ."

257. The hearing transcript records Mr. Langa's further comments in this regard:

[T]here is this perverse incentive and misaligned incentives and this encouragement to keep list prices high. And we've been participating in that system because the higher the list price, the higher the rebate . . . There is a significant demand for rebates.... We're spending almost \$18 billion a year in rebates, discount, and fees, and we have people with insurance with diabetes that don't get the benefit of that.

258. Eli Lilly admitted that it raises list prices as a quid pro quo for formulary positions. At the April 2019 Congressional hearing, Mike Mason, Senior Vice President of Eli Lilly testified:

Seventy-five percent of our list price is paid for rebates and discounts . . . \$210 of a vial of Humalog is paid for discounts and rebates. . . . We have to provide rebates [to PBMs] in order to provide and compete for that [formulary position] so that people can use our insulin.

In the very next question, Mr. Langa of Novo Nordisk was asked, "[H]ave you ever lowered a list price? His answer, "We have not."

259. Sanofi's Executive Vice President for External Affairs, Kathleen Tregoning, testified: "The rebates is [sic] how the system has evolved. . . . I think

the system became complex and rebates generated through negotiations with PBMs are being used to finance other parts of the healthcare system and not to lower prices to the patient.” Her written response to questions for the record acknowledged that “it is clear that payments based on a percentage of list price result in a higher margin [for PBMs] for the higher list price product than for the lower list price product.”

260. The PBM Defendants also conceded at the April 2019 Congressional hearing that they grant preferred, or even exclusive, formulary position because of higher Manufacturer Payments paid by the Manufacturer Defendants.

261. In her responses to questions for the record, Amy Bricker—former President of Express Scripts, a former PCMA board member, and now an executive at CVS Health—confirmed that “manufacturers lowering their list prices” would give patients “greater access to medications;” yet when asked to explain why Express Scripts did not grant an insulin with a lower list price preferred formulary status, answered, “Manufacturers do give higher discounts [i.e., payments] for exclusive [formulary] position . . .” When asked why the PBM would not include both costly and lower-priced insulin medications on its formulary, Ms. Bricker stated plainly, “We’ll receive less discount in the event we do that.”

262. As Dr. Dutta, SVP of OptumRx, perversely reasoned, the cheaper list-priced alternative Admelog is not given preference on the formulary because “it

would cost the payer more money to do that . . . [b]ecause the list price is not what the payer is paying. They are paying the net price.” But, of course, health plan payors do not pay the “net” price, even when “rebates” are passed-through, because the PBMs receive and retain countless other forms of payments that drive up the gap between the “list” price and the “net” price retained by drug manufacturers.

263. While all Defendants acknowledged before Congress their participation in conduct integral to the Insulin Pricing Scheme, none revealed its inner workings or the connection between their coordination and the economic harm that payors, like Plaintiff, and its Beneficiaries were unwittingly suffering. Instead, in an effort to obscure the true reason for precipitous price increases, each Defendant group pointed the finger at the other as the more responsible party.

264. The PBM Defendants testified to Congress that the Manufacturer Defendants are solely responsible for their list price increases and that the Manufacturer Payments that the PBM Defendants receive are not correlated to rising insulin prices.

265. On the contrary, the amount the Manufacturer Defendants kick back to the PBM Defendants is directly correlated to an increase in list prices—on average, a \$1 increase in Manufacturer Payments is associated with a \$1.17

increase in list price.¹⁴⁶ Reducing or eliminating Manufacturer Payments would lower prices and reduce health plan expenditures for payors and beneficiaries.

266. Further, in large part because of the increased list prices and related Manufacturer Payments, the PBM Defendants' profit per prescription has grown substantially over the same period that insulin prices have steadily increased. For example, since 2003 Defendant Express Scripts has seen its profit per prescription increase more than 500% per adjusted prescription.¹⁴⁷

267. Novo Nordisk's President Doug Langa submitted written testimony to Congress acknowledging "there is no doubt that the WAC [list price] is a significant component" of "what patients ultimately pay at the pharmacy counter." Yet, the Manufacturers urged upon Congress the fiction that the pharmacy benefit managers were solely to blame for insulin prices because of their demands for rebates in exchange for formulary placement. The Manufacturers claimed their hands were tied and sought to conceal their misconduct by suggesting that they have not profited from rising insulin prices.

268. Given the Manufacturers' claims that rebates were the sole reason for

¹⁴⁶ Neeraj Sood et al., *The Association Between Drug Rebates and List Prices*, Univ. of S. Cal. (Feb. 11, 2020), <https://healthpolicy.usc.edu/research/the-association-between-drug-rebates-and-list-prices/>.

¹⁴⁷ David Balto, *How PBMs Make the Drug Price Problem Worse*, The Hill (Aug. 31, 2016), <https://thehill.com/blogs/pundits-blog/healthcare/294025-how-pbms-make-the-drug-price-problem-worse/>.

rising prices, each was asked directly during the Congressional hearing to guarantee it would decrease list prices if rebates were restricted or eliminated. The spokespersons for Eli Lilly, Novo Nordisk, and Sanofi all said only that they would “consider it.”

269. In January 2021, the Senate Finance Committee (Grassley-Wyden) issued a report titled “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug” that detailed Congress’s findings after reviewing more than 100,000 pages of internal company documents from Sanofi, Novo Nordisk, Eli Lilly, CVS Caremark, Express Scripts, OptumRx, and Cigna. The report concluded, among other things:

A. The Manufacturer Defendants retain more revenue from insulin than in the 2000s—for example, Eli Lilly has reported a steady increase in Humalog revenue for more than a decade—from \$1.5 billion in 2007 to \$3 billion in 2018;

B. the Manufacturer Defendants have aggressively raised the list price of their insulin products absent significant advances in the efficacy of the drugs; and

C. the Manufacturer Defendants only spend a fraction of their revenue related to the at-issue drugs on research and development—Eli Lilly spent \$395 million on R&D costs for Humalog, Humulin, and Basaglar

between 2014–2018 during which time the company generated \$22.4 billion in revenue on these drugs.

270. The 2021 Senate Finance Committee Report summed up the benefit to the Manufacturer Defendants finding that “drug manufacturers increased insulin WAC [wholesale cost], in part to give them room to offer larger rebates to PBM and health insurers, all in the hopes that their product would receive preferred formulary placement. This pricing strategy translated into higher sales volumes and revenue for manufacturers.”¹⁴⁸

271. Under the Insulin Pricing Scheme, the Manufacturer Defendants pay the PBM Defendants opaque but significant Manufacturer Payments in exchange for formulary placement, which garners the Manufacturer Defendants greater revenues and steady profit margins. The PBM Defendants grant national formulary position to at-issue drugs in exchange for large Manufacturer Payments generated by inflated drug prices.

272. Inflated list prices also reap the manufacturer hundreds of millions of dollars in tax breaks because they can base their deductions for insulin donations on the inflated list prices.

273. Because of the increased list prices and related Manufacturer Payments, the PBM Defendants’ profit per prescription has grown exponentially

¹⁴⁸ U.S. S. Fin. Comm., *supra* n.9.

during the relevant period as well. A recent study published in the Journal of the American Medical Association concluded that the amount of money that goes to the PBM Defendants for each insulin prescription increased more than 150% from 2014 to 2018.¹⁴⁹ In fact, for transactions in which the PBM Defendants control the PBM and the pharmacy (e.g., Caremark-CVS pharmacy), these Defendants were capturing an astonishing 40% of the money spent on each insulin prescription (up from 25% just four years earlier), even though they do not contribute to the development, manufacture, innovation, or production of the product.

274. As detailed above, the PBM Defendants profit from the artificially inflated prices created by the Insulin Pricing Scheme in several ways, including: (1) retaining a significant, yet undisclosed, percentage of Manufacturer Payments under a variety of labels; (2) using rebate aggregators to further shield Manufacturer Payments from pass-through obligations; (3) using the inflated list price to generate profits from pharmacies, including through clawbacks and post-purchased discounts; and (4) relying on the inflated list price to drive up the PBMs' spread income, including through increased margins captured by their own affiliated pharmacies.

275. Over time, payors such as the City of Tacoma did secure contract

¹⁴⁹ Karen Van Nuys, et al., *Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans from 2014 to 2018*, J. Am. Med., Nov. 2021, at 11.

provisions guaranteeing payment to them of a certain amount of prescription drug rebate payments per paid brand name prescription drug claim. From 2015 to 2016, the City of Tacoma secured contract provisions guaranteeing payment to them of 80% of drug rebates. Critically, however, these “rebates” to the City of Tacoma were shrouded in secrecy and are only a fraction of the total secret Manufacturer Payments, particularly as “rebates” are narrowly defined and qualified by vague exceptions in the PBM Defendants’ contracts with payors. Starting in 2017, the City of Tacoma’s contracts provided that rather than receiving a percentage of drug rebates, the City would receive a flat set amount per brand prescription claim. By switching from a percentage-based rebate arrangement to a flat fee rebate arrangement, the PBM’s rebate payments continued in secrecy and allowed the PBM to excise greater profits by passing along an even smaller portion of the total secret Manufacturer Payments.

E. The Insulin Pricing Scheme Reflects the PBM Defendants’ Self-Dealing

276. The PBM Defendants depend on the lack of transparency to conduct their business. They have vigorously resisted any requirement that they disclose the details of their agreements with drug manufacturers and the kickbacks they receive from them, as well as their agreements with the insurers and pharmacies.¹⁵⁰

277. At the same time, the PBM Defendants have consistently insisted that

¹⁵⁰ *Id.*

they are transparent about the rebate payments and the amounts they remit to payors. For example, in 2011, OptumRx’s President stated that “[w]e want our clients to fully understand our pricing structure . . . [e]very day we strive to show our commitment to our clients, and one element of that commitment is to be open and honest about our pricing structure.”¹⁵¹ Express Scripts’ CEO similarly stated in 2017 that Express Scripts was “absolutely transparent” about rebate payments and that payors “know exactly how the dollars flow” with respect to those payments.¹⁵² And CVS executives have stated that it “provide[s] full visibility to our clients of all our contracts and the discounts that we negotiate on their behalf . . . And transparency—today we report and fully disclose not only to our clients, but to [Centers for Medicare and Medicaid Services].”¹⁵³

278. Health plan payors were not involved in the negotiation of the contracts between the PBM and Manufacturer Defendants, and the PBM Defendants disclosed only the fact that such relationships may exist. But the terms of the contracts, the consideration exchanged between the PBM and Manufacturer

¹⁵¹ UnitedHealth Group, *Prescription Solutions by OptumRx Receives 4th Consecutive TIPPS Certification for Pharmacy Benefits Transparency Standards* (Sept. 13, 2011), <https://web.archive.org/web/20210805182422/https://www.unitedhealthgroup.com/newsroom/2011/0913tipps.html>.

¹⁵² CBS News, *Express Scripts CEO Tim Wentworth Defends Role of PBMs in Drug Prices* (Feb. 7, 2017), <https://www.cbsnews.com/news/express-scripts-tim-wentworth-pbm-rising-drug-prices-mylan-epipen-heather-bresh/>.

¹⁵³ Congress.gov, *supra* n.131.

Defendants, and the means of reaching these determinations all were—and remain—shrouded in secrecy.

279. The PBM and Manufacturer Defendants thus created a “hide-the-ball” system where health plan payors like Plaintiff are not privy to rebate negotiations or contracts between the Manufacturers and the PBM Defendants. Through this “hide-the-ball” system, the PBM and Manufacturer Defendants are able to manipulate their rebate negotiations and contracts in their best interest, rather than in the best interest of health plan payors like Plaintiff.

280. Despite the PBM Defendants’ insistence that they are transparent with their health plan payors, there is zero transparency as to what money the PBM Defendants receive from the Manufacturer Defendants and what money the PBM Defendants remit to health plan payors like Plaintiff. The system is designed so that the PBM and Manufacturer Defendants retain control and profit.

281. This is evidenced by the PBM’s efforts to re-label manufacturer rebates to minimize their pass-through obligations, the PBM’s increasing use of and reliance on rebate aggregators, and the inability of health plan payors, such as Plaintiff, to conduct a meaningful audit of the PBM’s rebate arrangements with the Manufacturer Defendants and rebate aggregators.

1. Relabeling of “Rebates”

282. The consideration exchanged between the PBM and Manufacturer

Defendants is continually labeled and relabeled in order to allow the PBM Defendants to retain an increasing percentage of the total payments received from the Manufacturer Defendants while purporting to pass through increasing rebate amounts to health plan payors such as Plaintiff. As more payors have moved to contracts with the PBM Defendants that require the PBM Defendants to remit some or all of the manufacturer “rebates” through to the payor, the PBM Defendants have moved to relabel these manufacturer “rebates” more broadly as various “fees,” “discounts,” and the like in order to better shield them from scrutiny and minimize their pass-through obligations.

283. Specifically, in order to maintain their ever-growing profits, while claiming that “rebates” are pass through to payors, the PBM Defendants have relabeled the payments they received from the Manufacturer Defendants as, *inter alia*, “administrative fees,” “volume discounts,” “concurrent or retrospective discounts,” “service fees,” “fees for services rendered,” “fees for property provided,” “inflation fees,” or other industry monikers designed to obfuscate the substantial sums being secretly exchanged between the PBM and Manufacturer Defendants.

284. The Senate Commerce, Science and Transportation Committee recently released testimony from David Balto—a former antitrust attorney with the DOJ and Policy Director for the FTC’s Bureau of Competition—from a hearing on

fairness and transparency in drug pricing:

The PBM rebate system turns competition on its head with PBMs seeking higher, not lower prices to maximize rebates and profits. In the past decade, PBM profits have increased to \$28 billion annually...PBMs establish tremendous roadblocks to prevent payors from knowing the amount of rebates they secure. Even sophisticated buyers are unable to secure specific drug by drug rebate information. PBMs prevent payors from being able to audit rebate information. As the Council of Economic Advisors observed, the PBM market lacks transparency as “[t]he size of manufacturer rebates and the percentage of the rebate passed on to health plans and patients are secret.” Without adequate transparency, plan sponsors cannot determine if the PBMs are fully passing on any savings, or whether their formulary choices really benefit the plan and subscribers.¹⁵⁴

285. The relabeled, undisclosed Manufacturer Payments are substantial. “Administrative fees” are just one example. A heavily redacted complaint filed by Defendant Express Scripts in 2017 revealed that Express Scripts retains up to fifteen times more in “administrative fees” than it remits to payors in rebates.¹⁵⁵

286. These so-called administrative fees typically are based on a percentage of the list price—as opposed to a flat fee—such that even if the actual “administrative” cost associated with processing two drugs is the same, the “administrative fee” would be correspondingly higher for the higher-priced drug,

¹⁵⁴ Testimony of David A. Balto before the U.S. S. Comm. On Commerce, Sci., & Transp.: Subcomm. Consumer Prot., Prod. Safety, & Data Sec. entitled “Ensuring Fairness and Transparency in the Market for Prescription Drugs” (May 5, 2022), <https://www.commerce.senate.gov/services/files/5807DDD6-EA20-42A4-97B1-73541F832839>.

¹⁵⁵ Complaint, *Express Scripts, Inc. v. Kaleo, Inc.*, No. 4:17-cv-1520-RLW (E.D. Mo. May 16, 2017), ECF No. 1.

which again creates (by design) a perverse incentive to give preference to more expensive drugs.

287. These administrative fees and other payments are typically beyond a payor's contractual audit rights because those rights are limited to "rebate" payments and these "administrative fees" have been carved out from the definition of "rebates."

288. It has been suggested that pharmacy benefit managers "designate as much as twenty-five or thirty percent of the negotiated rebates as fees to avoid sharing the rebates."¹⁵⁶

289. Although the proportion of rebates retained by the PBM Defendants remains a secret, evidence suggests that the amounts of rebates passed on to the client varies dramatically among the PBM Defendants and their clients.¹⁵⁷ And there is reason to believe that the proportion of rebates retained by the PBM Defendants is substantial. A review of Texas-mandated pharmacy benefit manager disclosures showed that pharmacy benefit managers retain a much greater percentage of

¹⁵⁶ Joanna Shepherd, *Pharmacy Benefit Managers, Rebates, and Drug Prices: Conflicts of Interest in the Market for Prescription Drugs*, Yale Law & Pol'y Rev., https://openyls.law.yale.edu/bitstream/handle/20.500.13051/17295/auto_convert.pdf?sequence=3&isAllowed=y.

¹⁵⁷ *Id.*

manufacturer rebates than they let on.¹⁵⁸ Under the Texas law, pharmacy benefit managers are required to report the “aggregated rebates, fees, price protection payments, and any other payments collected from pharmaceutical drug manufacturers.” This review showed that in 2021, pharmacy benefit managers retained 13% of manufacturers’ total payments (\$752 million).¹⁵⁹ Between 2016 and 2021, pharmacy benefit managers retained between 9% and 21% of total manufacturer payments.¹⁶⁰

290. In an attempt to quantify the revenue pharmacy benefit managers receive from retained rebates, a September 2023 report by Nephron Research found that pharmacy benefit managers’ compensation from rebates and other kickbacks doubled between 2018 and 2022, from \$3.8 billion to \$7.6 billion.¹⁶¹

291. Further, because many rebate-sharing arrangements are based on a percentage of rebates received by the PBM Defendants, as drug manufacturers continue to artificially increase the price of insulin, the dollar amount retained by the PBM Defendants will continue to increase, even if the percentage passed through

¹⁵⁸ Adam Fein, *Texas Shows Us Where PBMs’ Rebates Go*, Drug Channels (Aug. 9, 2022), <https://www.drugchannels.net/2022/08/texas-shows-us-where-pbms-rebates-go.html>.

¹⁵⁹ *Id.*

¹⁶⁰ *Id.*

¹⁶¹ Sara Sirota, *Why We Should Ban PBM Rebates*, Am. Econ. Liberties Project (Feb. 13, 2024), https://www.economicliberties.us/our-work/why-we-should-ban-pbm-rebates/#_ftnref32.

stays the same.¹⁶² Thus, through the Insulin Pricing Scheme, the PBM Defendants continue to garner greater and greater profits at the expense of health plan payors like Plaintiff.

292. The opaque nature of these arrangements between the Manufacturer and PBM Defendants also makes it impossible for a given payor to discover, much less assess or confront, conflicts of interest that may affect it or its members or beneficiaries. The Senate Insulin Report observed with respect to these arrangements: “Relatively little is publicly known about these financial relationships and the impact they have on insulin costs borne by consumers.”¹⁶³

2. Rebate Aggregators

293. The PBM Defendants also use “rebate aggregators” to further the Insulin Pricing Scheme.

294. Rebate aggregators, sometimes called group purchasing organizations (“GPOs”), negotiate and collect manufacturer rebates on behalf of pharmacy benefit managers, including the PBM Defendants. These rebate aggregators collect rebates and other fees for their pharmacy benefit manager clients.

295. Between 2019 and 2021, Defendants Express Scripts, CVS Caremark,

¹⁶² *A View from Congress: Role of Pharmacy Benefit Managers in Pharmaceutical Markets*, H.R. Comm. on Oversight and Reform (Dec. 10, 2021), <https://oversight.house.gov/wp-content/uploads/2021/12/PBM-Report-12102021.pdf>.

¹⁶³ U.S. S. Fin. Comm., *supra* n.9.

and OptumRx each formed their own rebate aggregator to outsource the negotiation and collection of rebates and other fees to a subsidiary, and impose new fees on the Manufacturers, purportedly for the aggregator's services. These rebate aggregators, Ascent Health Services LLC (established and controlled by Express Scripts), Zinc Health Services, LLC (established by CVS Health and controlled by CVS Caremark), and Emisar Pharma Services LLC (established and controlled by OptumRx)—collectively the “Rebate Aggregator Defendants”—perform much of the same rebate negotiating and contracting functions that Defendants Express Scripts, CVS Caremark, and OptumRx previously handled directly.¹⁶⁴

296. The PBMs established these GPOs between 2019 and 2021, in response to mounting pressure from payors to pass through more rebates and other payments collected from the Manufacturers and Congressional action that was anticipated to require more transparency from the PBMs and prohibit PBMs from retaining rebates under the Anti-Kickback Statute.

297. To avoid passing rebates and other payments through to payors, the PBMs adjusted their business models by adding rebate aggregators to the pharmaceutical payment chain.

298. As summarized by the recent Community Oncology Alliance

¹⁶⁴ Before establishing Emisar, OptumRx worked with a second rebate aggregator, Coalition for Advanced Pharmacy Services (“CAPS”), that is operated by OptumRx's parent company, UnitedHealth Group.

report:¹⁶⁵

PBMs have increasingly “delegated” the collection of manufacturer rebates to “rebate aggregators,” which are often owned by or affiliated with the PBMs, without seeking authorization from plan sponsors and without telling plan sponsors. . . . Even some of the major PBMs (i.e., the “Big Three” PBMs) sometimes find themselves contracting with other PBMs’ rebate aggregators for the collection of manufacturer rebates. . . . In both the private sector and with respect to government health care programs, the contracts regarding manufacturer rebates (i.e., contracts between PBMs and rebate aggregators, as well as contracts between PBMs/rebate aggregators and pharmaceutical manufacturers) are not readily available to plan sponsors.

299. The PBM Defendants’ rebate aggregators allow the PBMs to further obfuscate the rebate payment trail and extract additional profits from their contracts with payors.

300. PCMA, the industry group of PBMs, stated that rebate aggregators “help PBMs to use scale and leverage to more aggressively negotiate with (drugmakers) to lower the cost of drugs for clients and consumers. The core mission of PBMs is to provide improved access to needed medications by lowering costs.”¹⁶⁶

301. In reality, the picture appears to be much different. The rebate aggregators are often either owned by the PBM Defendants or closely affiliated.

¹⁶⁵ Community Oncology Alliance, *supra* note 72.

¹⁶⁶ Marty Schladen, *Already concerned with drug costs, large employers, family pharmacists worry about more middlemen*, Ohio Cap. J. (Sep. 2, 2021 1AM), <https://ohiocapitaljournal.com/2021/09/02/already-concerned-with-drug-costs-large-employers-pharmacists-worry-about-another-layer-of-middlemen/>.

The PBM Defendants' contracts with these (often affiliated) rebate aggregators provide that the aggregator will negotiate and receive rebates from drug manufacturers for certain drugs based on the drug utilization of the participants of plans served by the PBM Defendants. The rebate aggregator will then pay the PBM Defendants some amount per prescription, which becomes part of the "rebate" the PBM Defendants must pass through (in whole or in part) to its clients, including Plaintiff. This system allows the (often affiliated) rebate aggregators to retain any difference between the rebates paid by the Manufacturer Defendants and the payments the rebate aggregators pay to the PBM Defendants.

302. As with the PBM Defendants, the Rebate Aggregator Defendants benefit from a higher list price. Both the PBM Defendants and the Rebate Aggregator Defendants retain a portion of the various fees, including administrative fees, they charge the Manufacturer Defendants. Since these fees are typically calculated as a percentage of the list price, the Rebate Aggregator Defendants, as well as the PBM Defendants, collect higher fees as a result of higher list prices. The PBM Defendants and Rebate Aggregator Defendants benefit from these higher fees, even though the services they provide stay the same.

303. The rebate-aggregator GPOs perform the same commercial contracting function that the PBMs once handled themselves, including negotiating with and collecting rebates and other fees from the Manufacturers. The various

categories of fees that the rebate aggregators extract are wide-ranging and can be hard to trace, such as entity administration fees, prescription data services fees, data portal fees, enterprise fees, and other charges. The PBM Defendants insist such fees are not rebates and therefore do not need to be passed on to health plans. For example, Defendant GPOs charge 1% to 2% as a “data fee” for access to their “data portals,” even if the drug manufacturers do not ask for or need that service. Other fees include a 2% to 5% Enterprise or “Formulary Compliance” fee so that a manufacturer can ensure that its drug remains on the PBMs’ formularies. These various fees are in addition to the PBMs’ typical administrative service fees of 3% to 5% of the wholesale drug price. And these fees are likewise tied to the list price, reinforcing the PBMs’ incentive to artificially inflate the price of diabetes medications.

304. Years ago, the PBM Defendants recognized the challenges to growing their earnings streams and, to that end, engaged consultants to assist them in generating new sources of income. For example, CVS Health hired McKinsey in 2011, which told CVS that its existing trade model would see a \$600-\$900 million decline in rebates over the next five years.¹⁶⁷

305. CVS created a new GPO entity in 2020 (Zinc) to charge a 1% GPO reporting fee, separate from administrative services fees, and included a new data

¹⁶⁷ McKinsey-Caremark-0003452 at 0003454, 0003456.

portal and reports, and an enterprise fee that purported to be for the “additional value” the new GPO brought to the manufacturer.¹⁶⁸

306. In short, the PBMs changed their business model, focusing less on revenue derived from rebates and spread pricing, and instead focusing on charging manufacturers numerous, additional fees, without having to provide any additional value or services to the manufacturers. But to avoid any accountability or traceability for those fees, or any potential obligation to pass through the amounts received from manufacturers to their clients, the PBMs used rebate aggregators to negotiate and collect those fees from the manufacturers.

307. Although the drug manufacturers understood the PBMs’ changing business model and felt the effects of those increased, additional fees, the drug manufacturers had little recourse or ability to push back, given the hold the PBM Defendants have over the market. Moreover, the PBMs threaten that they will disadvantage the manufacturers against their competitors if they do not pay the increased fees.

308. Dr. Steven Miller, who helped create Ascent while he was Chief Medical Officer at Cigna and Express Scripts, admitted that rebate aggregators benefit their respective PBMs by charging fees that are not considered rebates, and therefore do not need to be passed through to health plans and patients. “There are

¹⁶⁸ CVS-MDLINS-001880834 at 0841 & 0851.

lots of different fees you can charge. You can charge data fees. You can charge administrative. You can charge clinical fees. The fees fall into different buckets. . . You can double-, triple-dip on fees.”¹⁶⁹

309. Although PBMs promise their clients and the public transparency as to the amount of rebates received from the manufacturers and passed through to the clients, payors cannot trace these additional fees, as they are negotiated and collected by the rebate aggregators rather than by the affiliated PBMs that contract with payors. Payors’ audit rights also do not extend to these fees, nor do the PBMs disclose the various “fees” the rebate aggregators collect and retain to the SEC or elsewhere.

310. For example, UnitedHealth Group’s then-CEO Andrew Witty promised “full transparency” and committed “to a full 100% pass-through of all rebates we negotiate at the PBM back to the payer, the state, or the union” on UnitedHealth Group’s 2024 fourth-quarter earnings call.¹⁷⁰ But these promises are misleading in that “full transparency” excludes any fees paid to Emisar, as opposed to the PBM, even though those fees are then remitted to the PBM.

311. Additionally, further impeding any meaningful oversight, certain

¹⁶⁹ “BullXXXX” – the New Way Health Giants Hide Billions, Hunterbrook Media (January 6, 2026), <https://hntbrk.com/pbmppo/> (“Hunterbrook Report”).

¹⁷⁰ UnitedHealth Group (UNH) Q4 2024 Earnings Call Transcript (Jan. 16, 2025), <https://www.fool.com/earnings/call-transcripts/2025/01/16/unitedhealth-group-unh-q4-2024-earnings-call-trans/>

rebate aggregators are located offshore, including Defendant Ascent, in Switzerland, and Defendnat Emsiar, which is based in Ireland.

312. In August of 2025, the House Committee on Oversight and Government Reform opened a probe into Emisar and Ascent, “seeking information about how they use foreign headquartered group purchasing organizations (GPOs) to evade transparency and oversight in the United States.”¹⁷¹ The letters the Committee sent to Cigna and Optum Rx alleged that the creation of offshore rebate aggregators “appears to be yet another example of the institutional intent at opacity and avoidance of oversight within your company.”¹⁷²

313. The PBM Defendants claim that the rebate aggregators handle rebate negotiations and contracting, but these are the tasks the PBMs also claim to perform themselves.

314. The rebate aggregators, which amount in effect to shell corporations, are often thinly staffed and shielded from public view. For example, Zinc has no website or phone number, and its headquarters in Bloomington, Minnesota is a largely empty suite next door to other CVS offices.

315. Similarly, Emisar has no website, email, or phone contact information and few employees, most of whom are located in Ireland. Emisar’s small Dublin

¹⁷¹ <https://oversight.house.gov/release/chairman-comer-expands-pbm-investigation-seeks-information-about-foreign-headquartered-group-purchasing-organizations/>

¹⁷² Id. and letters cited therein.

offices are in an Optum office building.

316. Ascent occupies a one-floor headquarters in the Swiss town of Schaffhausen. When investigators went to those headquarters, they found approximately a half-dozen employees in the office. When a receptionist was asked how many people come to the office, she said “[j]ust a few.”

317. In testimony from May 2023 before a House Hearing on the Role of PBMs in Prescription Drug Markets, Greg Baker, the CEO of independent PBM AffirmedRx, testified: “These [PBM Defendant] GPOs were established, two of the three, overseas. If you go online and you look on LinkedIn, I have never been able to find more than 30 people associated with these big three GPOs, and they are bringing in close to \$200 billion a year in revenue for three entities.”¹⁷³

318. In other words, the offices from which Ascent, Emisar, and Zinc purportedly negotiate billions of dollars of discounts while also supposedly providing valuable services to drug manufacturers, are almost entirely empty and are housed in or next to their corporate affiliates. Despite bringing no value to the system, the rebate aggregators extract extraordinary payments, amounting to billions of dollars per year. Indeed, data portal fees and vendor fees ballooned from

¹⁷³ Transcript from Hearing before the Committee on Oversight and Accountability. House of Representatives, “The Role of PBMs in Prescription Drug Markets, Part I: Self-Interest or Healthcare?” (May 23, 2023) at 32, <https://www.congress.gov/118/meeting/house/116002/documents/HHRG-118-GO00-Transcript-20230523.pdf>.

near-zero in 2018 to over \$1.6 billion in 2022. One source estimated that the three entities bring in approximately \$50 million in revenue per employee—an estimate confirmed by former OptumRx and Emisar executive Kent Rogers, who estimated that the rebate aggregators bring in “tens of millions, if not close to \$100 million, per employee.” By comparison, Apple—one of the world’s most profitable companies—generated approximately \$2.4 million per employee in 2024.

319. Although the rebate aggregators are incorporated separately and some PBM Defendants have disclaimed that the rebate aggregators are sister companies, PBM Defendant employees often report to supervisors at the rebate aggregators, and the rebate aggregator and PBM employees often report to the same supervisors within the conglomerates.

320. All told, the advent of rebate aggregators in the already complicated chain of financial transactions between drug manufacturers, pharmacy benefit managers, and payors creates an additional veil obfuscating the rebate payment trail and facilitates the PBMs’ extraction of mislabeled rebates and additional fees from the Manufacturers without adding any value. Neither the rebate aggregators nor their parent companies report financial data specific to the rebate aggregators.

321. The rebate aggregators simply replicate tasks that the PBM Defendants previously conducted themselves. As the New York Times concluded following its extensive investigation into the PBM industry, rebate aggregators

“harvest billions of dollars in fees from drug companies, money that flows straight to [the PBMs’] bottom line and does nothing to reduce health care costs.”¹⁷⁴

322. As a former Zinc executive similarly conceded, “It was all on paper and it was all transactional money flowing through contracts. There was nothing I had to send to you or to sell to you.”¹⁷⁵ The executive explained: “There was nothing to sell you. It was just access to the formularies.”¹⁷⁶

323. A former Zinc executive also employed by CVS Caremark further reported: “You really don’t know a PBM from a GPO because there is no difference Think of the PBM/GPO as one entity [T]here was literally a temporary wall put up between Zinc and Caremark. No separate building Zinc and Caremark reported to the same VP.”¹⁷⁷

324. Indeed, the PBMs had to force manufacturers to purchase data access. According to a former Zinc executive, drugmakers would say “I don’t need it, I don’t want it,” but Zinc would threaten to “disadvantage you versus your

¹⁷⁴ N.Y. Times, *The Opaque Industry Secretly Inflating Prices for Prescription Drugs* (June 21, 2024),

<https://www.nytimes.com/2024/06/21/business/prescription-drug-costs-pbm.html>.

¹⁷⁵ “BullXXXX” – the New Way Health Giants Hide Billions, Hunterbrook Media (January 6, 2026), <https://hntrbrk.com/pbmppo/> (“Hunterbrook Report”).

¹⁷⁶ *Investigation Reveals the New Way Giants Like UnitedHealth Hide Billions From Patients*, YouTube (Jan. 12, 2026), https://www.youtube.com/watch?v=t2_iYAMY2FA.

¹⁷⁷ “BullXXXX” – the New Way Health Giants Hide Billions, Hunterbrook Media (January 6, 2026), <https://hntrbrk.com/pbmppo/> (“Hunterbrook Report”).

competitors,” even though the data was “minimal” and “not . . . very useful.”¹⁷⁸

325. A former employee of Ascent similarly conceded that the rebate aggregators brought no value but simply shifted funds across companies: “From here it looks like shifting moneyThey move money here and there.”¹⁷⁹

326. While the rebate aggregators now refer to themselves as GPOs, they do not play the role of a traditional GPO. The PBMs themselves already aggregated covered lives and wielded massive negotiating power. A manufacturer’s failure to obtain formulary access from those PBMs would be devastating. Consistent with this reality, Express Scripts stated in 2023: “Ascent is not a GPO.”¹⁸⁰ Today, Express Scripts tells a different story, falsely claiming that, in 2019, “Express Scripts . . . launched a GPO called Ascent Health Services” to “achieve deeper rebates to make prescription medicines more affordable.”

327. In an attempt to quantify the revenue PBMs receive from retained rebates, a 2023 report calculated PBM compensation from rebates and other kickbacks between 2018 and 2022 (the period during which rebate aggregators were introduced), and found that this compensation had *doubled*, from \$3.8 billion in 2018 to \$7.6 billion just a few years later.¹⁸¹ “This growth was fueled by

¹⁷⁸ *Id.*

¹⁷⁹ *Id.*

¹⁸⁰ *Id.*

¹⁸¹ Eric Percher, Trends in Profitability and Compensation of PBMs and PBM Contracting Entities, Nephron Research (Sept. 18, 2023),

increases in traditional administrative fees as well as the emergence of new data and PBM contracting entity fees.”¹⁸² During the same period, “administrative fees” grew from \$3.8 to \$5.8 billion.¹⁸³

328. The report also showed that that “Fees & GPO” became a larger percentage of the PBMs’ gross profits over “Rebates & Price Protection” and spread pricing, with growth accelerating between 2016 and 2020, which coincided with a proposal by the first Trump administration to remove the safe harbor for PBM rebates from federal anti-kickback laws.¹⁸⁴

329. And, as admitted by a former OptumRx executive who helped set up Emisar, OptumRx’s rebate aggregator, “The intention of the G.P.O. [rebate aggregator] is to create a fee structure that can be retained and not passed on to a client.”¹⁸⁵

330. The rebates retained by the PBM Defendants’ affiliated rebate aggregators and the revenues the PBM Defendants ultimately obtain from their

https://nephronresearch.bluematrix.com/sellside/AttachmentViewer.action?encrypt=1c65fc0e-f558-4f1d-891f-21c196a9f1ad&fileId=7276_04a77b17-d298-48a2-bd15-1c5ed22a6984&isPdf=false (last visited Nov. 6, 2024).

¹⁸² *Id.*

¹⁸³ Adam Fein, Texas Shows Us Where PBMs’ Rebates Go, Drug Channels (Aug. 9, 2022), <https://www.drugchannels.net/2022/08/texas-shows-us-where-pbms-rebates-go.html> (last visited Nov. 6, 2024).

¹⁸⁴ Nephron Research, *supra*.

¹⁸⁵ Rebecca Robbins & Reed Abelson, *The Opaque Industry Secretly Inflating Prices for Prescription Drugs*, N.Y. TIMES (June 21, 2024), <https://www.nytimes.com/2024/06/21/business/prescription-drug-costs-pbm.html>.

rebate aggregators is hidden. The contractual provisions between PBM Defendants and rebate aggregators—as well as those between PBM Defendants, rebate aggregators, and pharmaceutical manufacturers—also remain hidden from health plan payors. The contracts between health plan payors and the PBM Defendants are often silent on the role of rebate aggregators. For instance, a review of Orange County, California’s contract with OptumRx showed that the contract language did not address rebate dollars retained by OptumRx’s subcontracted or affiliated rebate aggregators.¹⁸⁶ Thus, PBM Defendants can conceal payments through these rebate aggregator agreements, allowing them to falsely claim that they pass through all or a substantial portion of their rebates, while pocketing large profits.

331. Before establishing Emisar, OptumRx worked with another rebate aggregator, the Coalition for Advanced Pharmacy Services, or “CAPS.” CAPS is also a subsidiary of OptumRx, and ultimately of UnitedHealth Group. A 2017 audit conducted by a local governmental entity on OptumRx related to its PBM activities from 2013 to 2015 was unable to verify the percentage of rebates OptumRx remitted to its client payor because OptumRx would not allow the auditor access

¹⁸⁶ Jonathan Levitt, *Pharmacy Benefit Managers and the Prescription Drug Supply Chain: Impact on Patients and Taxpayers*, Written Testimony Before the U. S. S. Comm. on Fin. (Feb. 2022), https://www.finance.senate.gov/imo/media/doc/Jonathan%20Levitt%20Testimony%20US%20Senate%20Committee%20on%20Finance%20-%20Frier%20Levitt%20-%20March%202023_Redacted1.pdf.

to its rebate contracts. The audit report explained:

Optum[Rx] has stated that it engaged the services of an aggregator to manage its rebate activity. Optum[Rx] shared that under this model, they are paid by their aggregator a certain amount per prescription referred. Then, the aggregator, through another entity, seeks rebates from the drug manufacturers, based upon the referred [Payor Client] prescription utilization, and retains any rebate amounts that may be received. Optum[Rx] states that they have paid [Payor Client] all amounts it has received from its aggregator, and that they do not have access to the contracts between the aggregator (and its contractors) and the manufacturer. However, our understanding is that Optum[Rx] has an affiliate relationship with its aggregator.¹⁸⁷

332. A footnote in the audit report clarifies that “Optum[Rx] contracted with Coalition for Advanced Pharmacy Services (CAPS), and CAPS in turn contracted with Express Scripts, Inc. (ESI).”¹⁸⁸

333. In other words, according to this report, OptumRx contracted with its own affiliate aggregator, CAPS, which then contracted with OptumRx’s co-conspirator Express Scripts, which then contracted with the Manufacturers for rebates related to OptumRx’s client’s drug utilization. OptumRx then used this complex relationship to mask the amount of Manufacturer Payments generated from its client’s utilization.

334. A subsequent audit by the same local entity, covering the period

¹⁸⁷ Laura Rogers & Stacey Thomas, Broward County Florida, Audit of Pharmacy Benefit Management Services Agreement, No. 18-13 (Dec. 7, 2017), available at https://cragenda.broward.org/docs/2018/CCCM/20180109_555/25990_2017_1212%20Exh1_OptumRx%20-%20Revised%20Item.pdf (last visited Apr. 24, 2024).

¹⁸⁸ *Id.* at n.3.

September 2017 to September 2018, concluded:

Several material weaknesses in Broward's agreement with Optum were identified, many of which are commonplace across pharmacy benefit manager agreements in general. Due to contract weaknesses, a comparison of Broward's PBM agreement, including rebate amounts received, to the Consultant's marketplace data is not feasible. Broward could save an estimated \$1,480,000 per year in net prescription drug benefit expenses (based upon minimum rebate guarantees) by switching from its current flawed agreement with Optum, to an agreement with its Coalition, which offers clearly defined terms, increased rebate guarantees and cost saving requirements.¹⁸⁹

335. Among other "loopholes" discovered in the contract were a number of "flawed" (i.e., vague and manipulable) definitions, including (a) the definition of "Rebates," which "allows the exclusion of monies that should be included" and (b) limitations with respect to "Pass Through Transparency Pricing."

336. As a result, these fees are neither passed through to payors nor subject to audit under the terms of payors' sponsor agreements with the PBMs. Because the rebate aggregators are PBM subsidiaries, however, the PBMs secure additional profits from each drug purchase.

337. Payors cannot trace these additional amounts, as they are negotiated and collected by the PBMs' affiliate-GPOs and not the PBM-entities that contract with payors. These amounts are not subject to audit, nor do the PBMs disclose the

¹⁸⁹ Broward County, Florida, Analysis of Broward County's Prescription Drug Coverage, https://www.broward.org/Auditor/Reports/Reports/082019_Exh1_BCRxDrug_19-15.pdf (last visited July 3, 2023).

various “fees” the GPOs collect and retain to the SEC or elsewhere. Discussing the lack of transparency regarding rebate aggregators, Stephanie Seadler, Vice President of Trade Relations at EmsanaRx noted that “And so while they [i.e., employers] are getting some rebates, they are not getting everything. They’re also not getting the data to help validate what they’re getting. I think that’s changed a lot with the GPOs because it’s easy for the PBM to say, ‘The GPO is a third party. We don’t own those contracts, and because we don’t own them, we can’t give the data and the transparency because they’re not ours.’ It’s time to rethink what that looks like.”¹⁹⁰

338. Although the revenues retained by the PBM Defendants and their respective rebate aggregators remain hidden, there is evidence to suggest the retained rebate amounts are substantial. A Medicare plan audited its pharmacy benefit manager and found that the “rebate aggregator collected all the dollars, and it only gave about 40% of those dollars to the PBM.”¹⁹¹ Thus, while the pharmacy benefit manager contract stated that the pharmacy benefit manager would pass through 90% of the rebates to the plan, it neglected to mention that “the PBM rebate

¹⁹⁰ Angela Maas, *How Do Pharma/PBM Contracts Play Role in Rebate Leakage? Part 2*, Managed Mkts. Insight & Tech. (Apr. 21, 2022), <https://www.mmitnetwork.com/aishealth/spotlight-on-market-access/how-do-pharma-pbm-contracts-play-role-in-rebate-leakage-part-2/>.

¹⁹¹ Rose McNulty, *In Drug Pricing, PBMs Called the “Arsonist and the Firefighter in One”*, Am. J. of Managed Care (Dec. 16, 2020) <https://www.ajmc.com/view/in-drug-pricing-pbms-called-the-arsonist-and-the-firefighter-in-one->.

aggregator had sucked 62% of the money out of the system.”¹⁹²

339. Dave Ricks, CEO of Eli Lilly, stated that the majority of the \$8 billion Eli Lilly paid in 2022 in rebate checks went to rebate aggregators, rather than directly to pharmacy benefit managers.¹⁹³

340. The January 2021 Senate Insulin Report summarized the Senate Finance Committee’s findings from its two-year probe into the Insulin Pricing Scheme and contained the following observation on these rebate aggregators:

[T]he recent partnership between Express Scripts and Prime Therapeutics may serve as a vehicle to avoid increasing legislative and regulatory scrutiny related to administrative fees by channeling such fees through a Swiss-based group purchasing organization (GPO), Ascent Health. While there are several regulatory and legislative efforts underway to prohibit manufacturers from paying administrative fees to PBMs, there is no such effort to change the GPO safe harbor rules. New arrangements used by PBMs to collect fees should be an area of continued investigative interest for Congress.¹⁹⁴

341. Federal regulations governing Medicare attempt to capture all possible forms of Direct or Indirect Remuneration (DIR) to PBMs (and plan sponsors), defining the term as “any form of price concession” received by a plan sponsor or PBM “from any source,” including “discounts, chargebacks, rebates, cash

¹⁹² *Id.*

¹⁹³ Arthur Allen, *A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen*, KFFHealthNews (May 22, 2023), <https://kffhealthnews.org/news/article/a-more-aggressive-ftc-is-starting-to-target-drug-mergers-and-industry-middlemen/>.

¹⁹⁴ Senate Insulin Report at 83.

discounts, free goods contingent on a purchase agreement, up-front payments, coupons, goods in kind, free or reduced-price services, grants, legal judgment amounts, settlement amounts from lawsuits or other legal action, and other price concessions or similar benefits and specifically including “price concessions from and additional contingent payments to network pharmacies that cannot reasonably be determined at the point of sale.”¹⁹⁵

342. The Department of Health and Human Services, Centers for Medicare & Medicaid Services (CMS) considers all of the following as DIR: rebates, grants, reduced price administrative services, PBM-retained rebates, PBM rebate guarantee amounts, all post-point of sale payments by pharmacies that are not included in the negotiating price including dispensing incentive payments, prompt pay discounts, and payment adjustments. On the other hand, “bona fide service fees from pharmaceutical manufacturers” and “remuneration for administrative services with no impact on the sponsor’s or PBM’s drug cost (e.g., PBM incentive payments)” are *not* considered DIR *but only to the extent they reflect fair market value for services rendered*.¹⁹⁶

343. Because the PBM Defendants retain and conceal most of the secret

¹⁹⁵ CMS, *Final Medicare Part D DIR Reporting Guidance for 2021* at 7, <https://www.cms.gov/files/document/final2021dirreportingreqsmemo508v3.pdf> (last visited Jan. 15, 2023).

¹⁹⁶ *Id.* at 6-7.

Manufacturer Payments that they receive, they reap exorbitant profits from the Insulin Pricing Scheme.

344. Even when payor clients receive a portion of the Manufacturer Payments from their PBM, the payors are significantly overcharged, given the extent to which Defendants have deceptively and egregiously inflated the prices of the at-issue drugs.

345. On September 20, 2024, the Federal Trade Commission brought suit against the PBM Defendants and their affiliated rebate aggregators for violations of Section 5 of the Federal Trade Commission Act “for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable patients.”¹⁹⁷

346. Specifically, the recent FTC Complaint revealed, among other things, (a) that the PBM Defendants’ affiliated rebate aggregators “now perform the same commercial contracting function that the PBMs previously handled directly” and that the PBM Defendants “simply moved their commercial rebate contracting functions” to their affiliated rebate aggregators; (b) that the rebate aggregators solicit commercial bids from manufacturers using rebate grids “with different

¹⁹⁷ *FTC v. CaremarkRx, LLC*, No. 221 0114 (FTC Sept. 20, 2024), ECF No. 9437, at 27.

rebate rates for different levels of exclusivity: exclusive coverage (1 of 1 manufacturer), dual coverage with another manufacturer (1 of 2), and multiple manufacturers (1 of many)”; and (c) that the rebate aggregators extract WAC-based fees from drug manufacturers as part of commercial negotiations but “provide no additional services to justify the higher payout on higher list price drugs from the assortment of WAC-based fees” the rebate aggregators extract from the manufacturers.

347. As explained in the FTC Administrative Complaint, the PBM Defendants and Rebate Aggregator Defendants “extracted and pocketed . . . [redacted] dollars without providing any additional value.”¹⁹⁸In 2024, the Illinois Attorney General recovered a \$45 million settlement from CVS Caremark for failing to pass through rebates to the state health plan that Caremark and Zinc represented. In addition to the money, the settlement agreement modified the contract between Illinois and CVS Caremark to ensure that rebates negotiated by Zinc, as well as Caremark itself, would be fully passed through to the state.¹⁹⁹

348. Publicly released documents from that case include agreements

¹⁹⁸ *Id.*

¹⁹⁹ Paige Minemyer, Report: CVS to pay \$45M as part of settlement with Illinois (July 25, 2024), at [https://www.fiercehealthcare.com/payers/report-cvs-pay-45m-part-settlement-illinois#:~:text=CVS%20Health's%20Caremark%20has%20agreed,of%20rebates%20that%20it%20owed](https://www.fiercehealthcare.com/payers/report-cvs-pay-45m-part-settlement-illinois#:~:text=CVS%20Health's%20Caremark%20has%20agreed,of%20rebates%20that%20it%20owed; see also Hunterbrook Report, supra); see also Hunterbrook Report, *supra*.

between Zinc and CVS Caremark and CVS Pharmacy which indicate CVS Caremark has the information on how money flows between the drugmakers, the rebate aggregator, the PBM, and plan clients—but CVS does not permit its plan clients access to this information.

349. Other States, such as Louisiana, Ohio, Vermont, and Michigan have also sued the PBM Defendants and their rebate aggregators alleging that PBMs such as Express Scripts and CVS Caremark used their rebate aggregators to fix drug prices.

350. On March 27, 2024, the Office of Personnel Management (OPM) issued its Final Audit Report of the American Postal Workers Union Health Plan’s Pharmacy Operations as Administered by Express Scripts for Contract Years 2016 to 2021, finding that Express Scripts overcharged the Health Plan and the Federal Employees Health Benefits Program (“FEHBP”) by almost \$45 million, including almost \$16 million of rebates withheld by Ascent.²⁰⁰

351. The report cited contract provisions that required “PBM transparency standards” in which “[t]he PBM agrees to provide pass-through transparent pricing

²⁰⁰ Office of Personnel Management, Office of the Inspector General, Office of Audits, Final Audit Report of the American Postal Workers Union Health Plan’s Pharmacy Operations as Administered by Express Scripts for Contract Years 2016 Through to 2021 (March 27, 2024), <https://www.oversight.gov/sites/default/files/documents/reports/2024-10/2022-SAG-029.pdf>.

based on the PBM’s cost for drugs . . . in which the [health plan] receives the value of the PBM’s negotiated discounts, rebates, credits or other financial benefits.”²⁰¹ The report also found that in 2019, Express Scripts established Ascent to “handle all drug manufacturer rebate administration”²⁰² and Ascent “kept a portion of the rebates,” which Ascent agreed to voluntarily return without conceding that it had violated the contract.²⁰³

352. OPM found the same issue when it audited the Compass Rose federal employee health plan in 2024 and discovered that Ascent kept 14.264%, or over \$10 million, of the total rebates it received from mid-2019 through 2021, even though the contract contained the same language about transparent drug pricing.²⁰⁴ “The differences in rebate percentages between what was received by the [health plan] and the FEHBP in comparison to the PBM’s drug manufacturer agreements were due to lower rebate percentages agreed to internally between the PBM and Ascent, thereby allowing Ascent to keep the portion of rebates that we are

²⁰¹ *Id.* at 8.

²⁰² *Id.* at 23.

²⁰³ *Id.*; see also Hunterbrook Report, *supra* at n.26.

²⁰⁴ Office of Personnel Management, Office of the Inspector General, Office of Audits, Final Audit Report, Audit of Compass Rose Health Plan’s Pharmacy Operations as Administered by Express Scripts for Contract Years 2017 through 2022 (November 14, 2024), <https://www.oversight.gov/sites/default/files/documents/reports/2025-01/2023-SAG-019.pdf>.

questioning.” Express Scripts again returned the money.²⁰⁵

353. In short, the PBM Defendants use their respective rebate aggregators to charge additional fees to drug manufacturers which are hidden from, and not passed on to, their health plan clients, often in contravention of specific contractual language. The PBM Defendants line their pockets with these additional fees while drug prices, including insulin prices, continue to rise, despite the PBM Defendants’ promises to lower costs.

354. Indeed, Defendants specifically misrepresent the purpose and effect of rebate aggregators. For example:

A. Express Scripts falsely represented that it was a “myth” that “Express Scripts created a group purchasing organization (GPO)—Ascent—to escape PBM regulations and maintain the high-price status quo.”²⁰⁶

B. Express Scripts falsely stated that, “[a]s a GPO, Ascent makes prescription drugs more affordable by aggregating purchasing across health plans and PBMs to negotiate greater discounts with pharmaceutical manufacturers. By leveraging its combined scale, Ascent helps ensure that manufacturers provide competitive rebates to the benefit of its plan sponsor clients.”²⁰⁷

²⁰⁵ *Id.*

²⁰⁶ Evernorth, Myths + Facts, <https://www.evernorth.com/esfacts/myths-facts>.

²⁰⁷ *Id.*

C. Express Scripts falsely stated: “In 2019, in response to out-of-control drug price inflation by pharmaceutical manufacturers, Express Scripts and a co-founder launched a GPO called Ascent Health Services. . . . On behalf of its participants, Ascent negotiates with pharmaceutical manufacturers to achieve deeper rebates to make prescription medicines more affordable.”²⁰⁸

D. A CVS spokesperson misrepresented that “CVS Caremark leverages Zinc as a GPO to help further drive down the cost of prescription drugs.”

E. CVS Health falsely represented that Zinc charges fees for “services rendered” and that manufacturers only pay a GPO portal fee “[i]f the manufacturer determines the portal’s capabilities offer value to the manufacturer.”²⁰⁹

F. OptumRx misrepresented that “Emisar . . . offers innovative data analytics services to pharmaceutical manufacturers” and that “[t]he fees for these data services are unrelated to the rebates and administrative fees disbursed to clients and are for services the manufacturer would otherwise

²⁰⁸ *Id.*

²⁰⁹ CVS Health Responses to Questions for the Record, Committee on Energy and Commerce (Mar. 12, 2026), <https://docs.house.gov/meetings/IF/IF14/20260122/118890/HMTG-119-IF14-Bio-JoynerD-20260122.pdf>.

develop or purchase from another entity.”²¹⁰

G. OptumRx falsely stated that it uses Emisar as a GPO because GPOs are “efficient and can offer lower costs” and that “[t]he result is greater scale and aggregated negotiating power to drive lower costs.”²¹¹

H. Ascent similarly misrepresents that it negotiates better pharmaceutical discounts and supply terms on behalf of health plans and offers transparent data.

I. The PBM Defendants likewise have continued to misrepresent that they pass through 100% of rebates and that they provide transparency, despite the fact that rebate aggregators syphon off rebates for themselves and their affiliates and obscure the flow of funds.²¹²

²¹⁰ OptumRx’s Answer to the Complaint, In the Matter of CaremarkRx LLC, No. 9437 (F.T.C. Oct. 9, 2024), https://www.ftc.gov/system/files/ftc_gov/pdf/611919.2024.10.09_optum_rxs_answer_to_complaint_0.pdf.

²¹¹ Optum, How Do Group Purchasing Organizations Help? (Jan. 27, 2026), <https://lp.optum.com/en/group-purchasing-organizations.html>.

²¹² See, e.g., Optum, How OptumRx Goes Further to Promote Transparency (Oct. 10, 2025), <https://business.optum.com/en/pharmacy-benefit-management.html> (stating that OptumRx is a “transparent pharmacy benefit manager” that provides “100% pass-through”); Express Scripts, How We Share the Value We Create with Clients, <https://www.evernorth.com/sites/default/files/2024-03/HowExpressScriptsSharesInTheValueWeCreate.pdf> (stating that Express Scripts offers “transparent pricing models” and that clients “[r]eceive 100% of the rebate amount”); CVS Health, CVS Health Introduces New Approach to Pricing of PBM Services (Dec. 5, 2018), <https://investors.cvshealth.com/news/news-details/2018/CVS-Health-Introduces-New-Approach-to-Pricing-of-Pharmacy->

355. These representations about rebate aggregators are false or misleading. By way of example, rebate aggregators increase costs by charging fees tied to list price, thus incentivizing the coverage of higher-cost drugs, including diabetes medications; rebate aggregators mislabel and syphon off rebates to avert 100% pass-through; rebate aggregators obscure the flow of funds rather than providing transparency; and rebate aggregators charge fees that are unrelated to the value of their services but instead represent rebates intended to buy formulary access.

3. Illusory Audit Provisions

356. The PBM Defendants are able to shield the true magnitude of profit from rebates and other fees through the relabeling of these rebates and the use of rebate aggregators. They also shield the true magnitude of profit by providing health plan payors, such as Plaintiff, no meaningful opportunity to audit their pharmacy benefit services and their contracts with the Manufacturer Defendants and rebate aggregators.

357. The PBM Defendants assert that their contracts with the Manufacturer Defendants and the rebate aggregators are confidential and proprietary. Accordingly, any audit done by a health plan payor, such as Plaintiff, would not

Benefit-Management-Services/default.aspx (stating that “CVS Caremark will pass through 100 percent of rebates to plan sponsors”).

reveal the details of the rebate arrangements. And because the rebate aggregators contract directly with the Manufacturer Defendants, the PBM Defendants can tell health plan payors that they have no insight into those contracts. By creating rebate aggregators, the PBMs have created a new middleman that allows them to sequester off payments made from Drug Manufacturers, without having to include any contractual language regarding these rebate aggregators in their contracts with health plan payors.

358. Health plan payors, such as Plaintiff, are left with no real avenue to ascertain what amount of rebates and fees the PBM Defendants receive from the Drug Manufacturers. Likewise, health plan payors, such as Plaintiff, are left with no real avenue to ascertain whether these rebates and fees are being passed through.

F. Insulin Adjuncts: Type 2 Medications

359. Over the past 15 years, the Manufacturer Defendants released several non-insulin medications that help control insulin levels. In 2010, Novo Nordisk released Victoza, and thereafter Eli Lilly released Trulicity and Sanofi released Soliqua. Novo Nordisk further expanded their GLP-1 patent portfolio with the approval of Xultophy and Ozempic.²¹³ In 2022, Eli Lilly received approval for yet another GLP-1, Mounjaro. Each of these medications can be used in conjunction

²¹³ Victoza, Trulicity, Ozempic, and Mounjaro are glucagon-like peptide-1 receptor agonists (“GLP-1”) and mimic the GLP-1 hormone produced in the body. Soliqua and Xultophy are combination long-acting insulin and GLP-1 drugs.

with insulins to control diabetes.

360. Manufacturers negotiate rebates and other fees with PBMs as a single diabetes drug class that includes insulin and GLP-1 receptor agonist (GLP-1) medications. This practice is known as “bundling”.

361. Manufacturer Defendants bundle medications to gain formulary access for multiple drugs in exchange for increased manufacturer payments to PBMs.

362. In 2013, Novo Nordisk tied its “exclusive” rebates for insulin to formulary access for GLP-1 medication, Victoza. The exclusive rebates of 57.5% for Novolin, Novolog, and Novolog Mix 70/30 were more than three times higher than the 18% rebate for plans that included two insulin products on their formulary. In order to qualify for the exclusive rebate, the plans would also need to list Victoza on their formulary, exclude all competing insulin products, and ensure existing patients switch from competitor diabetes medications.²¹⁴

363. Upon information and belief all Manufacturer Defendants negotiate the prices of insulin and GLP-1 medications through bundling.

364. The first GLP-1 was approved by the FDA in 2005 and was indicated for the treatment of Type 2 diabetes. Currently, the GLP-1 market is consolidated among a limited number of patent-holding entities, with Manufacturer Defendants

²¹⁴ U.S. S. Fin. Comm., *supra* n.9 at 78 and 79.

Eli Lilly, Novo Nordisk, and Sanofi controlling much of this market.

365. Through extensive patents and regulatory exclusivities, the Manufacturer Defendants have effectively barricaded competition from the GLP-1 market, giving them the ability to exercise comprehensive control over the price of GLP-1 medications.

366. To date, no generic alternative exists for any GLP-1 medication and the Manufacturer Defendants will continue to enjoy patent protection of their respective GLP-1 agonist molecules through at least 2030, if not later.²¹⁵

367. Novo Nordisk developed and sells three GLP-1 drugs indicated for Type 2 diabetes: Victoza (liraglutide), Xultophy (insulin degludec/liraglutide) and Ozempic (semaglutide). Novo Nordisk holds 62 patents related to semaglutide and liraglutide—46 of those patents are device patents unrelated to the therapeutic molecule of the GLP-1.²¹⁶

368. Eli Lilly developed and sells two GLP-1 drugs indicated for Type 2 diabetes: Trulicity (dulaglutide) and Mounjaro (tirzepatide/GIP). Eli Lilly holds 18 patents related to dulaglutide and tirzepatide. Of the 4 patents related to tirzepatide, 2 of those patents are device patents unrelated to the therapeutic molecule of the GLP-1. Eli Lilly has applied for 78 patents related to dulaglutide, 17 of which have

²¹⁵ Alhiary, Rasha *et al.* *Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists*, J. Am. Med. Ass'n 650-657, 330 (2023).

²¹⁶ *Id.*

been granted to date.²¹⁷


369. Sanofi developed Adylxin (lixisenatide) and Soliqua (insulin glargine/lixisenatide) but currently only sells Soliqua in the United States. Sanofi holds 42 patents related to lixisenatide – 29 of those patents are device patents unrelated to the therapeutic molecule of the GLP-1.²¹⁸

370. This patent stacking and evergreening ensures that generic and other branded GLP-1 cannot enter the market and gives Novo Nordisk, Eli Lilly, and Sanofi disproportionate pricing power over GLP-1 medications.

371. In addition to the limited competition in the GLP-1 landscape, Manufacturer and PBM Defendants use this disproportionate pricing power to steadily raise the price of GLP-1s, consistent with the broader Insulin Pricing Scheme.

²¹⁷ *Id.*

²¹⁸ *Id.*



372. As shown above, counterintuitively, list and net prices increased as more GLP-1 medications were approved and introduced. Between 2007 and 2017 the average list price of GLP-1s rose 15% per year despite the introduction of competing brands. The net price increased an average of 10% per year during the same time period.²¹⁹

373. The PBM Defendants are also central to these untethered price increases. As shown in the chart above, the growing disconnect between list prices and net prices of these drugs further demonstrates the PBM Defendants ill-gotten

²¹⁹ Sarpatwari, Ameet, *et al. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear*, Health Affairs, 40, 772–778 (2021).

gains through identical methods to those employed in the Insulin Pricing Scheme.

374. The absence of generics in the GLP-1 market allows manufacturers to keep prices artificially high. PBMs then realize the benefit of these artificially high prices through manufacturer payments in exchange for formulary placement. PBMs and manufacturers are thus incentivized to increase prices or maintain high, untethered prices for GLP-1s.

375. Further, GLP-1s are significantly more expensive in the United States compared to other countries, indicating that the increasing price of GLP-1s are untethered to any legal, competitive, or fair market price. For example, in 2023, the list price for a one-month supply of Ozempic was about \$936 in the United States, \$147 in Canada, \$103 in Germany, \$93 in the United Kingdom, \$87 in Australia, and \$83 in France.

376. In 2018, Victoza's list price in the United States was more than double its average list price in eleven comparable countries and Trulicity's list price in the United States was more than six times its average list price in eleven comparable countries. One study found that drug companies could profitably sell certain GLP-1s, including Ozempic, for \$0.89–\$4.73 per month.

377. In March 2024, PBM Defendant Evernorth entered into a financial guarantee agreement for GLP-1 spend with Manufacturer Defendants Novo Nordisk and Eli Lilly to limit the annual cost increase of GLP-1s to 15%.²²⁰

378. Like the caps put in place for insulin, Evernorth, Eli Lilly and Novo Nordisk's, agreement suggests that the prices of GLP-1s before March 2024, were not raised to cover costs of research and development, manufacture, distribution, or any other necessary expense. Such cost caps and savings guarantees indicate that the increasing price of GLP-1s were untethered to any legal, competitive, or fair market price. Further this agreement is prospective and does not mitigate damages already incurred by payors like Plaintiff, who have spent substantial sums on GLP-1 drugs in connection with the self-insured plan at-issue in this case.

G. Plaintiff Pays for the At-Issue Drugs

379. Defendants' schemes to make increasingly larger profits off of the at-issue drugs have devastating effects on consumers and come at a significant cost to health plan payors, like Plaintiff, who pay for their Beneficiaries' pharmaceutical purchases. Payors like Plaintiff rely on the PBM Defendants to control the costs of

²²⁰ *Evernorth Announces Industry First Financial Guarantee GLP-1 Spend*, Evernorth Health Servs. (Mar. 7, 2024) <https://www.evernorth.com/articles/evernorth-announces-industry-first-financial-guarantee-glp-1-spend>.

prescription medications and lower their administrative burdens. The resulting financial impact on Plaintiff is substantial given its unique obligations.

380. As a government entity, the City of Tacoma serves its residents by providing public safety, emergency management, and health services, among its numerous other vital roles. As local governments take on increased obligations traditionally borne by federal and state government, Plaintiff has more obligations with a limited budget. Consequently, any significant increase in spending can stress Plaintiff's overall budget and, in turn, negatively impact its ability to provide essential services to the community.

381. As an employer, Tacoma provides its Beneficiaries with ample benefits, including paying for a large portion of its Beneficiaries' pharmaceutical purchases. In this role, between 2014 and May 2024, Plaintiff spent over \$13 million on diabetes medications.

382. In its role as a payor, Tacoma maintains a self-funded plan. This means Plaintiff, rather than an insurance provider, pays for pharmaceutical benefits and prescription drugs, including the diabetes medications at issue here. Because of the City's self-funded status, it does not rely on a third-party insurer to pay for its Beneficiaries' medical care, pharmaceutical benefits, or prescription drugs.

383. The City of Tacoma pays for a significant portion of the price of the drugs at issue and has not knowingly participated in Defendants' Insulin Pricing

Scheme. In particular, after Beneficiaries pay their portions of the costs of insulin drugs manufactured by the Manufacturer Defendants, the City pays the remaining portions of the cost in connection with its self-insured plan for its Beneficiaries. Tacoma pays these amounts on a regular basis.

384. By purchasing the drugs at issue, Plaintiff has suffered losses because of the inflated prices resulting from Defendants' Insulin Pricing Scheme. Plaintiff pays artificially inflated costs resulting from the Insulin Pricing Scheme because its payments are derived from the artificially inflated insulin list prices. Plaintiff cannot avoid paying these sky-high, artificially inflated prices because of Defendants' exclusive control over the market for these life-saving drugs.

385. As a result of Defendants' Insulin Pricing Scheme, diabetes medications have consistently been a significant financial expense for Plaintiff. Plaintiff purchased diabetes medications, including those manufactured by the Manufacturer Defendants, such as Humalog, Humalog Mix 75/25, Humalog Mix 50/50, Humulin N, Humulin R, Humulin R 500, Humulin 70/30, Basaglar, Levemir, Novolog, Novolog Mix 70/30, Novolin R, Novolin N, Novolin 70/30, Toujeo Solostar, Apidra, Lantus, Mounjaro, Trulicity, Ozempic, Rybelsus, Victoza, and Xultophy.

386. Plaintiff relies on Prime Therapeutics in administering its health plans' pharmaceutical services. The services Prime Therapeutics has provided

Plaintiff include constructing and managing Plaintiff's pharmacy network (which included dispensing the at-issue drugs through the PBMs' retail and mail-order pharmacies) and adjudicating and processing pharmacy claims.

387. Through their agreement with Prime Therapeutics, Plaintiff relies on Express Scripts to limit and control its pharmaceutical drug costs. Specifically, Plaintiff relies on Express Scripts to conduct negotiations with Defendant Manufacturers for the at-issue drugs.

388. Defendant Express Scripts participated in the Insulin Pricing Scheme, which increased the prices Plaintiff paid for diabetic medications.

389. Neither the PBM nor the Manufacturer Defendants suffer losses from the Insulin Pricing Scheme. On the contrary, the PBM and Manufacturer Defendants financially benefit from the Insulin Pricing Scheme at Plaintiff's expense.

H. The Insulin Pricing Scheme Has Injured the City of Tacoma.

390. Plaintiff City of Tacoma provides health and pharmacy benefits to its Beneficiaries, including employees and their dependents. During the relevant period, Plaintiff has provided these benefits to approximately 10,000 individuals on an annual basis.

391. One of the primary benefits the City provides its Beneficiaries through its employee health plans is paying a significant portion of the Beneficiaries' prescription drug costs.

392. Through purchasing its Beneficiaries' prescription drugs, including the at-issue diabetes medications, Plaintiff has interacted with and engaged in business with the PBM Defendants concerning their pharmacy benefit services and the at-issue diabetes medications for years.

393. At all times until 2023, Plaintiff was unaware of the full nature and extent of the Insulin Pricing Scheme, Defendants' involvement and control over the Insulin Pricing Scheme, and the artificial inflation of the insulin prices it was paying as a result of Defendants' Insulin Pricing Scheme.

394. Plaintiff relied on Defendants' statements and material omissions made in furtherance of the Insulin Pricing Scheme.

395. Plaintiff relied on Defendants' misrepresentations in paying for the diabetes medications at issue at prices that would have been lower but for the Insulin Pricing Scheme devised and carried out by Defendants.

396. Health plan payors, including Plaintiff, were the direct and intended victims of the Insulin Pricing Scheme.

397. Plaintiff made payments for insulin based on the artificially inflated list prices that resulted from Defendants' Insulin Pricing Scheme.

398. Between 2014 and May 2024, Plaintiff spent over \$13 million on diabetes medications.

399. Defendants' relationship with the City of Tacoma are inherently unbalanced and their contracts adhesive. Although Defendants supply a vital service of a quasi-public nature, they nevertheless acted to exploit their superior bargaining positions to mislead Plaintiff and contravene Plaintiff's expectations, all at great expense to Plaintiff.

400. Defendants' misrepresentations, omissions, and misconduct in furtherance of the Insulin Pricing Scheme proximately caused economic damage to the City as a payor and purchaser of Defendant Manufacturers' at-issue drugs.

401. A substantial amount of Plaintiff's expenditures on diabetes medications is attributable solely to the artificial inflation of insulin list prices caused by Defendants' Insulin Pricing Scheme.

402. At all times before 2023, Plaintiff did not know and could not have known the full extent to which the prices it paid for diabetes medications were and continue to be artificially inflated due to Defendants' Insulin Pricing Scheme. Plaintiff lacked this knowledge because of Defendants' ongoing actions and omissions to conceal their scheme to raise the price of diabetic medications.

403. Consequently, Plaintiff unknowingly paid excess prices to the Manufacturer Defendants for diabetes medications for years despite receiving a

pass-through of some portion of rebates. The prices Plaintiff paid for these diabetes medications would have cost less but for Defendants' acts in carrying out the Insulin Pricing Scheme.

404. In short, Defendants' Insulin Pricing Scheme has directly and proximately caused Plaintiff to substantially overpay—and continue to overpay—for diabetes medications.

405. Because Defendants continue to generate exorbitant, unfair, and deceptive prices for the at-issue drugs through the Insulin Pricing Scheme, the harm to Plaintiff is ongoing.

V. TOLLING OF THE STATUTES OF LIMITATIONS

406. Plaintiff has diligently pursued and investigated its claims. Through no fault of its own, Plaintiff did not learn and—given Defendants' coordinated, successful efforts to mislead consumers and health plan payors like Plaintiff—could not have learned the full extent of the Insulin Pricing Scheme and the factual bases for its claims or the injuries suffered therefrom.

407. Consequently, the following tolling doctrines apply.

A. Accrual Rule

408. Defendants' acts, omissions, and misrepresentations alleged throughout this Complaint have continued to occur through the present day.

409. For example, in their 2022 SEC Form 10-K Annual Reports, the PBM Defendants represented that they work to reduce costs to the client.

410. Defendants continue to utilize rebates, relabeled fees, rebate aggregators, clawbacks, and spread pricing to profit from the Insulin Pricing Scheme.

411. Defendants set artificially inflated list prices for the at-issue insulin drugs. Each new list price is a new and independent act that harms Plaintiff. Plaintiff has overpaid for the at-issue drugs based on the artificially inflated and misrepresented list prices.

412. Plaintiff is overcharged for the at-issue drugs on a regular basis as a result of the Insulin Pricing Scheme. Each individual charge to Plaintiff based on the artificially inflated and misrepresented list prices constitutes a new and independent act in furtherance of the Insulin Pricing Scheme.

413. With each overpayment, Plaintiff suffers a new and accumulating injury. Every additional overpayment arising from Defendants' acts, omissions, and misrepresentations places additional stress on Plaintiff's budget, and in turn, on Plaintiff's ability to provide necessary services to its beneficiaries and the residents of Tacoma.

414. Had Defendants at any time ceased their wrongful conduct, further injury would have been avoided.

415. Accordingly, all applicable statutes of limitations are tolled.

B. Discovery Rule

416. Plaintiff was not aware of the full extent of the Insulin Pricing Scheme until shortly before filing this Complaint. Plaintiff was unaware of the extent to which it was economically injured and unaware that any economic injury was wrongfully caused. Nor did Plaintiff possess sufficient information concerning the injury complained of here, or its cause, to put Plaintiff or any reasonable person on notice that actionable conduct might have occurred.

417. The PBM and Manufacturer Defendants refused to disclose the actual prices of diabetes medications realized by Defendants or the details of the Defendants' negotiations and payments between each other or their pricing structures and agreements—Defendants labeled these trade secrets, shrouded them in confidentiality agreements, and circumscribed payor audit rights to protect them.

418. Each Defendant group affirmatively and fraudulently blamed the other for the price increases described herein, both during their Congressional testimonies and through the media. All Defendants disavowed wrongdoing and falsely claimed that their dealings with payors like Plaintiff were honest and transparent.

419. Plaintiff did not discover and could not have discovered until shortly before filing this Complaint facts sufficient to cause it or any reasonable person to

suspect that Defendants were engaged in the Insulin Pricing Scheme or that Plaintiff had suffered economic injury as a result of any or all Defendants' wrongdoing. Given Defendants' individual and coordinated efforts to obscure and conceal their misconduct, earlier diligent inquiry would not have disclosed the true facts had Plaintiff been aware of any cause to undertake such an inquiry.

420. Even today, lack of transparency in the pricing of diabetes medications and the arrangements, relationships, and agreements between and among the Manufacturer Defendants and the PBM Defendants, i.e., the Insulin Pricing Scheme, continue to obscure the full nature and extent of Defendants' unlawful conduct from Plaintiff and the general public.

421. For these reasons, the statutes of limitation did not begin to run until 2023 at the earliest.

C. Nullum Tempus

422. The City of Tacoma brings this case in its sovereign capacity for the benefit of the residents of Tacoma and the State of Washington.

423. The "regulatory oversight of health care benefit managers" is critical to "protect and promote the health, safety, and welfare of Washington residents." RCW 48.200.010(3).

424. In Washington, a pharmacy benefit manager "[m]ay not cause or knowingly permit the use of any advertisement, promotion, solicitation,

representation, proposal, or offer that is untrue, deceptive, or misleading.” RCW 48.200.280(2)(h).

425. Plaintiff provides numerous services for the public good of its residents and all residents of Washington State, including maintaining facilities for public recreation, safeguarding the City’s natural resources for the benefit of the public, and administering other services.

426. Defendants’ Insulin Pricing Scheme has resulted in artificially inflated and misleading list prices for the at-issue drugs.

427. As a result of Defendants’ Insulin Pricing Scheme, Plaintiff has overpaid for the at-issue drugs.

428. Each overpayment for the at-issue insulin drugs places additional stress on Plaintiff’s overall budget, and in turn, harms Plaintiff’s ability to provide these importance services for the public good of its residents and all residents of Washington State.

429. As a result of Defendants’ deceptive and misleading acts and omissions, Plaintiff is harmed in its ability to safeguard the City’s natural resources, maintain facilities for public recreation, and administer other important services.

430. Accordingly, Tacoma is exempt from the applicable statutes of limitation.

D. Fraudulent Concealment

431. Through the acts, omissions, and representations alleged throughout this Complaint, Defendants individually and through their conspiracy fraudulently concealed the fact of Plaintiff's economic injury and its cause.

432. Defendants' acts, omissions, and representations were calculated to lull and induce payors, including Plaintiff, into forbearing legal action or any inquiry that might lead to legal action. Defendants' acts, omissions, and representations were intended to and in fact did prevent Plaintiff from discovering operative facts supporting its claims.

433. Plaintiff acted diligently in pursuing this action once it became aware of facts sufficient to place it on notice of the extent to which it had been harmed and that such harm might have been attributable to misconduct by each or all Defendants, including through Defendants' coordinated efforts to implement and to conceal the Insulin Pricing Scheme.

434. Accordingly, all applicable statutes of limitation have been tolled.

E. Equitable Estoppel & Equitable Tolling

435. Defendants were under a continuous duty to disclose to Plaintiff the true character, quality, and nature of the prices upon which payments for diabetes medications were based, and the true nature of the services being provided—all of which would be and are now material to Plaintiff.

436. Instead of disclosing these facts, Defendants knowingly misrepresented and concealed them with a reasonable expectation that health plan payors, including Plaintiff, would act upon the misrepresentations and omissions.

437. Being unaware of the true facts and being unaware of the extent of the economic harm it was suffering, Plaintiff did indeed rely in good faith to its detriment on Defendants' misrepresentations and omissions.

438. In short, through Defendants' acts, omissions, and representations as alleged throughout this Complaint, Defendants knowingly misrepresented and concealed material facts with the expectation that Plaintiff would act upon them and would be misled thereby, which Plaintiff did in good faith and to its detriment.

439. Plaintiff acted diligently in pursuing this action once it became aware of facts sufficient to place it on notice of the extent to which it had been harmed and that such harm might have been attributable to misconduct by each or all Defendants, including through Defendants' coordinated efforts to implement and to conceal the Insulin Pricing Scheme. However, Defendants' misconduct served as an extraordinary circumstance that stood in Plaintiff's way and prevented Plaintiff from filing earlier.

440. Accordingly, Defendants are equitably estopped from relying on any statutes of limitation in defense of this action and all statutes of limitation have been equitably tolled.

VI. CLAIMS FOR RELIEF

COUNT ONE — VIOLATIONS OF THE RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS ACT (“RICO”) 18 U.S.C. §1962(C) (Against All Defendants)

441. Plaintiff incorporates by reference all preceding paragraphs up to Section V of this Complaint as though fully set forth herein.

442. Plaintiff brings this count against all Defendants for violations of 18 U.S.C. § 1962(c).

443. Defendants are (1) culpable “persons” who (2) willfully and knowingly (3) committed and conspired to commit two or more acts of mail and wire fraud (4) through a “pattern” of racketeering activity that (5) involves an “association in fact” enterprise, (6) the results of which had an effect on interstate commerce.

A. Defendants Are Culpable “Persons” Under RICO.

444. Defendants, separately, are “persons” as that term is defined in 18 U.S.C. § 1961(3) because each is capable of holding a legal or beneficial interest in property.

445. Each one of Defendants are separate entities and “persons” that are distinct from the RICO enterprises alleged below.

B. The Manufacturer–PBM RICO Enterprises

446. For the purposes of this claim, the RICO enterprises are nine separate associations-in-fact each consisting of one PBM Defendant and one Manufacturer Defendant, including those entities’ directors, employees, and agents:

- A. the Eli Lilly–CVS Caremark Enterprise;
- B. the Eli Lilly–Express Scripts Enterprise;
- C. the Eli Lilly–OptumRx Enterprise (together with the Eli Lilly–CVS Caremark Enterprise and the Eli Lilly–Express Scripts Enterprise, the “Eli Lilly–PBM Defendant Enterprises”);
- D. the Sanofi-Aventis–CVS Caremark Enterprise;
- E. the Sanofi-Aventis–Express Scripts Enterprise;
- F. the Sanofi-Aventis–OptumRx Enterprise (together with the Sanofi-Aventis–CVS Caremark Enterprise and the Sanofi-Aventis–Express Scripts Enterprise, the “Sanofi-Aventis-PBM Defendant Enterprises”);
- G. the Novo Nordisk–CVS Caremark Enterprise;
- H. the Novo Nordisk–Express Scripts Enterprise; and
- I. the Novo Nordisk–OptumRx Enterprise (together with the Novo Nordisk–CVS Caremark Enterprise and the Novo Nordisk–Express Scripts Enterprise, the “Novo Nordisk–PBM Defendant Enterprises”).

447. These nine association-in-fact enterprises are collectively referred to herein as the “Manufacturer–PBM Enterprises.”

448. Each Manufacturer–PBM Enterprise is a separate, ongoing, and continuing business organization consisting of corporations and individuals associated for the common purpose of manufacturing, selling, and facilitating the purchase of the Manufacturer Defendants’ products, including the at-issue drugs. For example:

A. Each of the three Eli Lilly–PBM Defendant enterprises associates for the common purpose of manufacturing, selling, distributing, and facilitating the purchase of Eli Lilly medications including Prozac, Cymbalta, and Zyprexa, as well as the at-issue Eli Lilly medications (Humulin N, Humulin R, Humulin R 500, Humulin 70/30, Humalog, Humalog Mix 50/50, Humalog Mix 75/25, and Basaglar), which are Eli Lilly’s primary source of revenue.

B. Each of the three Novo Nordisk–PBM Defendant enterprises associates for the common purpose of manufacturing, selling, distributing, and facilitating the purchase of Novo Nordisk medications for the treatment of obesity, hemophilia, and hormone imbalance, as well as the at-issue Novo Nordisk medications (Novolin R, Novolin N, Novolin 70/30, Novolog,

Levemir, and Novolog Mix 70/30), which account for more than three-quarters of Novo Nordisk's revenue.

C. Each of the three Sanofi–PBM Defendant enterprises associates for the common purpose of manufacturing, selling, distributing, and facilitating the purchase of Sanofi medications including Ambien, Plavix, and Dupixent, as well as the at-issue Sanofi medications (Lantus, Toujeo Solostar, and Apidra).

449. Each Manufacturer–PBM Enterprise engaged in the shared purpose of exchanging false list prices and secret Manufacturer Payments for preferred formulary positions for the at-issue drugs in order to control the market for diabetes medications and profit off diabetics and payors, including Plaintiff.

450. The members of each Manufacturer–PBM Enterprise are bound by contractual relationships, financial ties, and the ongoing coordination of activities.

451. There also is a common communication network by which the members of each Manufacturer–PBM Enterprise share information and meet on a regular basis. These communications include, but are not limited to, communications relating to the use of false list prices for the at-issue diabetes medications and the regular flow of Manufacturer Payments from each Manufacturer Defendant to the PBM Defendants in exchange for formulary placement.

452. Each Manufacturer–PBM Enterprise functions as a continuing but separate unit separate and apart from the pattern of racketeering activity in which it engages. Each Manufacturer–PBM Enterprise, for example, engages in the manufacture, distribution, and sale of medications and other products other than the at-issue insulin and insulin-analog medications. Additionally, each Manufacturer engages in conduct other than mail and wire fraud in furtherance of the Insulin Pricing Scheme.

453. At all relevant times, each of the Manufacturer–PBM Enterprises was operated and conducted for unlawful purposes by each Manufacturer Defendant and each PBM Defendant, namely, carrying out the Insulin Pricing Scheme.

454. Each Manufacturer–PBM Enterprise derived secret profits from these activities that were greater than those any one of the Manufacturer Defendants or PBM Defendants could obtain absent their misrepresentations regarding their non-transparent pricing schemes.

455. To accomplish this common purpose, each Manufacturer Defendant periodically and systematically inflated the prices of the at-issue drugs and then secretly paid a significant, yet undisclosed, portion of this inflated price back to each PBM Defendant in the form of Manufacturer Payments.

456. Each Manufacturer–PBM Enterprise did so willfully and with knowledge that Plaintiff paid for the at-issue drugs at prices directly based on the false list prices.

457. Each Manufacturer–PBM Enterprise’s inflation of the list prices and secret Manufacturer Payments was a quid pro quo exchange for preferred formulary placement.

458. Each Manufacturer–PBM Enterprise concealed from Plaintiff that these false prices and secret Manufacturer Payments resulted in each Manufacturer gaining formulary access without requiring significant price reductions and resulted in higher profits for each PBM Defendant, whose earnings increase the more inflated the price is and the more payment it receives from each Manufacturer Defendant.

459. Each Manufacturer–PBM Enterprise also shares a common purpose of perpetuating the use of the false list prices for the at-issue drugs as the basis for the price that payors, including Plaintiff, and diabetics pay for diabetes medications.

460. The Manufacturer Defendants would not be able to offer large pricing spreads to the PBM Defendants in exchange for favorable formulary positions without the use of the false list prices as the basis for the price paid by diabetics and payors, including Plaintiff, for the at-issue drugs.

461. The PBM Defendants share this common purpose because nearly all the revenue and profit generated from the at-issue drugs is tied to the falsely inflated prices generated by the Insulin Pricing Scheme. Without diabetics and payors, including Plaintiff, paying for diabetes medications based on the inflated list prices, the PBM Defendants' profits from the Insulin Pricing Scheme would decrease.

462. As a result, each PBM Defendant has, with the knowing and willful participation and assistance of each Manufacturer Defendant, engaged in hidden profit-making schemes falling into four general categories: (1) garnering undisclosed Manufacturer Payments from each Manufacturer Defendant that each PBM Defendant retains to a large extent, including by relabeling these payments and utilizing rebate aggregators to avoid their pass-through obligations; (2) generating substantial profits from pharmacies because of the falsely inflated prices, including through retaining clawbacks and post-purchase discounts; (3) generating spread income by charging their clients a higher amount than they pay pharmacies, with the spread income increasing with each list price increase; and (4) generating profits on the diabetes medications sold through each PBM Defendant's own mail-order and retail pharmacies, including by keeping secret discounts each Manufacturer Defendant provides to these affiliated pharmacies.

463. At all relevant times, each PBM Defendant and each Manufacturer Defendant has been aware of its respective Manufacturer-PBM Enterprise's

conduct, has been a knowing and willing participant in and coordinator of that conduct and has reaped profits from that conduct.

464. Neither any PBM Defendant nor any Manufacturer Defendant alone could have accomplished the purposes of the Manufacturer–PBM Enterprises without the other entity.

C. The Enterprises Misrepresent and Fail to Disclose Material Facts in Furtherance of the Insulin Pricing Scheme.

465. Each Manufacturer–PBM Enterprise knowingly made material misrepresentations to the public and health plan payors, including the Plaintiff, in furtherance of the Insulin Pricing Scheme, including publishing artificially inflated prices for insulin on published indices and representing that:

A. the false list prices for the at-issue diabetes medications were reasonably related to the actual prices realized by Defendants and were a reasonable and fair basis on which to base the price consumers and health plan payors, including Plaintiff, paid for these drugs;

B. each Manufacturer priced its at-issue drugs according to each drug’s value to the healthcare system and the need to fund innovation;

C. the Manufacturer Payments paid back to each PBM Defendant for each at-issue drug were for the benefit of health plan payors, including Plaintiff;

D. all “rebates” and discounts negotiated by the PBM Defendants with the Manufacturer Defendants were remitted to health plan payors, including Plaintiff;

E. the “rebates” negotiated by the members of each enterprise saved health plan payors, including Plaintiff, money;

F. each Manufacturer Defendant and each PBM Defendant were transparent with health plan payors, including Plaintiff, regarding the Manufacturer Payments, and that the PBMs did not retain any funds associated with prescription drug rebates or the margin between guaranteed reimbursement rates and the actual amount paid to the pharmacies; and

G. each PBM Defendant constructed formularies in a manner that lowered the price of the at-issue drugs and promoted the health and safety of diabetics.

466. Each false list price published by the Manufacturer Defendants constituted a material misrepresentation to consumers, health plan payors, including Plaintiff, and the public, in that each purported to be a fair market price for an at-issue drug, and each omitted to disclose the fraudulent spread between the list price and the net price of the medication or the basis therefor. Specific examples of such misrepresentations are set forth in Table 1 and Figures 3-11. Examples of other specific affirmative representations by each Defendant in furtherance of each

enterprise's Insulin Pricing scheme are set forth in paragraphs 194, 198–99, 206, 234–43, and 248–49.

467. At all times relevant to this Complaint, each Manufacturer–PBM Enterprise knew the above-described representations to be false.

468. At all times relevant to this Complaint, each Manufacturer–PBM Enterprise intentionally made these representations for the purpose of inducing consumers and health plan payors, including Plaintiff, into paying artificially inflated prices for diabetes medications.

469. Consumers and health plan payors, including Plaintiff, relied on the material misrepresentations and omissions made by each Manufacturer–PBM Enterprise in paying prices for the at-issue diabetes medications based upon the false prices generated by Insulin Pricing Scheme.

470. Additionally, each PBM–Manufacturer Enterprise relied on the list prices negotiated and published by the other PBM–Manufacturer Enterprises in setting their own list prices and determining the value of the kickbacks paid to the PBMs. Health plan payors, including Plaintiff, were injured by the inflated prices that arose as a result.

471. Each PBM Defendant convinced health plan payors, including Plaintiff, to pay prices for the at-issue drugs based on the false list prices by using the misrepresentations listed above to convince the health plan payors, including

Plaintiff, that they had secured lower prices when, in fact, they did the opposite, all while concealing the Insulin Pricing Scheme.

472. Without these misrepresentations and each Defendant's failure to disclose the Insulin Pricing Scheme, each Manufacturer-PBM Enterprise could not have achieved its common purpose, as consumers and health plan payors, including Plaintiff, would not have been willing to pay these false list prices.

D. Defendants' Use of the U.S. Mails and Interstate Wire Facilities.

473. Each of the Manufacturer-PBM Enterprises engaged in and affected interstate commerce because each engaged in some or all of the following activities across state boundaries: the sale, purchase, and/or administration of diabetes medications; the setting and publishing of the prices of these drugs; and the transmission of pricing information of diabetes medications; and/or the transmission and/or receipt of sales and marketing literature; and/or the transmission of diabetes medications through mail-order and retail pharmacies; and/or the transmission and/or receipt of invoices, statements, and payments related to the use or administration of diabetes medications; and/or the negotiations and transmissions of contracts related to the pricing of and payment for diabetes medications.

474. Each Manufacturer-PBM Enterprise participated in the administration of diabetes medications to millions of individuals located

throughout the United States, including in the City of Tacoma and elsewhere in this District.

475. The Manufacturer Defendants' and PBM Defendants' illegal conduct and wrongful practices were carried out by an array of employees, working across state boundaries, who necessarily relied upon frequent transfers of documents and information and products and funds through the U.S. mails and interstate wire facilities.

476. The nature and pervasiveness of the Insulin Pricing Scheme, which included each Manufacturer Defendant's and each PBM Defendant's corporate headquarters operations, necessarily required those headquarters to communicate directly and frequently by the U.S. mails and by interstate wire facilities with each other and with pharmacies, physicians, payors, and diabetics in the City of Tacoma and throughout Washington.

477. Each Manufacturer-PBM Enterprise's use of the U.S. mails and interstate wire facilities to perpetrate the Insulin Pricing Scheme involved thousands of communications including:

A. marketing materials about the published prices for diabetes medications, which each Manufacturer Defendant sent to each PBM Defendant located across the country, including in Tacoma and throughout Washington;

B. written and oral representations of the false list prices of diabetes medications that each Manufacturer Defendant and each PBM Defendant made at least annually and, in many cases, several times during a single year to the public;

C. thousands of written and oral communications discussing, negotiating, and confirming the placement of each Manufacturer Defendant's diabetes medications on each PBM Defendant's formulary;

D. written and oral representations made by each Manufacturer Defendant regarding information or incentives paid back to each PBM Defendant for each diabetes medication sold and/or to conceal these incentives or the Insulin Pricing Scheme;

E. written communications made by each Manufacturer Defendant, including checks, relating to Manufacturer Payments paid to each PBM Defendant to persuade it to advocate the at-issue diabetes medications;

F. written and oral communications with U.S. government agencies that misrepresented what the published prices were or that were intended to deter investigations into the true nature of the published prices or to forestall changes to reimbursement based on something other than published prices;

G. written and oral communications with payors, including Plaintiff, regarding the price of diabetes medications;

H. written and oral communications to health plan payors, including Plaintiff, that included marketing and solicitation material sent by each PBM Defendant regarding the existence, amount, or purpose of payments made by each Manufacturer Defendant to each PBM Defendant for the diabetes medications described herein and the purpose of each PBM Defendant's formulary;

I. transmission of published prices to third parties and payors, including Plaintiff;

J. receipts of money on tens of thousands of occasions through the U.S. mails and interstate wire facilities—the wrongful proceeds of the Insulin Pricing Scheme.

478. Although Plaintiff pleads the dates of certain communications in allegations incorporated into this Count, it cannot allege the precise dates of others without access to books and records within each Defendant's exclusive custody and control. Indeed, an essential part of the successful operation of the Insulin Pricing Scheme depended upon secrecy, and each of the Manufacturer Defendants and each PBM Defendant took deliberate steps to conceal its wrongdoing.

E. Conduct of the Manufacturer–PBM Enterprises’ Affairs.

479. Each Manufacturer Defendant and each PBM Defendant participates in the operation and management of Manufacturer–PBM Enterprises with which they are associated and, in violation of Section 1962(c) of RICO, and conduct or participate in the conduct of the affairs of those association-in-fact RICO enterprises, directly or indirectly. Such participation is carried out in the following ways:

A. Each Manufacturer Defendant and each PBM Defendant directly negotiates and controls the secret Manufacturer Payments provided to each PBM Defendant for diabetes medications.

B. Each PBM Defendant directly manages and controls their drug formularies and the placement of the at-issue diabetes medications on those formularies.

C. Each PBM Defendant intentionally selects higher-priced diabetes medications for formulary placement and excludes lower priced ones in order to generate larger profits and they coordinate with each Manufacturer Defendant to increase the availability and use of higher-priced medications because they are more profitable for both groups of Defendants.

D. Each Manufacturer Defendant directly controls the publication of the false list prices generated by the Insulin Pricing Scheme.

E. Each Manufacturer Defendant directly controls the creation and distribution of marketing, sales, and other materials used to inform each PBM Defendant of the profit potential from its diabetes medications.

F. Each PBM Defendant directly controls the creation and distribution of marketing, sales, and other materials used to inform payors and the public of the benefits and cost-saving potential of their formulary and negotiations with the Manufacturers.

G. Each PBM Defendant directs and controls each Manufacturer-PBM Enterprise's direct relationships with payors such as the Plaintiff by negotiating the terms of and executing the contracts that govern those relationships.

H. Each PBM Defendant directs and controls each Manufacturer-PBM Enterprise's Insulin Pricing Scheme by hiding, obfuscating, and laundering Manufacturer Payments through their affiliated entities in order to retain a large and undisclosed proportion of the Manufacturer Payments to the detriment of payors, including Plaintiff.

I. Each PBM Defendant distributes through the U.S. mail and interstate wire facilities, promotional and other materials that claim the Manufacturer Payments paid from each Manufacturer Defendant to each PBM Defendant save Plaintiff and other payors money on the at-issue drugs.

J. Each Manufacturer Defendant represented to health plan payors, including Plaintiff—by publishing and promoting false list prices without stating that these published prices differed substantially from the prices realized by each Manufacturer Defendant and each PBM Defendant—that the published prices of diabetes medications reflected or approximated the actual price realized by Defendants and resulted from transparent and competitive, fair market forces.

F. Defendants’ Pattern of Racketeering Activity.

480. The Manufacturer Defendants and the PBM Defendants have conducted and participated in the affairs of their respective Manufacturer–PBM Enterprises through a pattern of racketeering activity, including acts that are unlawful under 18 U.S.C. § 1341, relating to mail fraud, and 18 U.S.C. § 1343, relating to wire fraud.

481. The Manufacturer Defendants’ and the PBM Defendants’ pattern of racketeering involved thousands, if not hundreds of thousands, of separate instances of use of the U.S. mails or interstate wire facilities in furtherance of the Insulin Pricing Scheme. Each of these mailings and interstate wire transmissions constitutes a “racketeering activity” within the meaning of 18 U.S.C. § 1961(1). Collectively, these violations constitute a “pattern of racketeering activity,” within the meaning of 18 U.S.C. § 1961(5), in which the Manufacturer Defendants and

the PBM Defendants intended to defraud consumers and health plan payors, including Plaintiff.

482. By intentionally and falsely inflating the list prices, by misrepresenting the purpose behind both the Manufacturer Payments made from each Manufacturer Defendant to each PBM Defendant and each PBM Defendant's formulary construction, and by subsequently failing to disclose such practices to consumers and health plan payors, including Plaintiff, the Manufacturer Defendants and the PBM Defendants engaged in a fraudulent and unlawful course of conduct constituting a pattern of racketeering activity.

483. The Manufacturer Defendants' and the PBM Defendants' racketeering activities amounted to a common course of conduct, with similar patterns and purposes, intended to deceive Plaintiff.

484. Each separate use of the U.S. mails and/or interstate wire facilities employed by the Manufacturer Defendants and the PBM Defendants was related, had similar intended purposes, involved similar participants and methods of execution, and had the same results affecting the same victims, including Plaintiff.

485. The Manufacturer Defendants and the PBM Defendants engaged in the pattern of racketeering activity for the purpose of conducting the ongoing business affairs of the respective Manufacturer-PBM Enterprises with which each of them is and was associated in fact.

G. The RICO Defendants' Motive

486. The Manufacturer Defendants' and the PBM Defendants' motive in creating and operating the Insulin Pricing Scheme and conducting the affairs of the Manufacturer– PBM Enterprises described herein was to control the market for diabetes medications and falsely obtain sales of and profits from diabetes medications.

487. The Insulin Pricing Scheme was designed to, and did, encourage others, including payors such as Plaintiff, to advocate the use of each Manufacturer Defendant's products and to pay for those diabetes medications based on a falsely inflated price. Each Manufacturer Defendant used the Insulin Pricing Scheme to obtain formulary placement to sell more of its drugs without cutting into its profits. The PBM Defendants used the Insulin Pricing Scheme to falsely inflate the price payors such as Plaintiff paid for diabetes medications in order to profit off the Insulin Pricing Scheme, as discussed above.

H. The Manufacturer–PBM Enterprises' Insulin Pricing Scheme Injured Plaintiff.

488. Each Manufacturer–PBM Enterprise's violations of federal law and pattern of racketeering activity have directly and proximately caused Plaintiff to be injured in its business or property.

489. The prices Plaintiff pays for the at-issue drugs are tied directly to the false list prices generated by the Insulin Pricing Scheme.

490. No other intermediary in the supply chain has control over or is responsible for the list prices on which nearly all Plaintiff's payments are based other than the Manufacturer-PBM Defendant Enterprises.

491. Defendants collectively set the prices Plaintiff paid for the at-issue drugs.

492. During the relevant period, Plaintiff paid for the at-issue drugs.

493. Each Manufacturer-PBM Enterprise controlled and participated in the Insulin Pricing Scheme that was directly responsible for the false list prices upon which the price Plaintiff paid was based.

494. Plaintiff thus was damaged by the scheme. But for the illegal conduct of the Manufacturing-PBM Enterprises, including the misrepresentations and false prices created by the Insulin Pricing Scheme that each Manufacturer-PBM Enterprise employed, Plaintiff would have paid less for the medications.

495. While Defendants' scheme injured an enormous number of payors and plan members, Plaintiff's damages are separate and distinct from those of any other victim that was harmed by the Manufacturer-PBM Enterprises' Insulin Pricing Scheme.

496. By virtue of these violations of 18 U.S.C. § 1962(c), under the provisions of Section 1964(c) of RICO, Defendants are jointly and severally liable

to Plaintiff for three times the damages that were sustained, plus the costs of bringing this action, including reasonable attorneys' fees.

497. By virtue of these violations of 18 U.S.C. § 1962(c), under the provisions of Section 1964(a) of RICO, Plaintiff seeks injunctive relief against the Manufacturer Defendants and the PBM Defendants for their fraudulent reporting of prices, and their continuing acts to affirmatively misrepresent and/or conceal and suppress material facts concerning their false and inflated prices for diabetes medications, plus the costs of bringing this suit, including reasonable attorneys' fees.

498. Absent an injunction, the effects of this fraudulent, unfair, and unconscionable conduct will continue. Plaintiff continues to purchase the at-issue diabetes medications. Plaintiff will continue to pay based on the Defendants' false list prices. This continuing fraudulent, unfair, and unconscionable conduct is a serious matter that calls for injunctive relief as a remedy. Plaintiff seeks injunctive relief, including an injunction against the Manufacturer Defendants and the PBM Defendants to prevent them from affirmatively misrepresenting and/or concealing and suppressing material facts concerning their conduct in furtherance of the Insulin Pricing Scheme

**COUNT TWO — VIOLATIONS OF RICO, 18 U.S.C. § 1962(D) BY
CONSPIRING TO VIOLATE 18 U.S.C. § 1962(C)
(Against All Defendants)**

499. Plaintiff incorporates by reference all preceding paragraphs up to Section V, as well as Count I, of this Complaint as though fully set forth herein.

500. Section 1962(d) of RICO provides that it “shall be unlawful for any person to conspire to violate any of the provisions of subsection (a), (b), or (c) of this section.”

501. Defendants have violated § 1962(d) by agreeing and conspiring to violate 18 U.S.C. § 1962(c). The object of this conspiracy has been and is to conduct or participate in the Insulin Pricing Scheme.

502. As set forth in detail above, as well as in the Civil Conspiracy count below, Defendants each knowingly agreed to facilitate the Insulin Pricing Scheme and each has engaged in numerous overt and predicate fraudulent racketeering acts in furtherance of the conspiracy. Specifically, Defendants agreed to and did inflate the prices of the at-issue drugs in lockstep to achieve an unlawful purpose; Defendants agreed to and did make false or misleading statements or material omissions regarding the reasons for these price increases, the purpose of the Manufacturer Payments exchanged between Defendants and the PBMs’ formulary construction; and PBMs agreed to and did, in concert, request and receive larger Manufacturer Payments and higher prices in exchange for formulary placement.

503. The nature of the above-described Defendant co-conspirators' acts, material misrepresentations, and omissions in furtherance of the conspiracy gives rise to an inference that they not only agreed to the objective of an 18 U.S.C. § 1962(d) violation of RICO by conspiring to violate 18 U.S.C. § 1962(c), but they were aware that their ongoing fraudulent and extortionate acts have been and are part of an overall pattern of racketeering activity.

504. Defendants have engaged and continue to engage in the commission of overt acts, including the following unlawful racketeering predicate acts:

- A. multiple instances of mail fraud in violations of 18 U.S.C. § 1341;
- B. multiple instances of wire fraud in violations of 18 U.S.C. § 1343; and
- C. multiple instances of unlawful activity in violation of 18 U.S.C. § 1952.

505. Defendants' conspiracy to violate the above federal laws and the effects thereof detailed above are continuing and will continue. Plaintiff has been injured in its property by reason of these violations: Plaintiff has paid more for the at-issue drugs than it would have but for Defendants' conspiracy to violate 18 U.S.C. § 1962(c).

506. By virtue of these violations of 18 U.S.C. § 1962(d), Defendants are jointly and severally liable to Plaintiff for three times the damages Plaintiff has sustained, plus the cost of this action, including reasonable attorneys' fees.

**COUNT THREE — CIVIL CONSPIRACY
(Against All Defendants)**

507. Plaintiff incorporates by reference all preceding paragraphs up to Section V, as well as Counts I, II, and VI, of this Complaint as though fully set forth herein.

508. Defendants' conduct described throughout this Complaint as comprising and implementing the Insulin Pricing Scheme constituted a combination of two or more persons created and carried out for an unlawful purpose or a lawful purpose by unlawful means, further to which one or all Defendants committed an overt tortious or unlawful act.

509. Each and every Defendant knowingly and maliciously participated in the creation and implementation of the Insulin Pricing Scheme.

510. Each and every Defendant planned, assisted, and encouraged the Insulin Pricing Scheme.

511. Defendants aided and abetted one another to violate federal laws, including 18 U.S.C. § 1962(c) and the Washington Consumer Protection Act, as alleged herein.

512. Each Defendant agreed to carry out and carried out overt acts in furtherance of the Insulin Pricing Scheme that artificially inflated the price of diabetes medications to Plaintiff's detriment.

513. Each PBM Defendant made a conscious commitment to participate in the Insulin Pricing Scheme.

514. The Manufacturer Defendants agreed with each other and the PBM Defendants to intentionally raise their diabetes medication prices and then pay back a significant portion of those prices to the PBM Defendants.

515. In exchange for the Manufacturer Defendants inflating their prices and making large secret payments, the PBM Defendants agreed to and did grant preferred formulary status to the Manufacturer Defendants' diabetes medications.

516. Each Defendant shares a common purpose of perpetuating the Insulin Pricing Scheme and neither the PBM Defendants nor the Manufacturer Defendants alone could have accomplished the Insulin Pricing Scheme without their co-conspirators.

517. The PBM Defendants need the Manufacturer Defendants to inflate the list price of their diabetes medications and to make secret payments back to the PBM Defendants in order for the PBM Defendants to profit off the Insulin Pricing Scheme.

518. The Manufacturer Defendants need the PBM Defendants to grant certain diabetes medications preferred formulary placement in order to maintain access to payors and diabetics whose purchase of the at-issue drugs generated unearned and unwarranted revenue for all Defendants.

519. As discussed throughout this Complaint, the Insulin Pricing Scheme resulted from explicit agreements, direct coordination, constant communication, and exchange of information between the PBM Defendants and the Manufacturer Defendants.

520. In addition to the preceding direct evidence of an agreement, Defendants' conspiracy is also demonstrated by the following indirect evidence that infers Defendants conspired to engage in fraudulent conduct:

A. Defendants refuse to disclose the details of their pricing structures, agreements and sales figures in order to maintain the secrecy of the Insulin Pricing Scheme;

B. Numerous ongoing government investigations, hearings, and inquiries have targeted the Insulin Pricing Scheme and the collusion between the Manufacturer and PBM Defendants, including:

i. civil investigative demands to the Manufacturers from the States of California, Florida, Minnesota, and Washington relating to the pricing of their insulin products and their relationships with the

PBM Defendants;

ii. letters from numerous senators and representatives in recent years to the Justice Department and the Federal Trade Commission asking them to investigate potential collusion among Defendants;

iii. 2019 hearings before the House Oversight and Reform Committee on industry practices; and

iv. the Senate Finance Committee's recent two-year probe into the Insulin Pricing Scheme and the conspiracy between the Manufacturers and the PBMs, resulting in the Grassley-Wyden report, first published in 2021.

C. The astronomical rise in the price of the at-issue drugs coincides with PBM Defendants' rise in power within the pharmaceutical pricing system starting in 2003.

521. As a result of Defendants' unlawful and tortious acts, including violations of 18 U.S.C. § 1962(c) and the Washington Consumer Protection Act, Plaintiff has suffered actual damage and continues to be damaged by the conspiracy when it overpays for the diabetes medications.

COUNT FOUR — COMMON LAW FRAUD
**(Against Defendants Express Scripts, Ascent Health Services, Eli Lilly, Sanofi-
Aventis, and Novo Nordisk)**

522. Plaintiff incorporates by reference all preceding paragraphs up to Section V of this Complaint as though fully set forth herein.

523. As alleged extensively above, these Defendants affirmatively misrepresented and/or concealed and suppressed material facts concerning: (a) the true cost and/or price of the insulin products described herein; (b) the inflated and/or fraudulent nature of the list price(s) set and/or charged by these Defendants for the insulin products described herein; (c) the existence, amount, and/or purpose(s) of discounts and/or rebates offered and/or negotiated by these Defendants for those products; and (d) the role that these Defendants played in the price paid for the insulin products described herein, including but not limited to marketing material averring that these Defendants decrease the price of prescription drugs for consumers.

524. Defendants Express Scripts, Ascent Health Services, Eli Lilly, Sanofi-Aventis, and Novo Nordisk valued their profits over the trust, health, and safety of Plaintiff.

525. Necessarily, these Defendants took steps to ensure that their employees and co-conspirators did not reveal the details of the Insulin Pricing Scheme to Plaintiff.

526. These Defendants' false representations and omissions were material to Plaintiff.

527. These Defendants knew that their representations and omissions were false and misleading. They knew, for example, that the list prices for the at-issue drugs were inflated and untethered to market price. They knew that these list prices were artificially inflated to fund kickbacks to the PBM Defendants in exchange for preferred formulary placement.

528. Plaintiff reasonably relied on these Defendants' deception, and these Defendants intended that they would so rely. Plaintiff had no way of discerning that these Defendants were, in fact, deceiving them because they possessed exclusive knowledge regarding the nature of insulin pricing; intentionally concealed the foregoing from Plaintiff and the public; and made incomplete or negligent representations about the pricing of the insulin products and these Defendants' role in that pricing, while purposefully withholding material facts from Plaintiff that contradicted these representations.

529. Plaintiff relied on these Defendants' false list prices. Because of the Insulin Pricing Scheme, list prices have skyrocketed and the spread between list price and net price has ballooned in turn. Plaintiff is injured by this list and net price divergence. Through the scheme, these Defendants have forced payors, including Plaintiff, to pay not just for the drugs, but also for undisclosed kickbacks that are

paid to PBMs.

530. These Defendants took steps to ensure that their employees and co-conspirators did not reveal the details of the Insulin Pricing Scheme to Plaintiff.

531. These Defendants owed Plaintiff a duty to disclose, truthfully, all facts concerning the true cost of the at-issue medications and the inflated and fraudulent nature of their pricing; the existence, amount, flow, and purpose of rebates and discounts negotiated for those products; and the role that these Defendants played in increasing the price of the at-issue drugs.

532. These Defendants possessed superior knowledge of essential facts about the at-issue drugs and their prices. That information was peculiarly and exclusively in their control and not available to payors, including Plaintiff. In light of their misleading or incomplete representations, these Defendants also had an obligation to disclose facts related to the Insulin Pricing Scheme.

533. These Defendants' actions, representations, and misrepresentations demonstrate callous disregard for not only the rule of law but also public health. Indeed, as a direct result of these Defendants' actions, access to live-saving insulin medication has been limited, denied, or forgone.

534. These Defendants owed Plaintiff a duty to disclose, truthfully, all the facts concerning the true cost of the at-issue medications described herein and the inflated and fraudulent nature of their pricing; the existence, amount, and purpose of

rebates and discounts negotiated for those products; and the role that these Defendants played in increasing the price of the at-issue medications described herein.

535. These Defendants hatched their deceptive schemes and knew that Plaintiff did not know about (and could not reasonably discover) the manner in which they sought to artificially inflate the price of the insulin medications. These Defendants not only concealed all the facts concerning the true cost of the insulin products described herein, but went further to make affirmative misrepresentations in marketing materials and other communications, that these Defendants worked to lower the ultimate cost of prescription medications. These Defendants engaged in this fraudulent concealment at the expense of Plaintiff.

536. Plaintiff was not aware of the concealed and misrepresented material facts referenced above, and it would not have acted as it did, had it known the truth.

537. As a direct and proximate result of these Defendants' fraudulent scheme, Plaintiff sustained damages, including but not limited to paying excessive and inflated prices for the insulin products described herein.

538. These Defendants are liable to Plaintiff for damages in an amount to be proven at trial. Moreover, because these Defendants acted wantonly, maliciously, oppressively, recklessly, deliberately, and with intent to defraud Plaintiff for the purpose of enriching themselves to Plaintiff's detriment, these Defendants' conduct

warrants substantial damages in an amount to be determined at trial.

COUNT FIVE — UNJUST ENRICHMENT
**(Against Defendants Express Scripts, Ascent Health Services, Eli Lilly, Sanofi-
Aventis, and Novo Nordisk)**

539. Plaintiff incorporates by reference all preceding paragraphs up to Section V of this Complaint as though fully set forth herein.

540. Plaintiff brings this Count on behalf of itself.

541. This claim is alleged in the alternative to Plaintiff's claims for legal relief.

542. Defendants have knowingly benefitted from the Insulin Pricing Scheme described herein, including selling, setting prices for, and negotiating discounts for insulin products marketed and sold at an artificially inflated price.

543. Defendants have knowingly received and retained unjust benefits from Plaintiff as a result of the Insulin Pricing Scheme described herein, including in the form of gross prescription costs paid, copayments, and coinsurance payments, and inequity has resulted.

544. It is inequitable and unconscionable for Defendants to retain these benefits.

545. Because Defendants concealed the true nature of the payments they received and the amounts they purportedly pass through to the City of Tacoma, Plaintiff was not aware of the true facts concerning the Insulin Pricing Scheme

described herein and did not benefit from Defendants' misconduct.

546. Defendants knowingly accepted the unjust benefits of their fraudulent conduct.

547. Equity cannot in good conscience permit Defendants to be economically enriched for their unjust actions at Plaintiff's expense and in violation of state law, and therefore restitution or disgorgement or both of such economic enrichment is required.

**COUNT SIX — WASHINGTON CONSUMER PROTECTION ACT,
WASHINGTON REVISED CODE SECTION 19.86.010 *ET SEQ.*
(Against Defendants Express Scripts and Ascent Health Services)**

548. Plaintiff incorporates by reference all preceding paragraphs up to Section V of this Complaint as though fully set forth herein.

549. The Washington Consumer Protection Act ("Washington CPA") broadly prohibits "[u]nfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce." Wash. Rev. Code. § 19.86.010.

550. Defendants are "persons" as defined by Wash. Rev. Code § 19.86.010.

551. Plaintiff is a "person" as defined by Wash. Rev. Code § 19.86.010.

552. Defendants committed the acts complained of herein in the course of "trade" or "commerce" within the meaning of Wash. Rev. Code. § 19.86.010.

553. The Washington State Legislature has enacted Chapter 48.200 to regulate pharmacy benefit managers and health care benefit managers. Wash. Rev.

Code. § 48.200. In doing so, it found that the “regulatory oversight of health care benefit managers” is critical to “protect and promote the health, safety, and welfare of Washington residents.” Wash. Rev. Code. § 48.200.010(3).

554. Under this statute, a pharmacy benefit manager “[m]ay not cause or knowingly permit the use of any advertisement, promotion, solicitation, representation, proposal, or offer that is untrue, deceptive, or misleading.” Wash. Rev. Code. § 48.200.280(2)(h).

555. Defendants thus violated the Washington CPA, at a minimum by taking the following actions.

A. Making material misrepresentations regarding the true cost of the insulin products described herein that had the tendency to mislead consumers and health plan payors, such as Plaintiff, including, but not limited to, by publishing, setting, or distributing the list price of the insulin products described herein;

B. Engaging in advertising concerning the role that Defendants played in setting the price paid for the insulin products described herein, including but not limited to marketing material averring that PBM Defendants make efforts to decrease the price of prescription drugs for consumers;

C. Using the inflated list prices to determine the prices paid by

health plan payors, including Plaintiff, and failing to disclose the inflated nature of the list price(s) set and/or charged by Manufacturer Defendants for the insulin products described herein, with the knowledge, consent, and cooperation of the PBM Defendant(s);

D. Making material misrepresentations regarding or failing to disclose the existence, amount, and/or purpose(s) of discounts, rebates, and/or other payments offered by the Manufacturer Defendants to the PBM Defendants and/or negotiated by the PBM Defendants in exchange for inclusion and/or tier placement of the Manufacturer Defendants' products on the PBM Defendants' formularies;

E. Making material misrepresentations regarding or failing to disclose the portion of discounts, rebates, and/or other payments from the Manufacturer Defendants that the PBM Defendants keep;

F. Misleading health plan payors, including Plaintiff, as to the true nature of the value of the services provided and reaping illicit profits exponentially greater than the fair market value of the products and services provided;

G. Confusing and misleading health plan payors, including Plaintiff, regarding each Defendant's respective role in the Insulin Pricing Scheme in an attempt to evade liability;

H. Hiding, obfuscating, and laundering the Manufacturer Payments through the PBM Defendants' affiliated entities in order to retain a large and undisclosed proportion of the Manufacturer Payments to the detriment of health plan payors, including Plaintiff; and/or

I. Engaging in misleading, false, unfair and/or deceptive acts or practices by selling and/or facilitating the sale of the insulin products described herein at grossly inflated and/or fraudulently obtained price points.

556. These Defendants continue to make misrepresentations and publish false prices generated by the Insulin Pricing Scheme, and consumers and health plan payors, including Plaintiff, continue to purchase diabetes medications at inflated prices, notwithstanding the Manufacturer Defendants' price caps. The foregoing violations caused harm to Plaintiff, and are likely to harm Plaintiff in the future if Defendants' practices are not stopped.

557. Each at-issue purchase Plaintiff made of diabetes medications at the prices generated by the Insulin Pricing Scheme constitutes a separate violation of the Washington Consumer Protection Act.

558. These Defendants' acts and practices in violation of the Washington Consumer Protection Act caused Plaintiff to suffer injuries alleged herein, including but not limited to paying excessive and inflated prices for diabetes medications as described herein.

559. Furthermore, the City of Tacoma brings this cause of action in its sovereign capacity for the benefit of the State of Washington. The Washington Consumer Protection Act expressly authorizes local governments to enforce its provisions and to recover damages for violations of the Act, and this action is brought to promote the public welfare of the state and for the common good of the state.

560. Defendants are liable to Plaintiff for damages in amounts to be proven at trial, including attorneys' fees, costs, and treble damages, as well as any other remedies the Court may deem appropriate under Wash. Rev. Code. § 19.86.090.

I. PRAYER FOR RELIEF

WHEREFORE, Plaintiff prays for entry of judgment against the Defendants for all the relief requested herein and to which the Plaintiff may otherwise be entitled, specifically including, but without limitation, to wit:

A. A determination that Defendants have violated the Washington Consumer Protection Act, violated RICO, conspired to violate RICO, engaged in a civil conspiracy, engaged in a fraudulent scheme, and have been unjustly enriched;

B. Judgment in favor of Plaintiff and against the Defendants for damages in excess of the minimum jurisdictional requirements of this Court, in a specific amount to be proven at trial;

C. Injunctive relief in accordance with the Washington Consumer Protection Act (Wash. Rev. Code § 19.86.010 *et seq.*), 18 U.S.C. § 1964(a), and 18 U.S.C. § 1962(c), to the effect that Defendants, their affiliates, successors, transferees, assignees, and the officers, directors, partners, agents, and employees thereof, and all other persons acting or claiming to act on their behalf or in concert with them, be enjoined and restrained from in any manner continuing, maintaining or renewing the conduct, contract, conspiracy, or combination alleged herein in violation of Washington law and RICO, or from entering into any other contract, conspiracy, or combination having a similar purpose or effect, and from adopting or following any practice, plan, program, or device having a similar purpose or effect;

D. That Plaintiff:

1. be awarded restitution, damages (including but not limited to treble damages as permitted by Wash. Rev. Code § 19.86.010 *et seq.* and 18 U.S.C. §§ 1962(c) and 1964(a)), disgorgement, penalties, and all other legal and equitable relief to which Plaintiff may be entitled;

2. be awarded pre- and post-judgment interest as provided by law, and that such interest be awarded at the highest legal rate from

and after the date of service of the initial Complaint in this action;

3. recover its costs of this action, including its reasonable attorneys' fees; and

4. be awarded such other further relief as the case may require and the Court may deem just and proper under the circumstances.

II. JURY DEMAND

Plaintiff demands trial by jury on all issues so triable.

RESPECTFULLY SUBMITTED this 31st day of July, 2026.

CITY OF TACOMA

By: s/ Christopher D. Bacha
Christopher D. Bacha
City Attorney
Kimberly J. Cox
Deputy City Attorney
Office of the City Attorney
Civil Division
747 Market Street, Room 1120
Tacoma, WA 98402
Telephone: (253) 591-5885
cbacha@cityoftacoma.org
kcox@cityoftacoma.org

KELLER ROHRBACK L.L.P.

By: s/ David J. Ko
Derek W. Loeser, WSBA #24274
David J. Ko, WSBA #38299
Juli E. Farris, WSBA #17593
Laura R. Gerber, WSBA #34981
Rachel C. Bowanko, WSBA #61298
Andrew N. Lindsay, WSBA #60386
1201 Third Avenue, Suite 3400
Seattle, Washington 98101
Telephone: (206) 428-0563
dloeser@kellerrohrback.com
dko@kellerrohrback.com
jfarris@kellerrohrback.com
lgerber@kellerrohrback.com
rbowanko@kellerrohrback.com
alindsay@kellerrohrback.com

Attorneys for Plaintiff